Duodenal Infusion of Donor Feces for Recurrent<i>Clos

New England Journal of Medicine
368, 407-415
DOI: 10.1056/nejmoa1205037

Citation Report

#	Article	IF	Citations
1	Clostridium Difficile Infection. , 0, , 201-212.		0
3	The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing. PLoS Biology, 2008, 6, e280.	2.6	2,013
4	Clostridium difficile. Clinics in Laboratory Medicine, 2010, 30, 329-342.	0.7	21
5	HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World Journal of Gastroenterology, 2011, 17, 804.	1.4	33
6	Microbial genomics: an increasingly revealing interface in human health and disease. Genome Medicine, 2013, 5, 31.	3.6	2
7	Infections and inflammatory bowel disease: Challenges in <scp>A</scp>sia. Journal of Digestive Diseases, 2013, 14, 567-573.	0.7	17
8	Colonization resistance and microbial ecophysiology: using gnotobiotic mouse models and single-cell technology to explore the intestinal jungle. FEMS Microbiology Reviews, 2013, 37, 793-829.	3.9	85
9	Changing Epidemiology and Control of Clostridium difficile in Older Adults. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 143-150.	0.7	0
10	Human intestinal metagenomics: state of the art and future. Current Opinion in Microbiology, 2013, 16, 232-239.	2.3	62
11	Fecal Transplantation for Recurrent <scp>C</scp>lostridium difficile Infection in Older Adults: A Review. Journal of the American Geriatrics Society, 2013, 61, 1394-1398.	1.3	61
12	Intracolonic Vancomycin for Severe Clostridium difficile Colitis. Surgical Infections, 2013, 14, 532-539.	0.7	37
13	Metabolically re-modeling the drug pipeline. Current Opinion in Pharmacology, 2013, 13, 778-785.	1.7	33
14	New concepts in diagnostics for infectious diarrhea. Mucosal Immunology, 2013, 6, 876-885.	2.7	54
15	An exploratory study into the putative prebiotic activity of fructans isolated from Agave angustifolia and the associated anticancer activity. Anaerobe, 2013, 22, 38-44.	1.0	53
16	Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions. Current Gastroenterology Reports, 2013, 15, 337.	1.1	210
17	Clostridium Difficile Infection in Patients with HIV/AIDS. Current HIV/AIDS Reports, 2013, 10, 273-282.	1.1	31
18	Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection: Whatâ€™s Old Is New Again?. Current Infectious Disease Reports, 2013, 15, 101-103.	1.3	6
19	Targeting the Gutâ€“Liver Axis in Cirrhosis: Antibiotics and Non-Selective Î²-Blockers. Advances in Therapy, 2013, 30, 659-670.	1.3	30

#	Article	IF	Citations
20	Community-Acquired Clostridium difficile Infection: An Emerging Problem. Current Emergency and Hospital Medicine Reports, 2013, 1, 149-153.	0.6	6
21	Glycobiome: Bacteria and mucus at the epithelial interface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 25-38.	1.0	171
22	Is There a Role for Probiotics in the Prevention or Treatment of Food Allergy?. Current Allergy and Asthma Reports, 2013, 13, 622-630.	2.4	24
23	The Microbiome as a Therapeutic Target for Metabolic Diseases. Drug Development Research, 2013, 74, 376-384.	1.4	1
24	Transmission of Clostridium difficile in Foods. Infectious Disease Clinics of North America, 2013, 27, 675-685.	1.9	34
25	Probiotics, prebiotics, and the host microbiome: the science of translation. Annals of the New York Academy of Sciences, 2013, 1306, 1-17.	1.8	98
26	Analysis of the Human Gut Microbiome and Association With Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 774-777.	2.4	90
27	Le microbiote intestinal est lâ€™avenir de la multirÃ©sistance bactÃ©rienne. Journal Des Anti-infectieux, 2013, 15, 166-177.	0.1	2
28	IntÃ©rÃªt et technique de la transplantation fÃ©cale. Journal Des Anti-infectieux, 2013, 15, 187-192.	0.1	0
29	Fecal microbiota transplantation and donor standardization. Trends in Microbiology, 2013, 21, 443-445.	3.5	43
30	Temporal Bacterial Community Dynamics Vary Among Ulcerative Colitis Patients After Fecal Microbiota Transplantation. American Journal of Gastroenterology, 2013, 108, 1620-1630.	0.2	298
31	Microbiota-mediated colonization resistance against intestinal pathogens. Nature Reviews Immunology, 2013, 13, 790-801.	10.6	1,138
32	Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics forClostridium difficileand beyond. Expert Review of Gastroenterology and Hepatology, 2013, 7, 615-628.	1.4	18
33	Clostridium difficile Infection. Medical Clinics of North America, 2013, 97, 523-536.	1.1	18
34	The microbiome and cancer. Nature Reviews Cancer, 2013, 13, 800-812.	12.8	1,338
35	Fighting Obesity with Bacteria. Science, 2013, 341, 1069-1070.	6.0	98
36	Relationship Between theHLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology, 2013, 149, 1025.	2.0	213
37	Sequencing the human microbiome in health and disease. Human Molecular Genetics, 2013, 22, R88-R94.	1.4	123

#	Article	IF	Citations
38	Genomics, the origins of agriculture, and our changing microbeâ€scape: Time to revisit some old tales and tell some new ones. American Journal of Physical Anthropology, 2013, 152, 135-152.	2.1	52
39	Fulminant colitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 771-782.	1.0	4
40	New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut, 2013, 62, 1642-1652.	6.1	61
41	Diagnosis and Management of Clostridium difficile Infection. Clinical Gastroenterology and Hepatology, 2013, 11, 1216-1223.	2.4	56
42	Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection. Current Opinion in Microbiology, 2013, 16, 596-601.	2.3	41
43	Metabolomics. Current Opinion in Gastroenterology, 2013, 29, 378-383.	1.0	48
44	Clostridium difficile. Medicine, 2013, 41, 654-657.	0.2	2
45	The Hologenome Concept: Human, Animal and Plant Microbiota. , 2013, , .		58
46	Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. Anaerobe, 2013, 24, 20-24.	1.0	55
48	Recent Therapeutic Advances in Gastroenterology and Hepatology. Advances in Therapy, 2013, 30, 855-857.	1.3	0
49	Therapeutic Potential of Fecal Microbiota Transplantation. Gastroenterology, 2013, 145, 946-953.	0.6	543
50	The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. Current Opinion in Microbiology, 2013, 16, 240-245.	2.3	180
51	Fecal transplant: A safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 127-137.	1.0	89
52	Overview of Severe Clostridium difficile Infection. Critical Care Clinics, 2013, 29, 827-839.	1.0	23
54	Clostridium difficileinfection in children: a comprehensive review. Current Medical Research and Opinion, 2013, 29, 967-984.	0.9	43
56	The Pharmacobiotic Potential of the Gastrointestinal Tract Microâ€Biometabolomeâ€“Probiotic Connect: A Brief Commentary. Drug Development Research, 2013, 74, 353-359.	1.4	5
57	Hunting for cancer in the microbial jungle. Genome Medicine, 2013, 5, 42.	3.6	1
58	Clostridium difficileinfection in the twenty-first century. Emerging Microbes and Infections, 2013, 2, 1-8.	3.0	91

#	Article	IF	Citations
59	Massive Gastrointestinal Bleeding Secondary to Superior Mesenteric Arteriovenous Fistula. American Journal of Gastroenterology, 2013, 108, 1662-1665.	0.2	6
60	The microbiome explored: recent insights and future challenges. Nature Reviews Microbiology, 2013, 11, 213-217.	13.6	162
61	Treatment of age-related macular degeneration. Lancet, The, 2013, 382, 1230-1232.	6.3	24
62	Obese Humans With Nonalcoholic Fatty Liver Disease Display Alterations in Fecal Microbiota and Volatile Organic Compounds. Clinical Gastroenterology and Hepatology, 2013, 11, 876-878.	2.4	10
64	A wise consistency: engineering biology for conformity, reliability, predictability. Current Opinion in Chemical Biology, 2013, 17, 893-901.	2.8	50
66	Western Dietary Pattern and Sedentary Life: Independent Effects of Diet and Physical Exercise Intensity on NAFLD. American Journal of Gastroenterology, 2013, 108, 1932-1933.	0.2	20
67	<scp>A</scp> ntimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Molecular Medicine, 2013, 5, 1465-1483.	3.3	293
68	Fecal Microbiota Transplant: We Know Its History, but Can We Predict Its Future?. Mayo Clinic Proceedings, 2013, 88, 782-785.	1.4	4
70	A probiotic trial: tipping the balance of evidence?. Lancet, The, 2013, 382, 1228-1230.	6.3	10
71	Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Mayo Clinic in Arizona Experience. Mayo Clinic Proceedings, 2013, 88, 799-805.	1.4	52
73	Continuing Medical Education Exam: August 2013. Gastrointestinal Endoscopy, 2013, 78, 342.e1-342.e6.	0.5	0
74	Acute Gastroenteritis. Primary Care - Clinics in Office Practice, 2013, 40, 727-741.	0.7	66
75	Transient Flare of Ulcerative Colitis After Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Clinical Gastroenterology and Hepatology, 2013, 11, 1036-1038.	2.4	194
76	Muscle wasting: The gut microbiota as a new therapeutic target?. International Journal of Biochemistry and Cell Biology, 2013, 45, 2186-2190.	1.2	143
77	The intestinal microbiota and host immune interactions in the critically ill. Trends in Microbiology, 2013, 21, 221-229.	3.5	105
78	Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. American Journal of Gastroenterology, 2013, 108, 478-498.	0.2	1,413
79	Welcome to the Microgenderome. Science, 2013, 339, 1044-1045.	6.0	97
80	The startup bugs. Nature Biotechnology, 2013, 31, 279-281.	9.4	19

#	Article	IF	Citations
81	Translating the human microbiome. Nature Biotechnology, 2013, 31, 304-308.	9.4	30
82	Speculative strategies for new antibacterials: all roads should not lead to Rome. Journal of Antibiotics, 2013, 66, 371-386.	1.0	38
83	Medicines from microbiota. Nature Biotechnology, 2013, 31, 309-315.	9.4	135
84	If microbial ecosystem therapy can change your life, what's the problem?. BioEssays, 2013, 35, 508-512.	1.2	10
85	Ineffective delivery of diet-derived microRNAs to recipient animal organisms. RNA Biology, 2013, 10, 1107-1116.	1.5	198
86	Fecal Microbiota Transplantation â€" An Old Therapy Comes of Age. New England Journal of Medicine, 2013, 368, 474-475.	13.9	123
87	A gut prediction. Nature, 2013, 498, 48-49.	13.7	66
88	Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis. Expert Opinion on Pharmacotherapy, 2013, 14, 1529-1536.	0.9	7
89	Control of pathogens and pathobionts by the gut microbiota. Nature Immunology, 2013, 14, 685-690.	7.0	1,217
90	Influence of fermented milk products, prebiotics and probiotics on microbiota composition and health. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 139-155.	1.0	83
91	Fecal microbiota transplantation: a new standard treatment option forClostridium difficileinfection. Expert Review of Anti-Infective Therapy, 2013, 11, 447-449.	2.0	21
92	Probiotic strategies for treatment of respiratory diseases. Trends in Microbiology, 2013, 21, 485-492.	3.5	27
93	An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointestinal Endoscopy, 2013, 78, 240-249.	0.5	213
94	Therapy ofClostridium difficileinfection: perspectives on a changing paradigm. Expert Opinion on Pharmacotherapy, 2013, 14, 2375-2386.	0.9	5
96	The intricate association between gut microbiota and development of Type 1, Type 2 and Type 3 diabetes. Expert Review of Clinical Immunology, 2013, 9, 1031-1041.	1.3	66
97	Epidemiology of Clostridium difficile Infection. Journal of Pharmacy Practice, 2013, 26, 464-475.	0.5	201
98	Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates. Antimicrobial Agents and Chemotherapy, 2013, 57, 4872-4876.	1.4	64
99	Treatment ofClostridium difficileinfection: recent trial results. Clinical Investigation, 2013, 3, 875-886.	0.0	4

#	Article	IF	Citations
100	Artificial stool transplantation: progress towards a safer, more effective and acceptable alternative. Expert Review of Gastroenterology and Hepatology, 2013, 7, 291-293.	1.4	16
101	Clostridium difficileantibodies: a patent evaluation (WO2013028810). Expert Opinion on Therapeutic Patents, 2013, 23, 1635-1640.	2.4	2
103	When guests turn hostile. Nature, 2013, 494, 437-438.	13.7	3
104	Real or fakeâ€"faecal matter does the trick for recurrent CDI. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 129-129.	8.2	2
105	Duodenal Infusion of Feces for Recurrent Clostridium difficile. New England Journal of Medicine, 2013, 368, 2143-2145.	13.9	63
106	Human Microbiota and Pathogen-Associated Gastrointestinal Disease. , 2013, , 1-8.		0
107	ALS Untangled No. 21: Fecal transplants. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 482-485.	1.1	5
108	The Role of Probiotics and Prebiotics in Inducing Gut Immunity. Frontiers in Immunology, 2013, 4, 445.	2.2	197
109	Duodenal infusion of stool is more effective than vancomycin in patients with recurrentClostridium difficile. Evidence-Based Medicine, 2013, 18, 220-221.	0.6	2
112	Moving Fecal Microbiota Transplantation Into the Mainstream. Nutrition in Clinical Practice, 2013, 28, 589-598.	1.1	13
113	The intestinal microbiota and susceptibility to infection in immunocompromised patients. Current Opinion in Infectious Diseases, 2013, 26, 332-337.	1.3	114
114	Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection. Current Opinion in Gastroenterology, 2013, 29, 628-632.	1.0	28
115	Clostridium difficile. Current Opinion in Infectious Diseases, 2013, 26, 454-460.	1.3	9
116	Fecal transplantation. Current Opinion in Pediatrics, 2013, 25, 618-623.	1.0	3
117	Resolution of Severe Clostridium difficile Infection Following Sequential Fecal Microbiota Transplantation. Journal of Clinical Gastroenterology, 2013, 47, 735-737.	1.1	80
118	Evolutionary biology and anthropology suggest biome reconstitution as a necessary approach toward dealing with immune disorders. Evolution, Medicine and Public Health, 2013, 2013, 89-103.	1.1	63
119	Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial Diarrhea. Journal of Clinical Microbiology, 2013, 51, 2884-2892.	1.8	416
120	Cell-Based Therapeutics: The Next Pillar of Medicine. Science Translational Medicine, 2013, 5, 179ps7.	5.8	337

#	Article	IF	Citations
121	Ecological Modeling from Time-Series Inference: Insight into Dynamics and Stability of Intestinal Microbiota. PLoS Computational Biology, 2013, 9, e1003388.	1.5	487
122	Fecal Microbiota Transplantation and Emerging Treatments for Clostridium difficile Infection. Journal of Pharmacy Practice, 2013, 26, 498-505.	0.5	9
123	Dietary Inhibitors of Histone Deacetylases in Intestinal Immunity and Homeostasis. Frontiers in Immunology, 2013, 4, 226.	2.2	81
124	Clostridium difficile: New Challenges for an Old Foe. , 2013, , .		1
126	Presidential Practice of Dermatology. JAMA Dermatology, 2013, 149, 1032.	2.0	1
128	Hot topics in gut microbiota. United European Gastroenterology Journal, 2013, 1, 311-318.	1.6	50
130	The interplay between the gut microbiota and the immune system in the mechanism of type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 265-270.	1.2	25
131	Fecal transplantation for the treatment of recurrentClostridium difficileinfection. North American Journal of Medical Sciences, 2013, 5, 339.	1.7	21
132	Fecal microbiota transplantation: the state of the art. Gastroenterology Insights, 2013, 5, e13.	0.7	21
133	Analysis of the Intestinal Microbiome of a Recovered <i>Clostridium difficile</i> Patient after Fecal Transplantation. Digestion, 2013, 88, 243-251.	1.2	33
134	Fame and future of faecal transplantations â€“ developing nextâ€generation therapies with synthetic microbiomes. Microbial Biotechnology, 2013, 6, 316-325.	2.0	57
135	New guidance on the management of Clostridium difficile infection. The Prescriber, 2013, 24, 7-8.	0.1	3
136	Quantifying the impact of storage procedures for faecal bacteriotherapy in the critically endangered New Zealand Parrot, the Kakapo (Strigops habroptilus). Zoo Biology, 2013, 32, 620-625.	0.5	19
137	Overview of Clostridium difficile infection: implications for China. Gastroenterology Report, 2013, 1, 153-158.	0.6	11
138	The Human Gut Microbiome and Its Dysfunctions. Digestive Diseases, 2013, 31, 278-285.	0.8	65
139	Diagnosis of Clostridium difficile Infection: an Ongoing Conundrum for Clinicians and for Clinical Laboratories. Clinical Microbiology Reviews, 2013, 26, 604-630.	5.7	342
140	Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut, 2013, 62, 1505-1510.	6.1	387
141	Response to Tsai et al.. American Journal of Gastroenterology, 2013, 108, 1536-1537.	0.2	0

#	Article	IF	Citations
142	Response to Surawicz et al.. American Journal of Gastroenterology, 2013, 108, 1931-1932.	0.2	4
143	Fecal Microbiota Transplantation: Long-Term Safety Issues. American Journal of Gastroenterology, 2013, 108, 1537-1538.	0.2	9
144	A case for antibiotic perturbation of the microbiota leading to allergy development. Expert Review of Clinical Immunology, 2013, 9, 1019-1030.	1.3	31
145	Physician Outlook Toward Fecal Microbiota Transplantation in the Treatment of Clostridium difficile Infection. American Journal of Gastroenterology, 2013, 108, 1661-1662.	0.2	6
146	Fecal Microbiota Transplantation: A Novel Way to Treat Gastrointestinal Disorders. Alternative and Complementary Therapies, 2013, 19, 83-88.	0.1	1
147	The microbiome in inflammatory bowel disease and beyond. Clinical Medicine, 2013, 13, s29-s31.	0.8	0
148	Role of Fidaxomicin for the Treatment of Clostridium difficile Infection. Journal of Pharmacy Practice, 2013, 26, 491-497.	0.5	8
149	Clostridium difficile infection in older adults. Aging Health, 2013, 9, 403-414.	0.3	62
150	Cost-Effectiveness of Generic Antiretroviral Therapy. Annals of Internal Medicine, 2013, 158, 776.	2.0	3
151	Generic Antiretrovirals and HIV Care in the United States. Annals of Internal Medicine, 2013, 158, 777.	2.0	0
152	Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic. Beneficial Microbes, 2013, 4, 39-51.	1.0	52
153	Generic Antiretrovirals and HIV Care in the United States. Annals of Internal Medicine, 2013, 158, 777.	2.0	0
154	Fecal Microbiota Therapy for RecurrentClostridium difficileInfection in HIV-Infected Persons. Annals of Internal Medicine, 2013, 158, 779.	2.0	21
155	Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 2155-2165.	0.9	216
156	Medical Stool. Journal of Pediatric Gastroenterology and Nutrition, 2013, 56, 583-583.	0.9	0
157	Research Highlights: Highlights from the latest articles in personalized medicine. Personalized Medicine, 2013, 10, 231-233.	0.8	0
158	Safety, Tolerability, and Clinical Response After Fecal Transplantation in Children and Young Adults With Ulcerative Colitis. Journal of Pediatric Gastroenterology and Nutrition, 2013, 56, 597-601.	0.9	279
159	Fecal Transplant in Refractory Clostridium difficile Colitis. Deutsches Ärzteblatt International, 2013, 110, 108-15.	0.6	21

#	Article	IF	Citations
160	Emerging therapies for Clostridium difficile infection – focus on fidaxomicin. Infection and Drug Resistance, 2013, 6, 41.	1.1	22
161	Alternative Prostate Cancer Screening Strategies. Annals of Internal Medicine, 2013, 158, 778.	2.0	1
162	Cost-Effectiveness of Generic Antiretroviral Therapy. Annals of Internal Medicine, 2013, 158, 776.	2.0	5
163	Treatment Strategies for Recurrent Clostridium difficile Infection. Canadian Journal of Hospital Pharmacy, 2013, 66, 361-8.	0.1	21
164	Clostridium difficile and inflammatory bowel disease: Role in pathogenesis and implications in treatment. World Journal of Gastroenterology, 2013, 19, 7577.	1.4	133
165	Ancient Gut Microbiomes Shed Light on Modern Disease. Environmental Health Perspectives, 2013, 121, A118.	2.8	7
166	Prospects and challenges for intestinal microbiome therapy in pediatric gastrointestinal disorders. World Journal of Gastrointestinal Pathophysiology, 2013, 4, 91.	0.5	10
167	Fecal microbiota transplantation for severe enterocolonic fistulizing Crohnâ€™s disease. World Journal of Gastroenterology, 2013, 19, 7213.	1.4	102
168	Causes, consequences, and perspectives in the variations of intestinal density of colonization of multidrug-resistant enterobacteria. Frontiers in Microbiology, 2013, 4, 129.	1.5	33
169	Something Old, Something New, Something Borrowed.... Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 63-64.	0.7	4
170	Faecal transplants succeed in clinical trial. Nature, 2013, , .	13.7	1
171	Progress in the Discovery of Treatments for C. difficile Infection: A Clinical and Medicinal Chemistry Review. Current Topics in Medicinal Chemistry, 2013, 14, 152-175.	1.0	29
172	What's New in the Management of Bacterial Infections in the Era of Multidrug-Resistant Bacteria?. The Journal of the Korean Society for Transplantation, 2013, 27, 81.	0.2	3
173	Stability of Microbiota Facilitated by Host Immune Regulation: Informing Probiotic Strategies to Manage Amphibian Disease. PLoS ONE, 2014, 9, e87101.	1.1	64
174	Fecal Microbiota Transplantation for Gastrointestinal Diseases. Keio Journal of Medicine, 2014, 63, 69-74.	0.5	24
175	FDA faces regulatory challenges with new approaches to medicine. BMJ, The, 2014, 348, g1530-g1530.	3.0	2
176	Canadian Association of Gastroenterology Position Statement: Fecal Microbiota Transplant Therapy. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 66-68.	0.8	35
177	Efficacy and Safety of, and Patient Satisfaction with, Colonoscopic-Administered Fecal Microbiota Transplantation in Relapsing and Refractory Community- and Hospital-Acquired Clostridium difficile Infection. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 434-438.	0.8	27

#	Article	IF	Citations
178	Physician Attitudes toward the Use of Fecal Microbiota Transplantation for the Treatment of RecurrentClostridium difficileInfection. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 319-324.	0.8	41
179	Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis. World Journal of Gastroenterology, 2014, 20, 15163.	1.4	390
180	Cost-benefit relation of diet and probiotics in iatrogenic bowel irregularity (IBI). Frontiers in Pharmacology, 2014, 5, 14.	1.6	1
182	Policy: How to regulate faecal transplants. Nature, 2014, 506, 290-291.	13.7	125
183	Clostridium Difficile Infection. Deutsches Ärzteblatt International, 2014, 111, 723-31.	0.6	70
184	The microbiome revolution. Journal of Clinical Investigation, 2014, 124, 4162-4165.	3.9	233
185	Clostridium difficilein Children: To Treat or Not to Treat?. Pediatric Gastroenterology, Hepatology and Nutrition, 2014, 17, 80.	0.4	20
186	Probiotics as a Strategy to Improve Overall Human Health in Developing Countries. Journal of Probiotics & Health, 2014, 02, .	0.6	0
187	A Mathematical Model to Evaluate the Routine Use of Fecal Microbiota Transplantation to Prevent Incident and Recurrent Clostridium difficile Infection. Infection Control and Hospital Epidemiology, 2014, 35, 18-27.	1.0	30
188	Patience is a Virtue: An Argument for Delayed Surgical Intervention in Fulminant Clostridium difficile Colitis. American Surgeon, 2014, 80, 614-619.	0.4	10
190	Restoring the gut microbiome for the treatment of inflammatory bowel diseases. World Journal of Gastroenterology, 2014, 20, 3468.	1.4	32
191	Clostridium difficileInfection: A Worldwide Disease. Gut and Liver, 2014, 8, 1-6.	1.4	247
192	Tipping elements in the human intestinal ecosystem. Nature Communications, 2014, 5, 4344.	5.8	217
193	Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Therapeutic Advances in Chronic Disease, 2014, 5, 69-84.	1.1	53
194	Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. Expert Review of Anti-Infective Therapy, 2014, 12, 565-580.	2.0	76
195	The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection. Clinical Microbiology and Infection, 2014, 20, 1119-1125.	2.8	36
196	Clostridium difficile infection: current, forgotten and emerging treatment options. Journal of Comparative Effectiveness Research, 2014, 3, 547-557.	0.6	4
197	Microbiome manipulation modifies sex-specific risk for autoimmunity. Gut Microbes, 2014, 5, 485-493.	4.3	65

#	Article	IF	Citations
198	Clinical update for the diagnosis and treatment ofClostridium difficileinfection. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2014, 5, 1.	0.6	62
199	Microbial sequencing to improve individual and population health. Genome Medicine, 2014, 6, 103.	3.6	3
201	Clostridium difficile infection: management strategies for a difficult disease. Therapeutic Advances in Gastroenterology, 2014, 7, 72-86.	1.4	38
202	In this issue ofGut Microbes. Gut Microbes, 2014, 5, 83-85.	4.3	0
203	Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?. Proceedings of the Nutrition Society, 2014, 73, 490-497.	0.4	34
204	The potential for emerging therapeutic options forClostridium difficileinfection. Gut Microbes, 2014, 5, 696-710.	4.3	33
205	Therapeutic Modulation and Reestablishment of the Intestinal Microbiota With Fecal Microbiota Transplantation Resolves Sepsis and Diarrhea in a Patient. American Journal of Gastroenterology, 2014, 109, 1832-1834.	0.2	46
206	Response to Gorbach et al.. American Journal of Gastroenterology, 2014, 109, 1684-1685.	0.2	0
207	Faecal microbiota transplantation: from practice to legislation before considering industrialization. Clinical Microbiology and Infection, 2014, 20, 1112-1118.	2.8	26
208	Faecal transplantation and infectious diseases practitioners. Clinical Microbiology and Infection, 2014, 20, 1097.	2.8	2
209	A 10-Patient Case Study on the Influence of Two Different Probiotics on Individual Intestinal Microbiota. Journal of Alternative and Complementary Medicine, 2014, 20, 800-803.	2.1	4
210	Significant publications on infectious diseases pharmacotherapy in 2013. American Journal of Health-System Pharmacy, 2014, 71, 1974-1988.	0.5	10
211	Fecal Transplantation Treatment of Antibiotic-Induced, Noninfectious Colitis and Long-Term Microbiota Follow-Up. Case Reports in Medicine, 2014, 2014, 1-7.	0.3	37
212	Fecal Microbiota Transplantation in Inflammatory Bowel Disease. Medicine (United States), 2014, 93, e97.	0.4	77
213	Proceed with caution. Nature Reviews Microbiology, 2014, 12, 149-149.	13.6	0
217	Could fecal microbiota transplantation cure all Clostridium difficile infections?. Future Microbiology, 2014, 9, 1-3.	1.0	12
218	Should We Be Treating the Bugs instead of Cytokines and T Cells?. Digestive Diseases, 2014, 32, 403-409.	0.8	10
219	Practical implementation of faecal transplantation. Clinical Microbiology and Infection, 2014, 20, 1098-1105.	2.8	14

#	Article	IF	Citations
220	Comment on â€œIntestinal Inflammation Modulates Expression of the Iron-Regulating Hormone Hepcidin Depending on Erythropoietic Activity and the Commensal Microbiotaâ€• Journal of Immunology, 2014, 193, 5763.1-5763.	0.4	0
221	InfecciÃ³n por clostridium difficile: epidemiologÃa, diagnÃ³stico y estrategias terapÃ©uticas. Revista MÃ©dica ClÃnica Las Condes, 2014, 25, 473-484.	0.2	4
222	Faecal microbiota transplantation. Drug and Therapeutics Bulletin, 2014, 52, 141-144.	0.3	6
223	The Impact of Microbiota on Brain and Behavior: Mechanisms & Therapeutic Potential. Advances in Experimental Medicine and Biology, 2014, 817, 373-403.	0.8	247
224	Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn's and Colitis, 2014, 8, 1569-1581.	0.6	388
225	The Enteric Two-Step: nutritional strategies of bacterial pathogens within the gut. Cellular Microbiology, 2014, 16, 993-1003.	1.1	37
226	Rural and urban microbiota. Gut Microbes, 2014, 5, 351-356.	4.3	34
227	Bacterial spore-formers: friends and foes. FEMS Microbiology Letters, 2014, 358, 107-109.	0.7	7
228	Evaluation of TNM Status Changes Between the First Two CT Scans in Patients With Pancreatic Cancer. American Journal of Gastroenterology, 2014, 109, 1834-1835.	0.2	0
229	Faecal microbiota transplantation. British Journal of Surgery, 2014, 101, 887-888.	0.1	7
230	The chicken gastrointestinal microbiome. FEMS Microbiology Letters, 2014, 360, 100-112.	0.7	521
231	Faecal microbiota transplantation for Clostridium difficile infection. International Journal of Clinical Practice, 2014, 68, 363-368.	0.8	24
232	Gut Microbiota-Produced Succinate Promotes C.Âdifficile Infection after Antibiotic Treatment or Motility Disturbance. Cell Host and Microbe, 2014, 16, 770-777.	5.1	310
233	The role of the gut and microbes in the pathogenesis of spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 687-702.	1.4	87
234	Basic and clinical research in the AMC Renal Transplant Unit. Transplant Immunology, 2014, 31, 210-212.	0.6	0
237	The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre. Proceedings of the Nutrition Society, 2014, 73, 452-456.	0.4	8
238	Relapsing and Refractory Ulcerative Colitis in Children. Digestive Diseases, 2014, 32, 419-426.	0.8	10
239	Fecal Microbial Therapy. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 157-161.	0.9	15

#	Article	IF	Citations
240	Towards the determination of the nutritional needs of the body and its microbiome in sickness and in health. Current Opinion in Gastroenterology, 2014, 30, 175-177.	1.0	3
241	Therapeutic faecal microbiota transplantation. Current Opinion in Gastroenterology, 2014, 30, 97-105.	1.0	101
242	Fecal microbiota transplantation. Current Opinion in Gastroenterology, 2014, 30, 34-39.	1.0	83
243	Patients With Recalcitrant Clostridium difficileâ€“Associated Diarrhea Treated Successfully With Fidaxomicin. Infectious Diseases in Clinical Practice, 2014, 22, 92-95.	0.1	2
244	Fecal Transplant for Recurrent Clostridium difficile Infection in Children With and Without Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 588-592.	0.9	60
245	20 Things You Didnâ€™t Know About the Human Gut Microbiome. Journal of Cardiovascular Nursing, 2014, 29, 479-481.	0.6	12
246	Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia. Gut Microbes, 2014, 5, 333-339.	4.3	182
247	Effect of diet on the intestinal microbiota and its activity. Current Opinion in Gastroenterology, 2014, 30, 189-195.	1.0	74
248	Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2014, 48, 693-702.	1.1	375
249	The changing epidemiology of Clostridium difficile infection. Current Opinion in Gastroenterology, 2014, 30, 54-62.	1.0	50
250	Fecal microbiota transplantation for Clostridium difficile infection. Current Opinion in Gastroenterology, 2014, 30, 47-53.	1.0	27
251	Opportunistic Infections Due to Inflammatory Bowel Disease Therapy. Inflammatory Bowel Diseases, 2014, 20, 196-212.	0.9	105
252	The Microbiome and Diverticulitis. Diseases of the Colon and Rectum, 2014, 57, 544-545.	0.7	5
253	Irritable bowel syndrome, inflammatory bowel disease and the microbiome. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 15-21.	1.2	73
254	Clostridium difficile infection in solid organ transplant recipients. Current Opinion in Infectious Diseases, 2014, 27, 336-341.	1.3	14
255	Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies. Open Forum Infectious Diseases, 2014, 1, ofu069.	0.4	41
256	Tempered Enthusiasm for Fecal Transplantation?. Clinical Infectious Diseases, 2014, 59, 1348-1349.	2.9	8
257	Non-pulmonary Infectious Complications. Respiratory Medicine, 2014, , 135-163.	0.1	0

#	Article	IF	Citations
259	Identifying Gut Microbeâ€“Host Phenotype Relationships Using Combinatorial Communities in Gnotobiotic Mice. Science Translational Medicine, 2014, 6, 220ra11.	5.8	325
260	Exploring the influence of the gut microbiota and probiotics on health: a symposium report. British Journal of Nutrition, 2014, 112, S1-S18.	1.2	81
261	Clostridium difficile Infection: Clinical Challenges and Management Strategies. Critical Care Nurse, 2014, 34, 24-33.	0.5	16
262	The Gut Microbiota and Effects on Metabolism. , 2014, , 508-526.		4
263	Oral, Capsulized, Frozen Fecal Microbiota Transplantation for RelapsingClostridium difficileInfection. JAMA - Journal of the American Medical Association, 2014, 312, 1772.	3.8	554
265	Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective. World Journal of Gastroenterology, 2014, 20, 17737-17745.	1.4	143
266	Reply to Krause et al. Clinical Infectious Diseases, 2014, 59, 1349-1349.	2.9	3
267	Irritable bowel syndrome: A microbiome-gut-brain axis disorder?. World Journal of Gastroenterology, 2014, 20, 14105.	1.4	249
268	Role of Microbiota and Innate Immunity in RecurrentClostridium difficileInfection. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	43
269	Diet, the Gut Microbiome and the Metabolome in IBD. Nestle Nutrition Institute Workshop Series, 2014, 79, 73-82.	1.5	18
270	Fecal Microbiota Transplantation: An Interest in IBD?. Nestle Nutrition Institute Workshop Series, 2014, 79, 101-114.	1.5	1
271	Fecal Microbiota Transplantation Inducing Remission in Crohnâ€™s Colitis and the Associated Changes in Fecal Microbial Profile. Journal of Clinical Gastroenterology, 2014, 48, 625-628.	1.1	76
272	Intestinal Microbial Variation May Predict Early Acute Rejection after Liver Transplantation in Rats. Transplantation, 2014, 98, 844-852.	0.5	82
273	Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Clinical Microbiology and Infection, 2014, 20, 1343-1351.	2.8	40
274	Redefining the gut as the motor of critical illness. Trends in Molecular Medicine, 2014, 20, 214-223.	3.5	243
275	Donor fecal transfer for recurrent Clostridium difficile-associated diarrhea in heart transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 551-553.	0.3	16
276	Does the change on gastrointestinal tract microbiome affects host?. Brazilian Journal of Infectious Diseases, 2014, 18, 660-663.	0.3	4
278	Clostridium difficile infection and gut microbiota. Seminars in Colon and Rectal Surgery, 2014, 25, 124-127.	0.2	3

#	Article	IF	Citations
279	The dynamic microbiome. FEBS Letters, 2014, 588, 4131-4139.	1.3	173
280	The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead. Gastroenterology, 2014, 146, 1489-1499.	0.6	1,374
281	A Clinician's Primer on the Role of the Microbiome in Human Health and Disease. Mayo Clinic Proceedings, 2014, 89, 107-114.	1.4	187
282	Commensal bacteria mediated defenses against pathogens. Current Opinion in Immunology, 2014, 29, 16-22.	2.4	115
283	The More the Merrier? Reduced Fecal Microbiota Diversity in Preterm Infants Treated with Antibiotics. Journal of Pediatrics, 2014, 165, 8-10.	0.9	19
285	Clostridium Difficile Infection in Patients with Acute Myelogenous Leukemia and in Patients Undergoing Allogeneic Stem Cell Transplantation: Epidemiology and Risk Factor Analysis. Biology of Blood and Marrow Transplantation, 2014, 20, 823-828.	2.0	47
286	Efficacy of Combined Jejunal and Colonic Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Clinical Gastroenterology and Hepatology, 2014, 12, 1572-1576.	2.4	74
287	Treatment of recurrent Clostridium difficile infection: a systematic review. Infection, 2014, 42, 43-59.	2.3	68
289	Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis. Clinical Infectious Diseases, 2014, 58, 1507-1514.	2.9	128
290	Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radical Biology and Medicine, 2014, 68, 122-133.	1.3	147
291	Microbial composition analysis ofClostridium difficileinfections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations. Journal of Crohn's and Colitis, 2014, 8, 1133-1137.	0.6	21
292	Role of â€œWestern Dietâ€•in Inflammatory Autoimmune Diseases. Current Allergy and Asthma Reports, 2014, 14, 404.	2.4	341
295	Harnessing Microbiota to Kill a Pathogen: The sweet tooth of Clostridium difficile. Nature Medicine, 2014, 20, 248-249.	15.2	18
296	Clostridium difficile enteritis: A new role for an old foe. Journal of the Royal College of Surgeons of Edinburgh, 2014, 12, 256-262.	0.8	10
297	Harnessing Microbiota to Kill a Pathogen: Fixing the microbiota to treat Clostridium difficile infections. Nature Medicine, 2014, 20, 246-247.	15.2	42
298	Role of the Microbiota in Immunity and Inflammation. Cell, 2014, 157, 121-141.	13.5	3,494
299	Future directions in inflammatory bowel disease management. Journal of Crohn's and Colitis, 2014, 8, 726-734.	0.6	90
300	Relationship between gut microbiota and development of T cell associated disease. FEBS Letters, 2014, 588, 4195-4206.	1.3	84

#	Article	IF	Citations
301	Identification and Characterization of a Gene Cluster Required for Proper Rod Shape, Cell Division, and Pathogenesis in Clostridium difficile. Journal of Bacteriology, 2014, 196, 2290-2300.	1.0	44
302	AGA's Approach to the Microbiome. Gastroenterology, 2014, 146, 1119-1121.	0.6	4
303	Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study. Clinical Infectious Diseases, 2014, 58, 1515-1522.	2.9	397
304	The Gut Microbiome in Health and Disease. Gastroenterology, 2014, 146, 1433-1436.	0.6	60
305	What Nurses Need to Know About Fecal Microbiota Transplantation: Education, Assessment, and Care for Children and Young Adults. Journal of Pediatric Nursing, 2014, 29, 354-361.	0.7	7
306	AGA's Approach to the Microbiome. Clinical Gastroenterology and Hepatology, 2014, 12, 537-539.	2.4	0
307	Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?. Internal and Emergency Medicine, 2014, 9, 365-373.	1.0	98
308	Les probiotiques et leur place en mÃ©decine humaine. Journal Des Anti-infectieux, 2014, 16, 33-43.	0.1	5
309	Exploring & exploiting our â€˜other selfâ€™ â€“ Does the microbiota hold the key to the future therapy in Crohn's?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 399-409.	1.0	12
310	The Fire Within: Microbes Inflame Tumors. Cell, 2014, 157, 776-783.	13.5	133
311	Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist. Lancet Oncology, The, 2014, 15, e139-e147.	5.1	101
313	Fecal Microbiota Transplantation in the Treatment of Clostridium difficile Infections. American Journal of Medicine, 2014, 127, 479-483.	0.6	68
314	A Review of the Economics of Treating Clostridium difficile Infection. Pharmacoeconomics, 2014, 32, 639-650.	1.7	25
315	The microbiome: stress, health and disease. Mammalian Genome, 2014, 25, 49-74.	1.0	361
316	Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: A retrospective evaluation of 31 patients. Scandinavian Journal of Infectious Diseases, 2014, 46, 89-97.	1.5	52
317	Fecal Microbiota Transplantation: A Practical Update for the Infectious Disease Specialist. Clinical Infectious Diseases, 2014, 58, 541-545.	2.9	63
318	European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection. Clinical Microbiology and Infection, 2014, 20, 1-26.	2.8	931
319	A discrete genetic locus confers xyloglucan metabolism in select human gut Bacteroidetes. Nature, 2014, 506, 498-502.	13.7	400

#	Article	IF	Citations
320	Mechanisms of Obesity-Induced Gastrointestinal Neoplasia. Gastroenterology, 2014, 146, 357-373.	0.6	157
321	The Microbiome and Psoriatic Arthritis. Current Rheumatology Reports, 2014, 16, 407.	2.1	67
322	Clostridium difficile: Deleterious Impact on Hematopoietic Stem Cell Transplantation. Current Hematologic Malignancy Reports, 2014, 9, 85-90.	1.2	18
323	Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns. Mucosal Immunology, 2014, 7, 210-214.	2.7	101
324	Impact of Diet on Human Intestinal Microbiota and Health. Annual Review of Food Science and Technology, 2014, 5, 239-262.	5.1	173
325	From Stool Transplants to Next-Generation Microbiota Therapeutics. Gastroenterology, 2014, 146, 1573-1582.	0.6	168
326	Acute Inflammatory Surgical Disease. Surgical Clinics of North America, 2014, 94, 1-30.	0.5	17
327	Clostridium difficile recurrence is characterized by pro-inflammatory peripheral blood mononuclear cell (PBMC) phenotype. Journal of Medical Microbiology, 2014, 63, 1260-1273.	0.7	19
328	Human Genetics Shape the Gut Microbiome. Cell, 2014, 159, 789-799.	13.5	2,523
329	Diet-Microbiota-Health Interactions in Older Subjects: Implications for Healthy Aging. Interdisciplinary Topics in Gerontology, 2014, 40, 141-154.	3.6	27
330	Faecal microbiota transplantationâ€"the Austrian approach. Clinical Microbiology and Infection, 2014, 20, 1106-1111.	2.8	18
331	The bacteriomeâ€“mycobiome interaction and antifungal host defense. European Journal of Immunology, 2014, 44, 3182-3191.	1.6	96
333	Clostridium difficile Infection Update for the Hospital-Based Physician. Current Emergency and Hospital Medicine Reports, 2014, 2, 214-223.	0.6	0
334	Conservation and stewardship of the human microbiome. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14312-14313.	3.3	21
335	Review of the Emerging Treatment of Clostridium difficile Infection with Fecal Microbiota Transplantation and Insights into Future Challenges. Clinics in Laboratory Medicine, 2014, 34, 787-798.	0.7	31
336	Recovery of the Gut Microbiome following Fecal Microbiota Transplantation. MBio, 2014, 5, e00893-14.	1.8	267
337	Microbiota transplantation restores normal fecal bile acid composition in recurrentClostridium difficileinfection. American Journal of Physiology - Renal Physiology, 2014, 306, G310-G319.	1.6	341
338	Linking genetic variation in human Toll-like receptor 5 genes to the gut microbiome's potential to cause inflammation. Immunology Letters, 2014, 162, 3-9.	1.1	26

#	Article	IF	Citations
339	Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. Journal of Antimicrobial Chemotherapy, 2014, 69, 2901-2912.	1.3	73
340	Recurrent Clostridium difficile infection: The scope of the problem and management decisions. Seminars in Colon and Rectal Surgery, 2014, 25, 158-162.	0.2	1
341	Infectious Diarrhea: An Overview. Current Gastroenterology Reports, 2014, 16, 399.	1.1	30
342	Gastrointestinal Colonization with a Cephalosporinase-Producing Bacteroides Species Preserves Colonization Resistance against Vancomycin-Resistant Enterococcus and Clostridium difficile in Cephalosporin-Treated Mice. Antimicrobial Agents and Chemotherapy, 2014, 58, 4535-4542.	1.4	26
343	Clostridium difficile Infection: Update on Diagnosis, Epidemiology, and Treatment Strategies. Surgical Infections, 2014, 15, 490-502.	0.7	34
344	Update on Clostridium difficile infections. MÃ©decine Et Maladies Infectieuses, 2014, 44, 354-365.	5.1	17
345	Clostridium difficileinfection: molecular pathogenesis and novel therapeutics. Expert Review of Anti-Infective Therapy, 2014, 12, 131-150.	2.0	99
346	Clostridium difficile infection in diabetes. Diabetes Research and Clinical Practice, 2014, 105, 285-294.	1.1	24
347	Chemoprevention in Gastrointestinal Physiology and Disease. Natural products and microbiome. American Journal of Physiology - Renal Physiology, 2014, 307, G1-G15.	1.6	49
348	The intestinal microbiome in type 1 diabetes. Clinical and Experimental Immunology, 2014, 177, 30-37.	1.1	94
349	Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME Journal, 2014, 8, 1621-1633.	4.4	172
350	Journal Roundup. Journal of Hospital Infection, 2014, 87, 249-250.	1.4	0
351	Microbial Modulation of Insulin Sensitivity. Cell Metabolism, 2014, 20, 753-760.	7.2	215
352	Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Alimentary Pharmacology and Therapeutics, 2014, 39, 1003-1032.	1.9	130
353	Diet-Derived MicroRNAs: Separating the Dream from Reality. MicroRNA Diagnostics and Therapeutics, 2014, 1, .	0.0	6
354	Harnessing the Intestinal Microbiome for Optimal Therapeutic Immunomodulation. Cancer Research, 2014, 74, 4217-4221.	0.4	39
355	Case 25-2014. New England Journal of Medicine, 2014, 371, 668-675.	13.9	69
356	Starving our Microbial Self: The Deleterious Consequences of a Diet Deficient in Microbiota-Accessible Carbohydrates. Cell Metabolism, 2014, 20, 779-786.	7.2	614

#	Article	IF	Citations
357	Developing human gut microbiota as a class of therapeutics. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 79-80.	8.2	15
358	Intestinal decontamination of multidrug-resistant Klebsiella pneumoniae after recurrent infections in an immunocompromised host. Diagnostic Microbiology and Infectious Disease, 2014, 80, 87-89.	0.8	13
360	The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1425-1428.	1.3	97
361	Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome, 2014, 2, 13.	4.9	98
362	Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health. Annual Review of Pharmacology and Toxicology, 2014, 54, 559-580.	4.2	37
363	Donor feces infusion for eradication of Extended Spectrum beta-Lactamase producing Escherichia coli in a patient with end stage renal disease. Clinical Microbiology and Infection, 2014, 20, O977-O978.	2.8	93
364	The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 506-514.	8.2	5,773
365	Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease. Advances in Experimental Medicine and Biology, 2014, , .	0.8	59
366	Fecal Microbiota Therapy: Ready for Prime Time?. Infection Control and Hospital Epidemiology, 2014, 35, 28-30.	1.0	7
368	The Microbiota: A New Player in the Etiology of Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 1-8.	1.0	2
369	Managing Clostridium difficile in Inflammatory Bowel Disease (IBD). Current Gastroenterology Reports, 2014, 16, 393.	1.1	20
370	Fecal microbiota transplantation for management of Clostridium difficile infection. Indian Journal of Gastroenterology, 2014, 33, 301-307.	0.7	6
371	Navigating the Pediatric Microbiome: Emerging Evidence and Clinical Implications. Current Pediatrics Reports, 2014, 2, 93-101.	1.7	2
372	Pediatric Fecal Microbiota Transplantation. Current Pediatrics Reports, 2014, 2, 227-234.	1.7	2
373	Probiotic manipulation of the chronic rhinosinusitis microbiome. International Forum of Allergy and Rhinology, 2014, 4, 309-314.	1.5	60
374	Fecal transplantation poses dilemma for FDA. Nature Biotechnology, 2014, 32, 401-402.	9.4	18
375	The Microbiota, the Immune System and the Allograft. American Journal of Transplantation, 2014, 14, 1236-1248.	2.6	53
376	Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1344-1355.	1.4	20

#	Article	IF	Citations
377	Emergence of fecal microbiota transplantation as an approach to repair disrupted microbial gut ecology. Immunology Letters, 2014, 162, 77-81.	1.1	38
378	Clostridium Difficile Infection. Surgical Clinics of North America, 2014, 94, 1335-1349.	0.5	27
379	Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients. American Journal of Gastroenterology, 2014, 109, 1065-1071.	0.2	546
380	The Power of Poop: Patients Getting Ahead of Their Doctors Using Self-Administered Fecal Transplants. American Journal of Gastroenterology, 2014, 109, 777-778.	0.2	10
381	What Is the Value of a Food and Drug Administration Investigational New Drug Application for Fecal Microbiota Transplantation to Treat Clostridium difficile Infection?. Clinical Gastroenterology and Hepatology, 2014, 12, 289-291.	2.4	18
382	Fecal microbiota transplantation for Clostridium difficile infection: A surgeon×3s perspective. Seminars in Colon and Rectal Surgery, 2014, 25, 163-166.	0.2	1
383	Emerging insights on intestinal dysbiosis during bacterial infections. Current Opinion in Microbiology, 2014, 17, 67-74.	2.3	94
384	Metabolic self-destruction in critically ill patients: Origins, mechanisms and therapeutic principles. Nutrition, 2014, 30, 261-267.	1.1	50
385	Faecal transplantation for the treatment of Clostridium difficile infection: a review. International Journal of Antimicrobial Agents, 2014, 43, 201-206.	1.1	17
386	Faecal transplantation for Clostridium difficile infection. Three cases treated in Italy. Digestive and Liver Disease, 2014, 46, 475.	0.4	6
387	A patient with severe Crohn's colitis responds to Faecal Microbiota Transplantation. Journal of Crohn's and Colitis, 2014, 8, 256-257.	0.6	44
389	Guidance on Preparing an Investigational New Drug Application for Fecal Microbiota Transplantation Studies. Clinical Gastroenterology and Hepatology, 2014, 12, 283-288.	2.4	61
390	Is co-prescribing a multi-strain probiotic the solution for treating and preventing proton pump inhibitor (PPIs) induced Clostridium difficile associated diarrhoea (CDAD) while maintaining evidence based pharmacotherapy?. Advances in Integrative Medicine, 2014, 1, 52-54.	0.4	0
391	Gastrointestinal Tract Microbiota and Probiotics in Production Animals. Annual Review of Animal Biosciences, 2014, 2, 469-486.	3.6	158
392	Faecal microbiota transplantation: A sui generis biological drug, not a tissue. Annales Pharmaceutiques Francaises, 2014, 72, 217-220.	0.4	15
393	Clinical pearls in gastroenterology (2013). Disease-a-Month, 2014, 60, 345-353.	0.4	0
395	Staggered and Tapered Antibiotic Withdrawal With Administration of Kefir for Recurrent Clostridium difficile Infection. Clinical Infectious Diseases, 2014, 59, 858-861.	2.9	41
396	Clinical pearls in infectious diseases. Disease-a-Month, 2014, 60, 394-401.	0.4	0

#	Article	IF	Citations
397	Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective. Cellular and Molecular Life Sciences, 2014, 71, 183-203.	2.4	265
398	Deciphering the tÃªte-Ã-tÃªte between the microbiota and the immune system. Journal of Clinical Investigation, 2014, 124, 4197-203.	3.9	89
399	Clostridium difficile and the microbiota. Journal of Clinical Investigation, 2014, 124, 4182-4189.	3.9	200
400	RecurrentClostridium difficileinfections: The importance of the intestinal microbiota. World Journal of Gastroenterology, 2014, 20, 7416.	1.4	42
401	Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years?. World Journal of Gastroenterology, 2014, 20, 1192.	1.4	293
402	Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 14805.	1.4	97
403	Dangerous Ideas: resistant superbugs and the potential of the microbiome. British Journal of General Practice, 2014, 64, 637-637.	0.7	0
404	Use of gnotobiotic mice to identify and characterize key microbes responsible for the development of the intestinal immune system. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2014, 90, 313-332.	1.6	21
405	Increased Gut Permeability and Microbiota Change Associate with Mesenteric Fat Infl ammation and Metabolic Dysfunction in Diet-Induced Obese Mice. , 2014, , 77-102.		0
408	Mechanisms, Prevention and Management of Diarrhoea in Enteral Nutrition. , 2014, , 285-300.		0
409	Manipulation of the Host-Cell Pathways by Bacterial Enteropathogens. , 2014, , 148-172.		0
410	Timing and type of surgical treatment of Clostridium difficileâ€“associated disease. Journal of Trauma and Acute Care Surgery, 2014, 76, 1484-1493.	1.1	52
411	Clostridium difficile Infection Is on the Rise. American Journal of Nursing, 2014, 114, 62-67.	0.2	1
412	Response to Comment on â€œIntestinal Inflammation Modulates Expression of the Iron-Regulating Hormone Hepcidin Depending on Erythropoietic Activity and the Commensal Microbiotaâ€. Journal of Immunology, 2014, 193, 5763.2-5763.	0.4	0
413	Microbes and Allogeneic Transplantation. Transplantation, 2014, 97, 5-11.	0.5	17
414	Fecal Microbiota Transplantation. Journal of Clinical Gastroenterology, 2014, 48, S80-S84.	1.1	33
416	Identification of Recurrent Clostridium difficile Infection Using Administrative Codes: Accuracy and Implications for Surveillance. Infection Control and Hospital Epidemiology, 2015, 36, 893-898.	1.0	8
417	Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015. GE Portuguese Journal of Gastroenterology, 2015, 22, 259-267.	0.3	4

#	Article	IF	Citations
418	Approaches and developments in studying the human microbiome network. Israel Journal of Ecology and Evolution, 2015, 61, 90-94.	0.2	1
419	Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Alimentary Pharmacology and Therapeutics, 2015, 41, 835-843.	1.9	467
421	Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular Diseases. Circulation Journal, 2015, 79, 1882-1890.	0.7	57
422	Transplanting fresh donor faeces to cure symptomatic relapsingClostridium difficileinfection: a literature review. Gastrointestinal Nursing, 2015, 13, 48-54.	0.0	0
423	Application of density gradient for the isolation of the fecal microbial stool component and the potential use thereof. Scientific Reports, 2015, 5, 16807.	1.6	44
424	Fecal microbiota transplantation. Medicina Universitaria, 2015, 17, 192-194.	0.1	0
425	GI Surgery Annual. GI Surgery Annual, 2015, , .	0.0	0
429	Indole â€“ the scent of a healthy â€˜inner soilâ€™. Microbial Ecology in Health and Disease, 2015, 26, 27997.	3.8	21
430	Donor Recruitment for Fecal Microbiota Transplantation. Inflammatory Bowel Diseases, 2015, 21, 1600-1606.	0.9	122
432	Treating Clostridium difficile infections: Should fecal microbiota transplantation be reclassified from investigational drug to human tissue?. Contemporary Clinical Trials Communications, 2015, 1, 39-41.	0.5	0
433	WSES guidelines for management of Clostridium difficile infection in surgical patients. World Journal of Emergency Surgery, 2015, 10, 38.	2.1	78
434	Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of <scp>C</scp>lostridium difficile Infection. Pharmacotherapy, 2015, 35, 1016-1025.	1.2	30
435	Modeling the Context-Dependent Associations between the Gut Microbiome, Its Environment, and Host Health. MBio, 2015, 6, e01367-15.	1.8	2
436	Optimal screening and donor management in a public stool bank. Microbiome, 2015, 3, 75.	4.9	41
437	Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 741-752.	1.9	83
438	Faecal microbiota transplant for recurrentClostridium difficileinfection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Alimentary Pharmacology and Therapeutics, 2015, 42, 1011-1018.	1.9	104
439	Effect of Colchicine on Clostridium Difficile Infection Incidence, Recurrence, and Severity. Infectious Diseases in Clinical Practice, 2015, 23, 141-147.	0.1	1
440	Antibioticâ€associated diarrhea and the older dental patient: how do dentists respond?. Special Care in Dentistry, 2015, 35, 279-284.	0.4	0

#	Article	IF	Citations
441	Gut Microbiota and Energy Expenditure in Health and Obesity. Journal of Clinical Gastroenterology, 2015, 49, S13-S19.	1.1	22
442	Reciprocal interaction of diet and microbiome in inflammatory bowel diseases. Current Opinion in Gastroenterology, 2015, 31, 464-470.	1.0	31
443	Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World Journal of Gastroenterology, 2015, 21, 5359.	1.4	204
444	Microbiome as mediator: Do systemic infections start in the gut?. World Journal of Gastroenterology, 2015, 21, 10487.	1.4	31
445	A Survey Using the Social Networks Revealed Poor Knowledge on Fecal Microbiota Transplantation. Journal of Neurogastroenterology and Motility, 2015, 21, 294-295.	0.8	2
446	Intestinal Microbiota as Modulators of the Immune System. Journal of Immunology Research, 2015, 2015, 1-4.	0.9	19
448	Ecology and Evolution of the Human Microbiota: Fire, Farming and Antibiotics. Genes, 2015, 6, 841-857.	1.0	61
449	Antibiotic-associated diarrhea. , 0, , 349-351.		3
450	Low Awareness but Positive Attitudes Toward Fecal Transplantation in Ontario Physicians. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 30-32.	0.7	5
451	Emerging and Reemerging Infectious Disease Threats. , 2015, , 158-177.e6.		17
452	Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis. Frontiers in Microbiology, 2015, 6, 692.	1.5	83
453	Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection. Antibiotics, 2015, 4, 230-253.	1.5	53
454	Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond. Antibiotics, 2015, 4, 254-266.	1.5	7
455	Colonization Resistance of the Gut Microbiota against Clostridium difficile. Antibiotics, 2015, 4, 337-357.	1.5	60
456	A Review of Management of Clostridium difficile Infection: Primary and Recurrence. Antibiotics, 2015, 4, 411-423.	1.5	9
457	An Integrated Outlook on the Metagenome and Metabolome of Intestinal Diseases. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	8
458	Mechanisms of Microbeâ€“Host Interaction in Crohnâ€™s Disease: Dysbiosis vs. Pathobiont Selection. Frontiers in Immunology, 2015, 6, 555.	2.2	83
459	Nutritional Keys for Intestinal Barrier Modulation. Frontiers in Immunology, 2015, 6, 612.	2.2	156

#	Article	IF	Citations
460	Fecal microbiota transplantation: current clinical efficacy and future prospects. Clinical and Experimental Gastroenterology, 2015, 8, 285.	1.0	32
462	Low Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis. PLoS ONE, 2015, 10, e0133925.	1.1	58
463	Distinct but Spatially Overlapping Intestinal Niches for Vancomycin-Resistant Enterococcus faecium and Carbapenem-Resistant Klebsiella pneumoniae. PLoS Pathogens, 2015, 11, e1005132.	2.1	100
464	Gut Microbiota and Metabolic Disorders. Diabetes and Metabolism Journal, 2015, 39, 198.	1.8	182
465	Regulation of intestinal Th17 and Treg cells by gut microbiota. Inflammation and Regeneration, 2015, 35, 099-105.	1.5	2
466	Slipping through the Cracks: Linking Low Immune Function and Intestinal Bacterial Imbalance to the Etiology of Rheumatoid Arthritis. Autoimmune Diseases, 2015, 2015, 1-12.	2.7	9
467	Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease. Gastroenterology Research and Practice, 2015, 2015, 1-5.	0.7	81
468	Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. World Journal of Hepatology, 2015, 7, 1679.	0.8	27
469	IBS-like symptoms in patients with ulcerative colitis. Clinical and Experimental Gastroenterology, 2015, 8, 101.	1.0	31
470	Fecal Microbiota Transplantation for Treatment of Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2015, 49, 171-172.	1.1	1
471	Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents. Journal of Medicinal Chemistry, 2015, 58, 5164-5185.	2.9	99
472	Fecal Microbiota Transplantation: What We Know and What We Need to Know. Annals of Internal Medicine, 2015, 162, 662-663.	2.0	4
473	Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology, 2015, 149, 223-237.	0.6	460
474	Multiscale analysis of the murine intestine for modeling human diseases. Integrative Biology (United) Tj ETQq1 1 0.784314 rgBT /Ove	0.6	6
475	Fecal Microbiota Transplantation for Ulcerative Colitis: Not Just Yet. Gastroenterology, 2015, 149, 15-18.	0.6	31
476	Use of the Microbiome in the Practice of Epidemiology: A Primer on -Omic Technologies. American Journal of Epidemiology, 2015, 182, 1-8.	1.6	19
477	Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. Clinical Therapeutics, 2015, 37, 984-995.	1.1	437
479	A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease. Journal of Gastroenterology, 2015, 50, 928-939.	2.3	111

#	Article	IF	Citations
480	Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: a preliminary report. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1597-1601.	1.3	63
481	Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients. Journal of Infection and Chemotherapy, 2015, 21, 230-237.	0.8	65
482	Faecal microbiota transplantation: Key points to consider. Annales Pharmaceutiques Francaises, 2015, 73, 163-168.	0.4	8
483	Hospitalization Type and Subsequent Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 581-588.	2.5	124
484	Clostridium difficileinfection: A brief update on emerging therapies. American Journal of Health-System Pharmacy, 2015, 72, 1007-1012.	0.5	20
485	Systemic effects of gut microbiota and its relationship with disease and modulation. BMC Immunology, 2015, 16, 21.	0.9	61
486	The Principles and Practice of Nutritional Support. , 2015, , .		3
487	Fecal Microbiota Transplantation and Successful Resolution of Multidrug-Resistant-Organism Colonization. Journal of Clinical Microbiology, 2015, 53, 1986-1989.	1.8	83
488	Optimizing the Laboratory Diagnosis of Clostridium difficile Infection. Clinics in Laboratory Medicine, 2015, 35, 299-312.	0.7	16
489	Human Colon-Derived Soluble Factors Modulate Gut Microbiota Composition. Frontiers in Oncology, 2015, 5, 86.	1.3	5
490	Sa1774 Does the Donor Matter? Donor vs. Patient Effects in the Outcome of Next-Generation Fecal Transplant for Recurrent Clostridium difficile Infection. Gastroenterology, 2015, 148, S-328-S-329.	0.6	0
491	Pathogenesis of Clostridium difficile Infection and Its Potential Role in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1957-1966.	0.9	34
492	Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. Journal of Translational Medicine, 2015, 13, 298.	1.8	124
493	From Hype to Hope: The Gut Microbiota in Enteric Infectious Disease. Cell, 2015, 163, 1326-1332.	13.5	156
494	Clostridium difficile Infection: Current and Emerging Therapeutics. Current Treatment Options in Infectious Diseases, 2015, 7, 317-334.	0.8	2
495	The regulation of fecal microbiota for transplantation: An international perspective for policy and public health. Clinical Research and Regulatory Affairs, 2015, 32, 99-107.	2.1	15
496	Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons. Digestive Diseases, 2015, 33, 105-112.	0.8	28
497	Medical Therapy: The Future. , 2015, , 49-63.		0

#	Article	IF	Citations
498	The Role of Integrated Omics in Elucidating the Gut Microbiota Health Potentials. Microbiology Monographs, 2015, , 73-100.	0.3	2
499	Contentious hostâ€“microbiota relationship in inflammatory bowel disease â€“ can foes become friends again?. Scandinavian Journal of Gastroenterology, 2015, 50, 34-42.	0.6	33
500	TheAJTReport. American Journal of Transplantation, 2015, 15, 1-2.	2.6	0
501	The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies. Journal of Allergy and Clinical Immunology, 2015, 135, 3-13.	1.5	232
502	Microbiota and the human nature: know thyself. Environmental Microbiology, 2015, 17, 10-15.	1.8	12
503	The Contribution of Strains and Hosts to Outcomes in Clostridium difficile Infection. Infectious Disease Clinics of North America, 2015, 29, 51-61.	1.9	11
504	Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection. Infectious Disease Clinics of North America, 2015, 29, 109-122.	1.9	58
505	Infections and Autoimmune Diseases. , 2015, , 13-23.		2
506	Impact of commensal microbiota on the host pathophysiology: focusing on immunity and inflammation. Seminars in Immunopathology, 2015, 37, 1-3.	2.8	14
507	RzekomobÅ‚oniaste zapalenie jelit u dzieci. Pediatria Polska, 2015, 90, 48-53.	0.1	0
508	Microbiota Modulation of Myeloid Cells in Cancer Therapy. Cancer Immunology Research, 2015, 3, 103-109.	1.6	31
509	Fecal Microbiota Transplantation forClostridium difficileInfection. JAMA - Journal of the American Medical Association, 2015, 313, 725.	3.8	2
510	Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches. Current Treatment Options in Gastroenterology, 2015, 13, 105-120.	0.3	95
511	Human microbiota: â€˜The philosophers have only interpreted the world in various ways. The point, however, is to change itâ€™. Microbial Biotechnology, 2015, 8, 11-12.	2.0	6
512	Disease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease. Cell, 2015, 160, 447-460.	13.5	1,036
513	Treatment of Recurrent and SevereClostridium DifficileInfection. Annual Review of Medicine, 2015, 66, 373-386.	5.0	28
514	Beyond traditional pharmacology: new tools and approaches. British Journal of Pharmacology, 2015, 172, 3229-3241.	2.7	19
515	Predictive Values of Models of Clostridium difficile Infection. Infectious Disease Clinics of North America, 2015, 29, 163-177.	1.9	5

#	Article	IF	Citations
516	The influence of diet on the gut microbiota and its consequences for health. Current Opinion in Biotechnology, 2015, 32, 195-199.	3.3	148
517	Systematic discovery of probiotics. Nature Biotechnology, 2015, 33, 47-48.	9.4	16
518	Clostridium Difficile Infection: Risk Factors, Diagnosis and Management. Current Treatment Options in Gastroenterology, 2015, 13, 121-129.	0.3	15
519	Metabonomics and Gut Microbiota in Nutrition and Disease. Molecular and Integrative Toxicology, 2015, , .	0.5	5
520	Treatment of Clostridium difficile Infections. Infectious Disease Clinics of North America, 2015, 29, 93-108.	1.9	11
521	Media Discourse on the Social Acceptability of Fecal Transplants. Qualitative Health Research, 2015, 25, 1359-1371.	1.0	20
522	Microbiota-Mediated Inflammation and Antimicrobial Defense in the Intestine. Annual Review of Immunology, 2015, 33, 227-256.	9.5	227
523	DREAMing of benchmarks. Nature Biotechnology, 2015, 33, 49-50.	9.4	8
524	Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children. Scientific Reports, 2014, 4, 7485.	1.6	150
525	Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent <scp>C</scp>lostridium difficile infection â€“ an observational cohort study. Alimentary Pharmacology and Therapeutics, 2015, 41, 46-53.	1.9	129
526	New Role for Human Î±-Defensin 5 in the Fight against Hypervirulent Clostridium difficile Strains. Infection and Immunity, 2015, 83, 986-995.	1.0	29
527	Successful autologous fecal transplantation for chronic diversion colitis. Techniques in Coloproctology, 2015, 19, 51-52.	0.8	19
528	Low prevalence of Blastocystis sp. in active ulcerative colitis patients. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1039-1044.	1.3	48
529	Transmission of Atherosclerosis Susceptibility with Gut Microbial Transplantation. Journal of Biological Chemistry, 2015, 290, 5647-5660.	1.6	400
530	The gut microbiota and inflammatory bowel disease. Seminars in Immunopathology, 2015, 37, 47-55.	2.8	585
531	Les effets des rÃ©gimes et des stratÃ©gies diÃ©tÃ©tiques dans la polyarthrite rhumatoÃ¯de. Revue Du Rhumatisme (Edition Francaise), 2015, 82, 283-290.	0.0	1
532	Host genetic determinants of microbiota-dependent nutrition revealed by genome-wide analysis of Drosophila melanogaster. Nature Communications, 2015, 6, 6312.	5.8	100
533	The Human Microbiota and Pathogen Interactions. , 2015, , 347-356.		1

#	Article	IF	Citations
534	Investigational new treatments for Clostridium difficile infection. Drug Discovery Today, 2015, 20, 602-608.	3.2	15
536	The prevention and management of infections due to multidrug resistant organisms in haematology patients. British Journal of Clinical Pharmacology, 2015, 79, 195-207.	1.1	41
537	Dietary effects on human gut microbiome diversity. British Journal of Nutrition, 2015, 113, S1-S5.	1.2	350
538	Drugging the gut microbiome. Nature Biotechnology, 2015, 33, 228-231.	9.4	46
539	The gut microbiome: a clinically significant player in transplantation?. Expert Review of Clinical Immunology, 2015, 11, 781-783.	1.3	28
540	Fecal microbiota transplantation forClostridium difficileinfection: back to the future. Expert Opinion on Biological Therapy, 2015, 15, 1001-1014.	1.4	16
541	Les hÃ©patopathies stÃ©atosiques non alcooliques et le microbiote intestinal. Medecine Des Maladies Metaboliques, 2015, 9, 301-310.	0.1	0
542	Faecal microbiota transplantation for Clostridium difficile infection in the United Kingdom. Clinical Microbiology and Infection, 2015, 21, 578-582.	2.8	15
544	Microbiology and Ecology Are Vitally Important to Premedical Curricula. Evolution, Medicine and Public Health, 2015, 2015, eov014.	1.1	5
545	Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. Future Microbiology, 2015, 10, 1241-1255.	1.0	41
546	Personalized medicine going precise: from genomics to microbiomics. Trends in Molecular Medicine, 2015, 21, 461-462.	3.5	39
547	Fecal Microbiota Transplantation in Patients With Cancer Undergoing Treatment. Clinical Journal of Oncology Nursing, 2015, 19, 111-114.	0.3	9
548	The Mucosa-associated Microbiota of PSC Patients is Characterized by Low Diversity and Low Abundance of Uncultured Clostridiales II. Journal of Crohn's and Colitis, 2015, 9, 342-348.	0.6	106
549	Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. Drugs, 2015, 75, 1095-1118.	4.9	8
550	Pediatric severe pseudomembranous enteritis treated with fecal microbiota transplantation in a 13-month-old infant. Biomedical Reports, 2015, 3, 173-175.	0.9	22
551	The New Science of Metagenomics and the Challenges of Its Use in Both Developed and Developing Countries. , 2015, , 191-216.		6
552	Minimally Invasive Bariatric and Metabolic Surgery. , 2015, , .		3
553	First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe. Clinical Microbiology and Infection, 2015, 21, e82-e84.	2.8	7

#	Article	IF	Citations
554	Engineering the Microbiome: a Novel Approach to Immunotherapy for Allergic and Immune Diseases. Current Allergy and Asthma Reports, 2015, 15, 39.	2.4	13
555	Parallels Between Mammals and Flies in Inflammatory Bowel Disease. Healthy Ageing and Longevity, 2015, , 151-189.	0.2	1
556	Engineering the gut microbiota to treat hyperammonemia. Journal of Clinical Investigation, 2015, 125, 2841-2850.	3.9	154
557	Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infectious Diseases, 2015, 15, 191.	1.3	129
558	Treatment of Clostridium difficile infection in a French university hospital. Scandinavian Journal of Gastroenterology, 2015, 50, 1253-1260.	0.6	3
559	Clostridium difficile. , 2015, , 181-206.		1
561	Clostridium difficile Infection. New England Journal of Medicine, 2015, 372, 1539-1548.	13.9	1,014
562	What's trending in the infection prevention and control literature? From HIS 2012 to HIS 2014, and beyond. Journal of Hospital Infection, 2015, 89, 229-236.	1.4	9
566	Clostridium difficile in the Long-Term Care Facility: Prevention and Management. Current Geriatrics Reports, 2015, 4, 60-69.	1.1	23
567	Pseudomembranous colitis. Disease-a-Month, 2015, 61, 181-206.	0.4	88
568	Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Critical Care, 2015, 19, 37.	2.5	87
569	The gut microbiome in cardio-metabolic health. Genome Medicine, 2015, 7, 33.	3.6	92
570	Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome, 2015, 3, 10.	4.9	218
571	Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology, 2015, 149, 110-118.e4.	0.6	769
572	Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. New England Journal of Medicine, 2015, 372, 2296-2306.	13.9	4,059
573	The Human Microbiota: The Rise of an "Empire". Rambam Maimonides Medical Journal, 2015, 6, e0018.	0.4	11
574	A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clinical Infectious Diseases, 2015, 60, S144-S147.	2.9	51
575	Role of the Gut Microbiota in Maintaining GI Health: Highlights on Inflammatory Bowel Disease. Molecular and Integrative Toxicology, 2015, , 261-310.	0.5	0

#	Article	IF	Citations
576	An Integrative View of Microbiome-Host Interactions in Inflammatory Bowel Diseases. Cell Host and Microbe, 2015, 17, 577-591.	5.1	235
577	Drug-induced gastrointestinal disorders. Medicine, 2015, 43, 223-229.	0.2	1
578	Clostridium difficileinfection: New insights into therapeutic options. Critical Reviews in Microbiology, 2015, 42, 1-7.	2.7	2
579	Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. Expert Review of Molecular Diagnostics, 2015, 15, 219-234.	1.5	15
580	Fecal Microbiota Transplant for Clostridium difficile Colitisâ€“Induced Toxic Megacolon. American Journal of Gastroenterology, 2015, 110, 775-777.	0.2	23
581	Diagnosis and Management of Clostridium difficile Infection. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 031-043.	0.8	19
582	Administration of Spores of NontoxigenicClostridium difficileStrain M3 for Prevention of RecurrentC difficileInfection. JAMA - Journal of the American Medical Association, 2015, 313, 1719.	3.8	270
583	Recurrent Clostridium difficile infection: From colonization to cure. Anaerobe, 2015, 34, 59-73.	1.0	79
584	Fecal Microbiota Transplant to Treat Recurrent Clostridium difficile Infections. Critical Care Nurse, 2015, 35, 51-64.	0.5	16
585	Fecal Microbiota Transplantation for Clostridium difficile Infection. Annals of Internal Medicine, 2015, 162, 630-638.	2.0	311
586	The influence of the microbiota on the immune response to transplantation. Current Opinion in Organ Transplantation, 2015, 20, 1-7.	0.8	28
587	Towards a more comprehensive concept for prebiotics. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 303-310.	8.2	679
588	Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Pediatric Patients. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 1-3.	0.9	16
589	The gut microbiome in health and in disease. Current Opinion in Gastroenterology, 2015, 31, 69-75.	1.0	1,193
590	The molecular basis of Clostridium difficile disease and host response. Current Opinion in Gastroenterology, 2015, 31, 24-29.	1.0	19
591	Practice Parameters for the Management of Clostridium difficile Infection. Diseases of the Colon and Rectum, 2015, 58, 10-24.	0.7	43
592	Infectious diarrhoea. Medicine, 2015, 43, 253-258.	0.2	7
593	Microbiota Regulation of the Mammalian Gutâ€“Brain Axis. Advances in Applied Microbiology, 2015, 91, 1-62.	1.3	207

#	Article	IF	Citations
594	Why Is Initial Bacterial Colonization of the Intestine Important to Infants' and Children's Health?. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 294-307.	0.9	252
595	Continuous Proton Pump Inhibitor Therapy and the Associated Risk of RecurrentClostridium difficileInfection. JAMA Internal Medicine, 2015, 175, 784.	2.6	184
597	Fecal Microbiota Transplantation Via Nasogastric Tube for Recurrent Clostridium difficile Infection in Pediatric Patients. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 23-26.	0.9	66
598	Novel Microbiome-Based Therapeutics for Chronic Rhinosinusitis. Current Allergy and Asthma Reports, 2015, 15, 504.	2.4	36
599	Diagnosis and Treatment ofClostridium difficilein Adults. JAMA - Journal of the American Medical Association, 2015, 313, 398.	3.8	395
600	Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Infection Control and Hospital Epidemiology, 2015, 36, 438-444.	1.0	63
601	The microbiota in inflammatory bowel disease. Journal of Gastroenterology, 2015, 50, 495-507.	2.3	196
602	Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology, 2015, 149, 102-109.e6.	0.6	1,161
603	Faecal microbiota transplantation inClostridium difficileinfections. Infectious Diseases, 2015, 47, 114-116.	1.4	5
605	Clostridium difficile Infection. Clinical and Translational Gastroenterology, 2015, 6, e92.	1.3	5
606	Next-Generation Sequencing for Infectious Disease Diagnosis and Management. Journal of Molecular Diagnostics, 2015, 17, 623-634.	1.2	151
607	A small-molecule antivirulence agent for treating Clostridium difficile infection. Science Translational Medicine, 2015, 7, 306ra148.	5.8	117
608	Using a Novel Lysin To Help Control Clostridium difficile Infections. Antimicrobial Agents and Chemotherapy, 2015, 59, 7447-7457.	1.4	48
609	Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1379-1391.	1.4	41
612	Advancing gut microbiome research using cultivation. Current Opinion in Microbiology, 2015, 27, 127-132.	2.3	44
613	The Microbiome and Cancer: Is the â€˜Oncobiomeâ€™ Mirage Real?. Trends in Cancer, 2015, 1, 24-35.	3.8	73
615	A unified initiative to harness Earth's microbiomes. Science, 2015, 350, 507-508.	6.0	195
616	The human microbiome. Cmaj, 2015, 187, 825-825.	0.9	3

#	Article	IF	Citations
617	Of Microbes and Men: Figure 1. Diabetes Care, 2015, 38, 1817-1819.	4.3	3
618	Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. Annual Review of Microbiology, 2015, 69, 445-461.	2.9	256
619	Fecal microbiota transplantation restores dysbiosis in patients with methicillin resistant Staphylococcus aureus enterocolitis. BMC Infectious Diseases, 2015, 15, 265.	1.3	52
620	The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options. International Journal of Antimicrobial Agents, 2015, 46, S47-S50.	1.1	19
621	Dysbiotic gut microbiome: A key element of Crohn's disease. Comparative Immunology, Microbiology and Infectious Diseases, 2015, 43, 36-49.	0.7	59
622	A different kind of â€œallogeneic transplantâ€: successful fecal microbiota transplant for recurrent and refractoryClostridium difficileinfection in a patient with relapsed aggressive B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 512-514.	0.6	14
623	Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options. Drugs and Aging, 2015, 32, 639-647.	1.3	21
624	Fecal microbiota transplant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2015, 50, 1010-1010.	1.3	29
625	The Microbiota and Microbiome in Aging: Potential Implications in Health and Ageâ€Related Diseases. Journal of the American Geriatrics Society, 2015, 63, 776-781.	1.3	224
626	Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Scientific Reports, 2015, 5, 12955.	1.6	76
627	Editorial: a simple faecal preparation protocol for faecal microbiota transplantation. Alimentary Pharmacology and Therapeutics, 2015, 41, 320-320.	1.9	3
628	DNA-Microarray-based Genotyping of Clostridium difficile. BMC Microbiology, 2015, 15, 158.	1.3	8
629	Changes seen in gut bacteria content and distribution with obesity: causation or association?. Postgraduate Medicine, 2015, 127, 863-868.	0.9	48
630	Whole-genome sequencing targets drug-resistant bacterial infections. Human Genomics, 2015, 9, 19.	1.4	86
634	Monitoring in real time the cytotoxic effect of Clostridium difficile upon the intestinal epithelial cell line HT29. Journal of Microbiological Methods, 2015, 119, 66-73.	0.7	20
635	Fecal Microbiota Transplant Protocol forClostridium DifficileInfection. Laboratory Medicine, 2015, 46, e19-e23.	0.8	23
636	C. difficile Infection: Changing Epidemiology and Management Paradigms. Clinical and Translational Gastroenterology, 2015, 6, e99.	1.3	104
637	The Importance of Colonization with Clostridium difficile on Infection and Transmission. Current Infectious Disease Reports, 2015, 17, 499.	1.3	12

#	Article	IF	Citations
638	Infection Complications After Abdominal Organ Transplantation. , 2015, , 33-56.		0
639	Abdominal Solid Organ Transplantation. , 2015, , .		1
640	Where are we heading to in pharmacological IBD therapy?. Pharmacological Research, 2015, 100, 220-227.	3.1	36
641	The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2015, 29, 202-212.	1.4	32
643	Microbiota Organ and Bariatric Surgery. , 2015, , 43-55.		0
644	Why infectious disease research needs community ecology. Science, 2015, 349, 1259504.	6.0	330
647	Fecal microbiota transplantation: A â€˜How-Toâ€™ guide for nurses. Collegian, 2015, 22, 445-451.	0.6	5
648	â€œBringing Up Babyâ€•to Tolerate Germs. Immunity, 2015, 43, 842-844.	6.6	5
649	The Multi-Modal Immune Pathogenesis of Atopic Eczema. Trends in Immunology, 2015, 36, 788-801.	2.9	68
651	Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health?. Gastroenterology, 2015, 149, 848-850.	0.6	5
652	Could microbial therapy boost cancer immunotherapy?. Science, 2015, 350, 1031-1032.	6.0	36
654	Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes. Diabetes Care, 2015, 38, 159-165.	4.3	519
656	The interplay between the intestinal microbiota and the immune system. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 9-19.	0.7	60
657	Development of Fecal Microbiota Transplantation Suitable for Mainstream Medicine. Clinical Gastroenterology and Hepatology, 2015, 13, 246-250.	2.4	46
658	Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000â€“2012. Clinical Microbiology and Infection, 2015, 21, 48-53.	2.8	38
659	Pulsed faecal microbiota transplantation for recalcitrant recurrent Clostridium difficile infection. Clinical Microbiology and Infection, 2015, 21, e23-e24.	2.8	1
661	Perturbations of mucosal homeostasis through interactions of intestinal microbes with myeloid cells. Immunobiology, 2015, 220, 227-235.	0.8	6
662	Fecal microbiota transplantation through midâ€gut for refractory <scp>C</scp>rohn's disease: Safety, feasibility, and efficacy trial results. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 51-58.	1.4	266

#	Article	IF	Citations
663	The rest of the story: the microbiome and gastrointestinal infections. Current Opinion in Microbiology, 2015, 23, 121-125.	2.3	22
665	The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. European Journal of Immunology, 2015, 45, 17-31.	1.6	229
666	Gutâ€“Liver Axis in Alcoholic Liver Disease. Gastroenterology, 2015, 148, 30-36.	0.6	558
667	An in vitro culture model to study the dynamics of colonic microbiota in Syrian golden hamsters and their susceptibility to infection with Clostridium difficile. ISME Journal, 2015, 9, 321-332.	4.4	17
668	Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature, 2015, 517, 205-208.	13.7	1,506
669	Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 355-359.	0.2	13
670	Intestinal Microbiota Transplantation, a Simple and Effective Treatment for Severe and Refractory Clostridium Difficile Infection. Digestive Diseases and Sciences, 2015, 60, 181-185.	1.1	77
671	Synthetic Microbes As Drug Delivery Systems. ACS Synthetic Biology, 2015, 4, 358-364.	1.9	117
672	Molecular ecological tools to decipher the role of our microbial mass in obesity. Beneficial Microbes, 2015, 6, 61-81.	1.0	28
673	Faecal microbiota transplantation for recurringClostridium difficileinfection in a patient with Crohn's disease and ileorectal anastomosis. BMJ Case Reports, 2016, 2016, bcr2016217209.	0.2	5
674	Fecal microbiota transplantation: Literature review. Journal of Nursing Education and Practice, 2016, 6, .	0.1	0
675	5. Entwicklung des Mikrobioms beim Neugeborenen und Kleinkind. , 2016, , .		0
676	20. FÃkale Mikrobiota-Transplantation. , 2016, , .		0
677	A randomized clinical trial on the effectiveness of a symbiotic product to decolonize patients harboring multidrug-resistant Gram-negative bacilli. Revista Da Sociedade Brasileira De Medicina Tropical, 2016, 49, 559-566.	0.4	26
678	Novel Strategies to Combat Antimicrobial Resistance. Journal of Infectious Disease and Therapy, 2016, 4, .	0.1	23
679	Clostridium difficile: Current Status and Treatment Perspectives. Journal of Infectious Diseases and Treatment, 2016, 2, .	0.0	0
680	Microbiome of the upper airway focusing on chronic rhinosinusitis and allergic rhinitis. Allergy Asthma & Respiratory Disease, 2016, 4, 399.	0.3	1
681	Gut Microbiota in Multiple Sclerosis. , 2016, , 113-125.		4

#	Article	IF	Citations
682	2016, 105, 1695-1700.	0.0	0
683	Correlating the Gut Microbiome to Health and Disease. , 2016, , 261-291.		5
684	Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clinical Endoscopy, 2016, 49, 257-265.	0.6	209
685	Involvement of Reduced Microbial Diversity in Inflammatory Bowel Disease. Gastroenterology Research and Practice, 2016, 2016, 1-7.	0.7	82
686	Traditional Chinese Medicine QPYF as Preventive Treatment forClostridium difficileAssociated Diarrhea in a Mouse Model. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-7.	0.5	9
687	Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy. Stem Cells International, 2016, 2016, 1-16.	1.2	28
688	Fecal Microbiota Transplantation Using Upper Gastrointestinal Tract for the Treatment of Refractory or Severe ComplicatedClostridium difficileInfection in Elderly Patients in Poor Medical Condition: The First Study in an Asian Country. Gastroenterology Research and Practice, 2016, 2016, 1-6.	0.7	30
689	Pathogenic role of the gut microbiota in gastrointestinal diseases. Intestinal Research, 2016, 14, 127.	1.0	108
690	Comparison of pediatric and adult antibiotic-associated diarrhea andClostridium difficileinfections. World Journal of Gastroenterology, 2016, 22, 3078.	1.4	112
691	Fecal Transplantation using a Nasoenteric Tube during an Initial Episode of Severe Clostridium difficile Infection. Infection and Chemotherapy, 2016, 48, 31.	1.0	5
692	Microbial Genomics. , 2016, , 101-106.		1
693	The Gut Microbiota in Immune-Mediated Inflammatory Diseases. Frontiers in Microbiology, 2016, 7, 1081.	1.5	315
694	Gut microbiota in autism and mood disorders. World Journal of Gastroenterology, 2016, 22, 361.	1.4	300
695	The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation. Frontiers in Cellular and Infection Microbiology, 2016, 6, 15.	1.8	60
696	Mucosal Prevalence and Interactions with the Epithelium Indicate Commensalism of Sutterella spp.. Frontiers in Microbiology, 2016, 7, 1706.	1.5	214
697	Considerations For Optimizing Microbiome Analysis Using a Marker Gene. Frontiers in Nutrition, 2016, 3, 26.	1.6	40
698	Respiratory Microbiome of New-Born Infants. Frontiers in Pediatrics, 2016, 4, 10.	0.9	44
699	Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. International Journal of Molecular Sciences, 2016, 17, 578.	1.8	55

#	Article	IF	Citations
700	Advances in the Microbiome: Applications to Clostridium difficile Infection. Journal of Clinical Medicine, 2016, 5, 83.	1.0	23
703	Gut Microbiota and Coronary Artery Disease. International Heart Journal, 2016, 57, 663-671.	0.5	55
704	The Role of the Gut Microbiome on Chronic Kidney Disease. Advances in Applied Microbiology, 2016, 96, 65-94.	1.3	86
705	Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. PLoS ONE, 2016, 11, e0147210.	1.1	130
707	Faecal microbiota transplantation: a review of FMT as an alternative treatment forClostridium difficileinfection. Bioscience Horizons, 2016, 9, hzw007.	0.6	12
708	Fecal Microbiota Transplant in Patients With Re current Clostridium Difficile Infection. Deutsches Ärzteblatt International, 2016, 113, 583-9.	0.6	35
709	A High Rate of Alternative Diagnoses in Patients Referred for Presumed Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2016, 50, 742-746.	1.1	33
710	Longâ€term microbiota and virome in a ZÃ¼rich patient after fecal transplantation against Clostridium difficile infection. Annals of the New York Academy of Sciences, 2016, 1372, 29-41.	1.8	38
711	Repeated fecal microbiota transplantation in a child with ulcerative colitis. Pediatrics International, 2016, 58, 781-785.	0.2	20
712	Fecal Microbiota Transplantation for Treatment of Severe, Recurrent, and Refractory Clostridium difficile Infection in a Severely Immunocompromised Patient. Infectious Diseases in Clinical Practice, 2016, 24, 237-240.	0.1	2
713	Prebiotics and synbiotics. Current Opinion in Gastroenterology, 2016, 32, 110-119.	1.0	65
714	Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine. Arthritis and Rheumatology, 2016, 68, 2646-2661.	2.9	463
715	Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1020-1025.	0.9	25
716	In vitro inhibitory activity of probiotic products against oral Candida species. Journal of Applied Microbiology, 2016, 121, 254-262.	1.4	31
717	Microbiota as Therapeutic Targets. Digestive Diseases, 2016, 34, 558-565.	0.8	14
718	Plantâ€“soil feedbacks: connecting ecosystem ecology and evolution. Functional Ecology, 2016, 30, 1032-1042.	1.7	83
720	Perinatal Microbiomesâ€™ Influence on Preterm Birth and Pretermsâ€™ Health. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, e193-e203.	0.9	32
721	Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation forClostridium difficileinfection. Alimentary Pharmacology and Therapeutics, 2016, 43, 445-457.	1.9	135

#	Article	IF	Citations
722	Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1927-1932.	1.4	42
723	Editorial Commentary: Where to Place the New Treatments forClostridium difficileInfection?. Clinical Infectious Diseases, 2016, 63, 735-736.	2.9	4
724	The prebiotic concept and human health: a changing landscape with riboflavin as a novel prebiotic candidate?. European Journal of Clinical Nutrition, 2016, 70, 1348-1353.	1.3	45
725	Dietâ€“microbiota interactions as moderators of human metabolism. Nature, 2016, 535, 56-64.	13.7	1,602
726	Cost Averted With Timely Fecal Microbiota Transplantation in the Management of Recurrent Clostridium difficile Infection in Alberta, Canada. Journal of Clinical Gastroenterology, 2016, 50, 747-753.	1.1	18
727	Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation. Journal of Physical Education and Sports Management, 2016, 2, a000448.	0.5	50
728	The Human Microbiome and Public Health: Social and Ethical Considerations. American Journal of Public Health, 2016, 106, 414-420.	1.5	36
729	Gut microbiota and type 2 diabetes mellitus. EndocrinologÃa Y NutriciÃ³n (English Edition), 2016, 63, 560-568.	0.5	64
730	Fecal microbiota transplantation to fight Clostridium difficile infections and other intestinal diseases. Bacteriophage, 2016, 6, e1251380.	1.9	14
731	Successful Fecal Microbiota Transplantation as an Initial Therapy for Clostridium difficile Infection on an Outpatient Basis. Internal Medicine, 2016, 55, 999-1000.	0.3	6
732	Human Genetics: The Basics. , 0, , .		3
733	Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut, 2016, 65, 1061-1069.	6.1	68
734	Lactobacillus probiotics in the prevention of diarrhea associated with Clostridium difficile: a systematic review and Bayesian hierarchical meta-analysis. CMAJ Open, 2016, 4, E706-E718.	1.1	29
735	Fit for cure? Microbiota and GVHD. Blood, 2016, 128, 2004-2005.	0.6	1
736	Microbiota: Reseeding the gut. Nature, 2016, 540, S109-S112.	13.7	11
737	The Microbiome and Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2016, 36, 340-348.	1.8	15
738	Oral supplementation of healthy adults with 2â€²-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. British Journal of Nutrition, 2016, 116, 1356-1368.	1.2	148
739	Clostridium difficile Infection. Microbiology Spectrum, 2016, 4, .	1.2	12

#	Article	IF	Citations
740	Role of the intestinal mucosa in acute gastrointestinal GVHD. Hematology American Society of Hematology Education Program, 2016, 2016, 119-127.	0.9	6
741	Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk. Current Opinion in Lipidology, 2016, 27, 615-622.	1.2	36
742	Fecal microbiota transplant in patients with Clostridium difficile infection. Journal of Trauma and Acute Care Surgery, 2016, 81, 756-764.	1.1	48
743	Probiotics History. Journal of Clinical Gastroenterology, 2016, 50, S116-S119.	1.1	119
744	Novel therapies for severe Clostridium difficile colitis. Current Opinion in Critical Care, 2016, 22, 1.	1.6	7
745	New and emerging therapies for Clostridium difficile infection. Current Opinion in Infectious Diseases, 2016, 29, 546-554.	1.3	42
746	Current status of the microbiome in renal transplantation. Current Opinion in Nephrology and Hypertension, 2016, 25, 570-576.	1.0	22
748	Biome engineeringâ€2020. Microbial Biotechnology, 2016, 9, 553-563.	2.0	28
749	Antibiotics as deep modulators of gut microbiota: between good and evil. Gut, 2016, 65, 1906-1915.	6.1	463
750	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. American Journal of Physiology - Renal Physiology, 2016, 311, G1018-G1036.	1.6	64
751	Beyond killing. Evolution, Medicine and Public Health, 2016, 2016, 148-157.	1.1	87
752	Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases. Digestive Diseases, 2016, 34, 279-285.	0.8	22
753	Editorial Commentary: The Dawning of Microbiome Remediation for Addressing Antibiotic Resistance. Clinical Infectious Diseases, 2016, 62, 1487-1488.	2.9	17
754	Faecal microbiota transplantation for recurrent Clostridium difficile infection and beyond: risks and regulation. Journal of Hospital Infection, 2016, 92, 115-116.	1.4	11
755	The human gut microbiome impacts health and disease. Comptes Rendus - Biologies, 2016, 339, 319-323.	0.1	28
757	Probiotics as an Alternative Therapy for Helicobacter pylori-Associated Diseases. , 2016, , 543-574.		0
758	Predictors of Early Failure After Fecal Microbiota Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study. American Journal of Gastroenterology, 2016, 111, 1024-1031.	0.2	105
759	The microbiota and immune response during Clostridium difficile infection. Anaerobe, 2016, 41, 79-84.	1.0	28

#	Article	IF	Citations
760	Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. Journal of Hospital Infection, 2016, 93, 286-289.	1.4	59
761	Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-resistant opportunistic pathogens: a review. Infectious Diseases, 2016, 48, 587-592.	1.4	95
762	From IBS to DBS. Journal of Investigative Medicine High Impact Case Reports, 2016, 4, 232470961664845.	0.3	7
763	Can microbiota research change our understanding of neurodegenerative diseases?. Neurodegenerative Disease Management, 2016, 6, 81-85.	1.2	27
764	Use your antibiotics wisely. Consequences to the intestinal microbiome. FEMS Microbiology Letters, 2016, 363, fnw081.	0.7	11
765	Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes, 2016, 7, 22-39.	4.3	697
766	Gut microbiota analysis reveals a marked shift to bifidobacteria by a starter infant formula containing a synbiotic of bovine milkâ€derived oligosaccharides and <scp>B</scp>ifidobacterium animalis subsp. lactisâ€...<scp>CNCM I</scp>â€3446. Environmental Microbiology, 2016, 18, 2185-2195.	1.8	68
768	Development and maintenance of intestinal regulatory T cells. Nature Reviews Immunology, 2016, 16, 295-309.	10.6	442
769	The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therapeutic Advances in Gastroenterology, 2016, 9, 606-625.	1.4	152
770	Environmental management in the gut: fecal transplantation to restore the intestinal ecosystem. Infectious Diseases, 2016, 48, 593-595.	1.4	10
771	Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets. Translational Research, 2016, 176, 38-68.	2.2	140
772	Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science, 2016, 352, 586-589.	6.0	461
773	Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science, 2016, 352, 535-538.	6.0	341
774	Microbiome sequencing: challenges and opportunities for molecular medicine. Expert Review of Molecular Diagnostics, 2016, 16, 795-805.	1.5	33
775	Transplanting a Microbial Organ: the Good, the Bad, and the Unknown. MBio, 2016, 7, .	1.8	13
776	Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Current Infectious Disease Reports, 2016, 18, 19.	1.3	13
777	Microbiome therapeutics â€" Advances and challenges. Advanced Drug Delivery Reviews, 2016, 105, 44-54.	6.6	198
778	Microbial therapeutic interventions. Seminars in Fetal and Neonatal Medicine, 2016, 21, 418-423.	1.1	14

#	Article	IF	Citations
779	Microbiome mediation of infections in the cancer setting. Genome Medicine, 2016, 8, 40.	3.6	71
780	The Gut Microbiota in Type 2 Diabetes. , 2016, , 275-293.		0
781	Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. Transplantation Proceedings, 2016, 48, 402-407.	0.3	26
782	Fine-tuning of the mucosal barrier and metabolic systems using the diet-microbial metabolite axis. International Immunopharmacology, 2016, 37, 79-86.	1.7	16
784	Colonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota. Endoscopy International Open, 2016, 04, E610-E613.	0.9	72
785	Clostridium difficile infection. Nature Reviews Disease Primers, 2016, 2, 16020.	18.1	588
786	Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. Trends in Molecular Medicine, 2016, 22, 458-478.	3.5	630
789	How to Manipulate the Microbiota: Fecal Microbiota Transplantation. Advances in Experimental Medicine and Biology, 2016, 902, 143-153.	0.8	25
790	Rebooting the microbiome. Gut Microbes, 2016, 7, 353-363.	4.3	24
791	Layerâ€byâ€Layer Encapsulation of Probiotics for Delivery to the Microbiome. Advanced Materials, 2016, 28, 9486-9490.	11.1	239
792	Microbiotaâ€”myeloid cell crosstalk beyond the gut. Journal of Leukocyte Biology, 2016, 100, 865-879.	1.5	76
793	Endoscopic peroral jejunal fecal microbiota transplantation. Digestive and Liver Disease, 2016, 48, 1336-1339.	0.4	24
794	Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Medicine, 2016, 14, 134.	2.3	142
795	Microbiota y diabetes mellitus tipo 2. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 560-568.	0.8	111
796	Clostridium difficile Infection and Fecal Microbiota Transplant. AACN Advanced Critical Care, 2016, 27, 324-337.	0.6	51
797	Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis. Current Rheumatology Reports, 2016, 18, 63.	2.1	6
798	When pathogenic bacteria meet the intestinal microbiota. Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20150504.	1.8	100
799	Comprehensive microbiome analysis of tonsillar crypts in IgA nephropathy. Nephrology Dialysis Transplantation, 2017, 32, gfw343.	0.4	40

#	Article	IF	Citations
800	Mucosa-reparing and microbiota-balancing therapeutic effect of Bacillus subtilis alleviates dextrate sulfate sodium-induced ulcerative colitis in mice. Experimental and Therapeutic Medicine, 2016, 12, 2554-2562.	0.8	44
801	Engineering Human Microbiota: Influencing Cellular and Community Dynamics for Therapeutic Applications. International Review of Cell and Molecular Biology, 2016, 324, 67-124.	1.6	12
802	Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Medicine, 2016, 14, 155.	2.3	86
803	Microbiome in Transplantation. , 2016, , 939-949.		0
804	Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection. Open Forum Infectious Diseases, 2016, 3, ofw133.	0.4	57
805	Other Bacterial Infections After Hematopoietic Stem Cell or Solid Organ Transplantation. , 2016, , 397-414.		0
806	The Gut Microbiome as Therapeutic Target in Central Nervous System Diseases: Implications for Stroke. Neurotherapeutics, 2016, 13, 762-774.	2.1	89
807	Ã‰lie Metchnikoff (1845â€“1916): celebrating 100 years of cellular immunology and beyond. Nature Reviews Immunology, 2016, 16, 651-656.	10.6	55
813	Causality of small and large intestinal microbiota in weight regulation and insulin resistance. Molecular Metabolism, 2016, 5, 759-770.	3.0	142
815	Optimizing the diagnostic testing ofClostridium difficileinfection. Expert Review of Anti-Infective Therapy, 2016, 14, 801-808.	2.0	7
816	Review: Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. Arthritis and Rheumatology, 2016, 68, 35-45.	2.9	187
817	Fecal microbiota transplantation for the treatment of Clostridium difficile infection. Journal of Hospital Medicine, 2016, 11, 56-61.	0.7	43
818	Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. Mucosal Immunology, 2016, 9, 1360-1365.	2.7	64
819	Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes, 2016, 7, 365-383.	4.3	136
820	Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Internal Medicine Journal, 2016, 46, 479-493.	0.5	88
821	The esophageal microbiota in health and disease. Annals of the New York Academy of Sciences, 2016, 1381, 21-33.	1.8	119
822	Any Future for Fecal Microbiota Transplantation as Treatment Strategy for Inflammatory Bowel Diseases?. Digestive Diseases, 2016, 34, 74-81.	0.8	22
823	Clostridium difficile colitis: pathogenesis and host defence. Nature Reviews Microbiology, 2016, 14, 609-620.	13.6	436

#	Article	IF	Citations
824	Interplay between gut microbiota, its metabolites and human metabolism: Dissecting cause from consequence. Trends in Food Science and Technology, 2016, 57, 233-243.	7.8	22
825	The gut microbiota: A treasure for human health. Biotechnology Advances, 2016, 34, 1210-1224.	6.0	158
826	Fecal microbial transplantation in a pediatric case of recurrent Clostridium difficile infection and specific antibody deficiency. Pediatric Allergy and Immunology, 2016, 27, 872-874.	1.1	6
828	The effects of low-level laser irradiation on breast tumor in mice and the expression of Let-7a, miR-155, miR-21, miR125, and miR376b. Lasers in Medical Science, 2016, 31, 1775-1782.	1.0	13
829	An assessment of the future impact of alternative technologies on antibiotics markets. Journal of Pharmaceutical Policy and Practice, 2016, 9, 34.	1.1	7
830	Role of the intestinal mucosa in acute gastrointestinal GVHD. Blood, 2016, 128, 2395-2402.	0.6	39
831	Endoscopic Delivery of Fecal Biotherapy in Inflammatory Bowel Disease. Gastrointestinal Endoscopy Clinics of North America, 2016, 26, 707-717.	0.6	7
832	Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections. American Journal of Gastroenterology, 2016, 111, 1834-1840.	0.2	74
833	Microbial Herd Protection Mediated by Antagonistic Interaction in Polymicrobial Communities. Applied and Environmental Microbiology, 2016, 82, 6881-6888.	1.4	42
834	Non-invasive fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient presenting with hypertensive disorder post interventionem. Zeitschrift Fur Gastroenterologie, 2016, 54, 1143-1146.	0.2	3
835	The Microbiome: a Revolution in Treatment for Rheumatic Diseases?. Current Rheumatology Reports, 2016, 18, 62.	2.1	44
836	Therapeutic manipulation of the microbiota: past, present, and considerations for the future. Clinical Microbiology and Infection, 2016, 22, 905-909.	2.8	42
837	Transplantation of a bacterial consortium ameliorates trinitrobenzenesulfonic acid-induced colitis and intestinal dysbiosis in rats. Future Microbiology, 2016, 11, 887-902.	1.0	10
838	Class I PI3-kinase or Akt inhibition do not impair axonal polarization, but slow down axonal elongation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2574-2583.	1.9	7
839	Seeking safe stool: Canada needs a universal donor model. Cmaj, 2016, 188, E431-E432.	0.9	18
841	Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity. EBioMedicine, 2016, 13, 37-45.	2.7	65
842	Diagnostic test accuracy of glutamate dehydrogenase for Clostridium difficile: Systematic review and meta-analysis. Scientific Reports, 2016, 6, 29754.	1.6	21
844	Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection. Annals of Internal Medicine, 2016, 165, 609.	2.0	486

#	Article	IF	Citations
845	Rethinking Strategies to Select Antibiotic Therapy inClostridium difficileinfection. Pharmacotherapy, 2016, 36, 1281-1289.	1.2	4
846	The gutâ€“brain connection: triggering of brain autoimmune disease by commensal gut bacteria. Rheumatology, 2016, 55, ii68-ii75.	0.9	30
847	Control of Intestinal Regulatory T Cells by Human Commensal Bacteria. , 2016, , 591-601.		0
848	Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. BMC Microbiology, 2016, 16, 255.	1.3	64
850	Policy and regulations in light of the human body as a â€˜superorganismâ€™ containing multiple, intertwined symbiotic relationships. Clinical Research and Regulatory Affairs, 2016, 33, 39-48.	2.1	10
851	The Microbiomeâ€“Gutâ€“Brain Axis and the Consequences of Infection and Dysbiosis. American Journal of Gastroenterology Supplements (Print), 2016, 3, 33-40.	0.7	3
854	A single gene of a commensal microbe affects host susceptibility to enteric infection. Nature Communications, 2016, 7, 11606.	5.8	31
856	Letter: avoiding misconceptions about elimination diet for eosinophilic oesophagitis â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 100-101.	1.9	0
857	Letter: a simple outâ€patient faecal microbiota transplant technique. Alimentary Pharmacology and Therapeutics, 2016, 44, 101-101.	1.9	1
858	Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders. BMJ Open Gastroenterology, 2016, 3, e000087.	1.1	53
859	Fecal Microbiota Transplantation as a Novel Therapy for Ulcerative Colitis. Medicine (United States), 2016, 95, e3765.	0.4	28
861	The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. Journal of Clinical Gastroenterology, 2016, 50, 403-407.	1.1	176
862	Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2016, 50, 398-402.	1.1	102
863	Is the Lower Gastrointestinal Route Really Preferred Over the Upper Gastrointestinal Route for Fecal Microbiota Transfer?. Journal of Clinical Gastroenterology, 2016, 50, 895-895.	1.1	6
864	The Use and Efficacy of Fecal Microbiota Transplantation for Refractory Clostridium difficile in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 2704-2710.	0.9	9
865	Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2016, 22, 2182-2190.	0.9	175
866	Gastroenvironmental distress: metaphorical antecedents of the gut microbiome. Medical Humanities, 2016, 42, 121-127.	0.6	3
867	Human Microbiome and its Association With Health and Diseases. Journal of Cellular Physiology, 2016, 231, 1688-1694.	2.0	98

#	Article	IF	Citations
868	Understanding Luminal Microorganisms and Their Potential Effectiveness in Treating Intestinal Inflammation. Inflammatory Bowel Diseases, 2016, 22, 194-201.	0.9	8
869	Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transplant Infectious Disease, 2016, 18, 628-633.	0.7	100
870	The Gut Microbiome and Obesity. Current Oncology Reports, 2016, 18, 45.	1.8	230
871	Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Medicine, 2016, 8, 47.	3.6	100
872	MDSINE: Microbial Dynamical Systems INference Engine for microbiome time-series analyses. Genome Biology, 2016, 17, 121.	3.8	209
873	Fecal Microbiota Transfer 2.0. Journal of Infectious Diseases, 2016, 214, 169-170.	1.9	2
874	Fecal Microbiota Transplantation by Freeze-Dried Oral Capsules for Recurrent Clostridium difficile Infection. Open Forum Infectious Diseases, 2016, 3, ofw091.	0.4	31
875	Addressing Infectious Disease Challenges by Investigating Microbiomes. ACS Infectious Diseases, 2016, 2, 453-455.	1.8	2
876	Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection. Journal of Clinical Gastroenterology, 2016, 50, 624-630.	1.1	93
877	The intestinal microbiome and surgical disease. Current Problems in Surgery, 2016, 53, 257-293.	0.6	24
878	Fecal microbiota transplantation via fluoroscopy-guided nasojejunal catheter placement: indications, technique, and the role of radiology. Abdominal Radiology, 2016, 41, 2020-2025.	1.0	5
879	Reduction of Antibiotic Resistance Genes in Intestinal Microbiota of Patients With RecurrentClostridium difficileInfection After Fecal Microbiota Transplantation. Clinical Infectious Diseases, 2016, 63, 710-711.	2.9	38
880	Understanding the mechanisms of faecal microbiota transplantation. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 508-516.	8.2	377
881	New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases. Clinical and Translational Immunology, 2016, 5, e87.	1.7	85
882	The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. Nature Reviews Rheumatology, 2016, 12, 446-455.	3.5	112
883	Management of candidemia in patients withClostridium difficileinfection. Expert Review of Anti-Infective Therapy, 2016, 14, 679-685.	2.0	7
884	Microbiota and pathogen â€˜pas de deuxâ€™: setting up and breaking down barriers to intestinal infection. Pathogens and Disease, 2016, 74, ftw051.	0.8	20
885	Reply. Gastroenterology, 2016, 150, 286-287.	0.6	1

#	Article	IF	Citations
886	Targeting the ecology within: The role of the gutâ€"brain axis and human microbiota in drug addiction. Medical Hypotheses, 2016, 93, 77-80.	0.8	50
887	Fecal microbiota transplant for Clostridium difficile infection in older adults. Therapeutic Advances in Gastroenterology, 2016, 9, 273-281.	1.4	13
888	Gut microbiota and colorectal cancer. Genes and Environment, 2016, 38, 11.	0.9	46
889	How the microbiota shapes rheumatic diseases. Nature Reviews Rheumatology, 2016, 12, 398-411.	3.5	122
890	Colonization potential to reconstitute a microbe community in patients detected early after fecal microbe transplant for recurrent C. difficile. BMC Microbiology, 2016, 16, 5.	1.3	19
891	Ridinilazole: a novel therapy for Clostridium difficile infection. International Journal of Antimicrobial Agents, 2016, 48, 137-143.	1.1	41
892	Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1744-1754.	0.9	45
893	FMT Happens: Regulating Fecal Microbiota Therapy in Canada; What You Need to Know. World Medical and Health Policy, 2016, 8, 95-106.	0.9	1
894	Transfer of Viral Communities between Human Individuals during Fecal Microbiota Transplantation. MBio, 2016, 7, e00322.	1.8	90
895	Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria. Drug Resistance Updates, 2016, 27, 59-71.	6.5	39
897	Fecal microbiota transplantation: in perspective. Therapeutic Advances in Gastroenterology, 2016, 9, 229-239.	1.4	302
898	Fecal Microbiota Transplant. Hospital Medicine Clinics, 2016, 5, 58-70.	0.2	1
899	Expanded Evidence for Frozen Fecal Microbiota Transplantation forClostridium difficileInfection. JAMA - Journal of the American Medical Association, 2016, 315, 137.	3.8	6
900	Toward Rational Donor Selection in Faecal Microbiota Transplantation for IBD. Journal of Crohn's and Colitis, 2016, 10, 375-376.	0.6	9
901	Adapting Koch's postulates. Science, 2016, 351, 224-226.	6.0	151
902	Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis. Gut, 2016, 65, 728-729.	6.1	13
903	Novel approaches to treatingClostridium difficile-associated colitis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 193-204.	1.4	6
904	Understanding the mechanisms and drivers of antimicrobial resistance. Lancet, The, 2016, 387, 176-187.	6.3	1,633

#	Article	IF	Citations
905	Novel therapeutic strategies for Clostridium difficile infections. Expert Opinion on Therapeutic Targets, 2016, 20, 269-285.	1.5	8
906	Proton pump inhibitors affect the gut microbiome. Gut, 2016, 65, 740-748.	6.1	885
907	Antimicrobial therapy of acute diarrhoea: a clinical review. Expert Review of Anti-Infective Therapy, 2016, 14, 193-206.	2.0	54
908	The Microbiome, Systemic Immune Function, and Allotransplantation. Clinical Microbiology Reviews, 2016, 29, 191-199.	5.7	39
909	Safety and Durability of RBX2660 (Microbiota Suspension) for RecurrentClostridium difficileInfection: Results of the PUNCH CD Study. Clinical Infectious Diseases, 2016, 62, 596-602.	2.9	140
910	Establishing a Fecal Microbiota Transplant Service for the Treatment ofClostridium difficileInfection. Clinical Infectious Diseases, 2016, 62, 908-914.	2.9	88
911	Fecal microbiota transplantation in children: a brief review. Pediatric Research, 2016, 80, 2-6.	1.1	43
912	Diagnosis and Treatment of Clostridium difficile Infection. Infectious Diseases in Clinical Practice, 2016, 24, 3-10.	0.1	26
913	Killing of VREEnterococcus faecalisby commensal strains: Evidence for evolution and accumulation of mobile elements in the absence of competition. Gut Microbes, 2016, 7, 90-96.	4.3	14
914	Predictors of fecal transplant failure. European Journal of Gastroenterology and Hepatology, 2016, 28, 826-830.	0.8	33
915	Can attention to the intestinal microbiota improve understanding and treatment of anorexia nervosa?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 565-569.	1.4	33
916	Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease. Internal Medicine Journal, 2016, 46, 266-273.	0.5	22
917	Fecal Microbiota Transplantation for Ulcerative Colitis: FoMenTing Change?. Digestive Diseases and Sciences, 2016, 61, 2154-2155.	1.1	2
918	Reflections from Infection Prevention 2015: beating the bugs, improving the systems and thinking outside the box. Journal of Infection Prevention, 2016, 17, 37-41.	0.5	1
919	New Therapeutic Strategies for Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2016, 36, 005-014.	1.8	41
920	Targeting Dysbiosis for the Treatment of Liver Disease. Seminars in Liver Disease, 2016, 36, 037-047.	1.8	40
922	Protective and pro-inflammatory roles of intestinal bacteria. Pathophysiology, 2016, 23, 67-80.	1.0	67
923	Manipulating Bacterial Communities by in situ Microbiome Engineering. Trends in Genetics, 2016, 32, 189-200.	2.9	216

#	Article	IF	Citations
924	A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection. Journal of Infectious Diseases, 2016, 214, 173-181.	1.9	277
925	Gastric Helicobacter pylori Infection Affects Local and Distant Microbial Populations and Host Responses. Cell Reports, 2016, 14, 1395-1407.	2.9	122
926	Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 150-160.	8.2	128
927	Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 111-118.	1.0	28
928	TLR-7 activation enhances IL-22â€“mediated colonization resistance against vancomycin-resistant enterococcus. Science Translational Medicine, 2016, 8, 327ra25.	5.8	77
929	Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Clinical Gastroenterology and Hepatology, 2016, 14, 1433-1438.	2.4	190
930	Clinical implications of antibiotic impact on gastrointestinal microbiota andClostridium difficileinfection. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1145-1152.	1.4	30
931	Intestinal stem cells and intestinal homeostasis in health and in inflammation: A review. Surgery, 2016, 159, 1237-1248.	1.0	22
932	Self-Limited Sepsis Syndrome Following Fecal Microbiota Therapy for Refractory C. difficile Infection. Digestive Diseases and Sciences, 2016, 61, 2488-2491.	1.1	1
933	Faecal microbiota transplantationâ€”A clinical view. International Journal of Medical Microbiology, 2016, 306, 310-315.	1.5	13
934	Step-up fecal microbiota transplantation (FMT) strategy. Gut Microbes, 2016, 7, 323-328.	4.3	52
935	Fecal microbiota transplantation for recurrent Clostridium difficile infection: The patient experience. American Journal of Infection Control, 2016, 44, 554-559.	1.1	19
936	Therapies on the horizon forClostridium difficileinfections. Expert Opinion on Investigational Drugs, 2016, 25, 541-555.	1.9	22
937	The human microbiota: novel targets for hospital-acquired infections and antibiotic resistance. Annals of Epidemiology, 2016, 26, 342-347.	0.9	35
938	Signaling in Host-Associated Microbial Communities. Cell, 2016, 164, 1288-1300.	13.5	130
939	Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice. Gut Microbes, 2016, 7, 101-114.	4.3	107
940	Gut inflammation and microbiome in spondyloarthritis. Rheumatology International, 2016, 36, 457-468.	1.5	14
941	Adverse events in faecal microbiota transplant: aÂreview of the literature. Journal of Hospital Infection, 2016, 92, 117-127.	1.4	160

#	Article	IF	Citations
942	Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework. FEMS Microbiology Letters, 2016, 363, fnv241.	0.7	11
943	Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With RecurrentClostridium difficileInfection. JAMA - Journal of the American Medical Association, 2016, 315, 142.	3.8	511
944	Research in Review: Driving Critical Care Practice Change. American Journal of Critical Care, 2016, 25, 76-84.	0.8	1
945	Estimating the risks of faecal transplants. Journal of Hospital Infection, 2016, 92, 128-129.	1.4	1
946	Emerging Frontiers in Drug Delivery. Journal of the American Chemical Society, 2016, 138, 704-717.	6.6	776
947	Patient needs and research priorities in probiotics: A quantitative KOL prioritization analysis with emphasis on infants and children. PharmaNutrition, 2016, 4, 19-28.	0.8	6
948	Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study. Clinical and Experimental Nephrology, 2016, 20, 731-739.	0.7	85
949	Spectrum of Clostridium difficile infections: Particular clinical situations. Anaerobe, 2016, 37, 3-7.	1.0	4
950	The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nature Reviews Nephrology, 2016, 12, 169-181.	4.1	258
951	Clinical and Healthcare Burden of Multiple Recurrences ofClostridium difficileInfection. Clinical Infectious Diseases, 2016, 62, 574-580.	2.9	116
952	The microbiome, HLA, and the pathogenesis of uveitis. Japanese Journal of Ophthalmology, 2016, 60, 1-6.	0.9	27
953	Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 387-394.	0.6	256
955	Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design. FEMS Microbiology Reviews, 2016, 40, 117-132.	3.9	303
956	Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation. Digestive and Liver Disease, 2016, 48, 242-247.	0.4	53
957	Recurrent Clostridium difficile infection and the microbiome. Journal of Gastroenterology, 2016, 51, 1-10.	2.3	27
958	Fecal Microbiota Transplant. Journal of Intensive Care Medicine, 2016, 31, 577-586.	1.3	23
959	Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence. Gut, 2016, 65, 225-237.	6.1	317
960	Upper Versus Lower Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent or Refractory Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2017, 51, 145-150.	1.1	52

#	Article	IF	Citations
961	Fecal Transplantation Successfully Treats Recurrent Dâ€Lactic Acidosis in a Child With Short Bowel Syndrome. Journal of Parenteral and Enteral Nutrition, 2017, 41, 896-897.	1.3	31
962	A human gut ecosystem protects against C. difficile disease by targeting TcdA. Journal of Gastroenterology, 2017, 52, 452-465.	2.3	28
963	The possible mechanisms of the human microbiome in allergic diseases. European Archives of Oto-Rhino-Laryngology, 2017, 274, 617-626.	0.8	84
964	Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases. Molecular Nutrition and Food Research, 2017, 61, 1600129.	1.5	110
965	Gut microbiota: A player in aging and a target for anti-aging intervention. Ageing Research Reviews, 2017, 35, 36-45.	5.0	346
966	Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes, 2017, 8, 303-309.	4.3	64
967	Microbiomes in respiratory health and disease: An Asiaâ€Pacific perspective. Respirology, 2017, 22, 240-250.	1.3	88
969	Fecal microbial transplantation as a therapeutic option in patients colonized with antibiotic resistant organisms. Gut Microbes, 2017, 8, 221-224.	4.3	26
970	The microbiome as a source of new enterprises and job creation: Considering clinical faecal and synthetic microbiomeÂtransplants and therapeutic regulation. Microbial Biotechnology, 2017, 10, 4-5.	2.0	9
971	Gut Microbiota Mediates Protection Against Enteropathy Induced by Indomethacin. Scientific Reports, 2017, 7, 40317.	1.6	33
972	Geriatric Infectious Diseases: Current Concepts on Diagnosis and Management. Journal of the American Geriatrics Society, 2017, 65, 631-641.	1.3	50
973	Intestinal Microbiota: Facts and Fiction. Digestive Diseases, 2017, 35, 139-147.	0.8	28
974	Fecal Microbiota Transplantation. Gastroenterology Clinics of North America, 2017, 46, 171-185.	1.0	161
975	Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Journal of Clinical Microbiology, 2017, 55, 1002-1010.	1.8	59
976	The AGAâ€™s Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics. Gastroenterology, 2017, 152, 681-684.	0.6	56
977	Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. Gut Microbes, 2017, 8, 225-237.	4.3	77
978	The gut microbiome in human neurological disease: A review. Annals of Neurology, 2017, 81, 369-382.	2.8	388
979	Gut microbiome-based medical methodologies for early-stage disease prevention. Microbial Pathogenesis, 2017, 105, 122-130.	1.3	20

#	Article	IF	Citations
980	Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection â€“ fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Alimentary Pharmacology and Therapeutics, 2017, 45, 899-908.	1.9	148
981	Clostridium difficileâ€“Associated Diarrhea in the Oncology Patient. Journal of Oncology Practice, 2017, 13, 25-30.	2.5	40
982	Breaking down the gut microbiome composition in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 628-636.	1.4	38
983	Is intensity the solution for FMT in ulcerative colitis?. Lancet, The, 2017, 389, 1170-1172.	6.3	15
984	The role of the gut microbiota in sepsis. The Lancet Gastroenterology and Hepatology, 2017, 2, 135-143.	3.7	198
986	Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut Microbes, 2017, 8, 238-252.	4.3	295
987	Small Molecules That Sabotage Bacterial Virulence. Trends in Pharmacological Sciences, 2017, 38, 339-362.	4.0	111
988	The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?. Therapie, 2017, 72, 21-38.	0.6	28
989	Role of microbial communities in the pathogenesis of periodontal diseases and caries. Journal of Clinical Periodontology, 2017, 44, S23-S38.	2.3	176
990	Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota. Gut Microbes, 2017, 8, 276-288.	4.3	39
994	Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes, 2017, 8, 253-267.	4.3	234
995	The microbiome in allergic disease: Current understanding and future opportunitiesâ€”2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2017, 139, 1099-1110.	1.5	264
996	Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft- versus -host-disease. Haematologica, 2017, 102, e210-e213.	1.7	111
997	Antibiotics, gut microbiota, environment in early life and type 1 diabetes. Pharmacological Research, 2017, 119, 219-226.	3.1	44
998	Possible Alternative Predictors of Failure of Fecal Microbiota Transplant for Therapy of Recurrent C difficile Infection. American Journal of Gastroenterology, 2017, 112, 390-391.	0.2	1
999	European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017, 66, 569-580.	6.1	793
1000	Effect of Aging on the Composition of Fecal Microbiota in Donors for FMT and Its Impact on Clinical Outcomes. Digestive Diseases and Sciences, 2017, 62, 1002-1008.	1.1	37
1001	Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. Gastroenterology, 2017, 152, 1671-1678.	0.6	334

#	Article	IF	Citations
1002	Antibiotic treatment for Clostridium difficile -associated diarrhoea in adults. The Cochrane Library, 2017, 2017, CD004610.	1.5	161
1003	Is chronic rhinosinusitis an infectious disease? Insights from a microbiota metaâ€analysis. Environmental Microbiology, 2017, 19, 1359-1362.	1.8	0
1004	Dysbiosis and the immune system. Nature Reviews Immunology, 2017, 17, 219-232.	10.6	1,102
1005	Roles of the intestinal microbiota in pathogen protection. Clinical and Translational Immunology, 2017, 6, e128.	1.7	142
1006	Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet, The, 2017, 389, 1218-1228.	6.3	908
1007	Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study. American Journal of Gastroenterology, 2017, 112, 940-947.	0.2	164
1008	Emerging treatments for primary sclerosing cholangitis. Expert Review of Gastroenterology and Hepatology, 2017, 11, 451-459.	1.4	12
1009	Cardiac Ultrasound Is a Competency of Critical Care Medicine. Critical Care Medicine, 2017, 45, 1555-1557.	0.4	7
1010	The Absence of Fever Is Associated With Higher Mortality and Decreased Antibiotic and IV Fluid Administration in Emergency Department Patients With Suspected Septic Shock. Critical Care Medicine, 2017, 45, e575-e582.	0.4	44
1011	Effects of IV Acetaminophen on Core Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults: A Randomized Controlled Trial. Critical Care Medicine, 2017, 45, 1199-1207.	0.4	24
1012	JPEN Journal Club 26. Small Trials With Dramatic Findings. Journal of Parenteral and Enteral Nutrition, 2017, 41, 517-519.	1.3	6
1013	Factors Leading to Transmission Risk of Acinetobacter baumannii*. Critical Care Medicine, 2017, 45, e633-e639.	0.4	28
1014	Effects of Hypercapnia and Hypercapnic Acidosis on Hospital Mortality in Mechanically Ventilated Patients*. Critical Care Medicine, 2017, 45, e649-e656.	0.4	66
1015	Core Domains for Clinical Research in Acute Respiratory Failure Survivors: An International Modified Delphi Consensus Study. Critical Care Medicine, 2017, 45, 1001-1010.	0.4	68
1016	The Economic and Clinical Impact of Sustained Use of a Progressive Mobility Program in a Neuro-ICU*. Critical Care Medicine, 2017, 45, 1037-1044.	0.4	18
1017	Electroencephalography Predicts Poor and Good Outcomes After Cardiac Arrest: A Two-Center Study*. Critical Care Medicine, 2017, 45, e674-e682.	0.4	113
1018	Intestinal Microbiology and Ecology in Crohnâ€™s Disease and Ulcerative Colitis. , 2017, , 67-74.		1
1019	The Molecular Revolution in Cutaneous Biology: Investigating the SkinÂMicrobiome. Journal of Investigative Dermatology, 2017, 137, e119-e122.	0.3	39

#	Article	IF	Citations
1020	Cutaneous Burn Injury Modulates Urinary Antimicrobial Peptide Responses and the Urinary Microbiome. Critical Care Medicine, 2017, 45, e543-e551.	0.4	15
1021	Brain Gray Matter MRI Morphometry for Neuroprognostication After Cardiac Arrest. Critical Care Medicine, 2017, 45, e763-e771.	0.4	16
1022	Early Systolic Dysfunction Following Traumatic Brain Injury: A Cohort Study. Critical Care Medicine, 2017, 45, 1028-1036.	0.4	44
1023	The intestinal microbiota, energy balance, and malnutrition: emphasis on the role of short-chain fatty acids. Expert Review of Endocrinology and Metabolism, 2017, 12, 215-226.	1.2	30
1024	Homeostatic Immunity and the Microbiota. Immunity, 2017, 46, 562-576.	6.6	840
1025	Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. Therapeutic Advances in Gastroenterology, 2017, 10, 373-381.	1.4	35
1026	Comparative effectiveness of faecal microbiota transplant by route of administration. Journal of Hospital Infection, 2017, 96, 349-352.	1.4	19
1027	Clostridium difficile Infection in Older Adults: Systematic Review of Efforts to Reduce Occurrence and Improve Outcomes. The Consultant Pharmacist, 2017, 32, 24-41.	0.4	4
1028	What happened toKoch's postulates in diarrhoea?. Environmental Microbiology, 2017, 19, 2926-2934.	1.8	10
1029	Tracking microbial colonization in fecal microbiota transplantation experiments via genome-resolved metagenomics. Microbiome, 2017, 5, 50.	4.9	78
1030	Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 2017, 11, 1180-1199.	0.6	323
1031	Allied Commensal Forces against Vancomycin-Resistant Enterococci. Cell Host and Microbe, 2017, 21, 559-560.	5.1	11
1032	Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?. Annals of Pharmacotherapy, 2017, 51, 804-810.	0.9	15
1034	Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 903-911.	0.9	91
1035	Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2017, 62, 2870-2875.	1.1	31
1036	Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nature Microbiology, 2017, 2, 17057.	5.9	553
1037	Antibiotic-Associated Apoptotic Enterocolitis in the Absence of a Defined Pathogen: The Role of Intestinal Microbiota Depletion*. Critical Care Medicine, 2017, 45, e600-e606.	0.4	38
1038	Aesthetics, Ethics, and Fecal Microbiota Transplantations. American Journal of Bioethics, 2017, 17, 51-52.	0.5	1

#	Article	IF	Citations
1039	Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. Journal of Cystic Fibrosis, 2017, 16, 291-298.	0.3	25
1040	Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology, 2017, 152, 799-811.e7.	0.6	498
1041	Consensus report: faecal microbiota transfer â€“ clinical applications and procedures. Alimentary Pharmacology and Therapeutics, 2017, 45, 222-239.	1.9	95
1042	Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System. Cell Metabolism, 2017, 26, 110-130.	7.2	572
1043	The Microbiome and Immune Regulation After Transplantation. Transplantation, 2017, 101, 56-62.	0.5	22
1044	Systematic review with metaâ€analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2017, 46, 213-224.	1.9	210
1045	Microbiota-Based Therapies for Clostridium difficile and Antibiotic-Resistant Enteric Infections. Annual Review of Microbiology, 2017, 71, 157-178.	2.9	45
1046	The resilience of the intestinal microbiota influences health and disease. Nature Reviews Microbiology, 2017, 15, 630-638.	13.6	696
1047	Editorial: yoga for QoL in ulcerative colitisâ€”any better than other supportive activities?. Alimentary Pharmacology and Therapeutics, 2017, 46, 201-202.	1.9	2
1048	Alteration of the gut microbiota in Chinese population with chronic kidney disease. Scientific Reports, 2017, 7, 2870.	1.6	192
1049	How to: Establish and run a stool bank. Clinical Microbiology and Infection, 2017, 23, 924-930.	2.8	120
1050	Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis?. Diagnostic Microbiology and Infectious Disease, 2017, 88, 322-329.	0.8	56
1051	Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 116-125.	0.9	106
1052	Topical Antimicrobial Treatments Can Elicit Shifts to Resident Skin Bacterial Communities and Reduce Colonization by Staphylococcus aureus Competitors. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	48
1053	Microbiota Analysis Using an Illumina MiSeq Platform to Sequence 16S rRNA Genes. Current Protocols in Mouse Biology, 2017, 7, 100-129.	1.2	37
1054	Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence ofClostridium difficileinfection. Expert Review of Gastroenterology and Hepatology, 2017, 11, 611-622.	1.4	11
1055	Early Gut Microbiota Intervention Suppresses DSS-Induced Inflammatory Responses by Deactivating TLR/NLR Signalling in Pigs. Scientific Reports, 2017, 7, 3224.	1.6	39
1057	DistinguishingClostridium difficileRecurrence From Reinfection: Independent Validation of Current Recommendations. Infection Control and Hospital Epidemiology, 2017, 38, 891-896.	1.0	19

#	Article	IF	Citations
1058	Commensal microbes provide first line defense against Listeria monocytogenes infection. Journal of Experimental Medicine, 2017, 214, 1973-1989.	4.2	173
1059	Optimizing methods and dodging pitfalls in microbiome research. Microbiome, 2017, 5, 52.	4.9	420
1060	The path towards microbiome-based metabolite treatment. Nature Microbiology, 2017, 2, 17075.	5.9	103
1061	Bacteriophage transfer during faecal microbiota transplantation inClostridium difficileinfection is associated with treatment outcome. Gut, 2018, 67, gutjnl-2017-313952.	6.1	241
1062	Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection. Artificial Intelligence in Medicine, 2017, 78, 1-13.	3.8	28
1063	The interplay between host immune cells and gut microbiota in chronic inflammatory diseases. Experimental and Molecular Medicine, 2017, 49, e339-e339.	3.2	146
1064	Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. Gut Microbes, 2017, 8, 440-450.	4.3	56
1065	Gut microbiota and host defense in critical illness. Current Opinion in Critical Care, 2017, 23, 257-263.	1.6	43
1067	Gut microbiota and acute graft-versus-host disease. Pharmacological Research, 2017, 122, 90-95.	3.1	15
1068	Editorial: Making Fecal Microbiota Transplantation Easier to Swallow: Freeze-Dried Preparation for Recurrent Clostridium difficile Infections. American Journal of Gastroenterology, 2017, 112, 948-950.	0.2	17
1069	The gut microbiome and cardiovascular risk: current perspective and gaps of knowledge. Future Cardiology, 2017, 13, 191-194.	0.5	9
1070	Fecal microbiota transplantation for gastrointestinal disorders. Current Opinion in Gastroenterology, 2017, 33, 8-13.	1.0	34
1071	Transmission of the gut microbiota: spreading of health. Nature Reviews Microbiology, 2017, 15, 531-543.	13.6	150
1072	External Validation of Three Prediction Tools for Patients at Risk of a Complicated Course of Clostridium difficile Infection: Disappointing in an Outbreak Setting. Infection Control and Hospital Epidemiology, 2017, 38, 897-905.	1.0	11
1073	Faecal transplantation for the treatment of Clostridium difficile infection in a marmoset. BMC Veterinary Research, 2017, 13, 150.	0.7	20
1074	Fecal Microbiota Transplantation: Do We Need Harmonization?. Clinical Infectious Diseases, 2017, 64, 1292-1292.	2.9	8
1076	Are non-communicable diseases chronically communicable: A role for the human microbiota?. Medical Hypotheses, 2017, 104, 126-127.	0.8	2
1077	Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases, 2017, 215, 1117-1123.	1.9	81

#	Article	IF	Citations
1079	Mining the fecal proteome: from biomarkers to personalised medicine. Expert Review of Proteomics, 2017, 14, 445-459.	1.3	36
1080	Clostridium difficile. Clinics in Laboratory Medicine, 2017, 37, 341-369.	0.7	28
1081	Fecal Microbiota Transplantation in Patients With Blood Disorders Inhibits Gut Colonization With Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study. Clinical Infectious Diseases, 2017, 65, 364-370.	2.9	204
1082	The development of probiotics for womenâ€™s health. Canadian Journal of Microbiology, 2017, 63, 269-277.	0.8	50
1083	The Gut Microbiota and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1-15.	1.2	624
1084	Reproductive Microbiomes: A New Thread in the Microbial Network. Reproductive Sciences, 2017, 24, 1482-1492.	1.1	45
1085	Fecal Microbiota Transplant vs Oral Vancomycin Taper: Important Undiscussed Limitations. Clinical Infectious Diseases, 2017, 64, 1292-1293.	2.9	3
1086	Microbiota-targeted therapies on the intensive care unit. Current Opinion in Critical Care, 2017, 23, 167-174.	1.6	47
1087	Pathophysiology of the Gut and the Microbiome in the Host Response. Pediatric Critical Care Medicine, 2017, 18, S46-S49.	0.2	30
1088	A Perspective on Brainâ€“Gut Communication: The American Gastroenterology Association and American Psychosomatic Society Joint Symposium on Brainâ€“Gut Interactions and the Intestinal Microenvironment. Psychosomatic Medicine, 2017, 79, 847-856.	1.3	23
1089	Oral Teicoplanin as an Alternative First-Line Regimen in Clostridium difficile Infection in Elderly Patients: A Case Series. Clinical Drug Investigation, 2017, 37, 699-703.	1.1	10
1091	Characterization of the Fecal Bacterial Microbiota of Healthy and Diarrheic Dairy Calves. Journal of Veterinary Internal Medicine, 2017, 31, 928-939.	0.6	123
1092	Modulation of Gut Microbiota in Pathological States. Engineering, 2017, 3, 83-89.	3.2	26
1093	Mechanisms and consequences of intestinal dysbiosis. Cellular and Molecular Life Sciences, 2017, 74, 2959-2977.	2.4	401
1094	The Human Microbiota in Health and Disease. Engineering, 2017, 3, 71-82.	3.2	583
1095	Microbiome Tools for Forensic Science. Trends in Biotechnology, 2017, 35, 814-823.	4.9	93
1096	Gut Microbiota in Cardiovascular Health and Disease. Circulation Research, 2017, 120, 1183-1196.	2.0	1,079
1097	The intestinal microenvironment in sepsis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 2574-2583.	1.8	108

#	Article	IF	Citations
1098	Cadazolid for the treatment of Clostridium difficile. Expert Opinion on Investigational Drugs, 2017, 26, 509-514.	1.9	24
1099	Donor Considerations in Fecal Microbiota Transplantation. Current Gastroenterology Reports, 2017, 19, 10.	1.1	21
1100	Fecal microbiota transplant in severe and severe-complicatedClostridium difficile: A promising treatment approach. Gut Microbes, 2017, 8, 289-302.	4.3	150
1101	Gut-sparing treatment of urinary tract infection in patients at high risk ofClostridium difficileinfection. Journal of Antimicrobial Chemotherapy, 2017, 72, 522-528.	1.3	18
1102	Conflicts of interest and expertise of independent commenters in news stories about medical research. Cmaj, 2017, 189, E553-E559.	0.9	11
1103	Successful Therapy of Severe Pseudomembranous Clostridium difficile Colitis Using a Combination of Fecal Microbiota Therapy and Fidaxomicin. Medical Principles and Practice, 2017, 26, 182-184.	1.1	2
1104	A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection. Infection Control and Hospital Epidemiology, 2017, 38, 196-202.	1.0	48
1105	An evaluation of the therapeutic potential of fecal microbiota transplantation to treat infectious and metabolic diseases. EMBO Molecular Medicine, 2017, 9, 1-3.	3.3	19
1106	Microbiome and chronic inflammatory bowel diseases. Journal of Molecular Medicine, 2017, 95, 21-28.	1.7	14
1107	Clostridium difficile infection: Updates in management. Indian Journal of Gastroenterology, 2017, 36, 3-10.	0.7	6
1108	The emerging metabolic view of Clostridium difficile pathogenesis. Current Opinion in Microbiology, 2017, 35, 42-47.	2.3	42
1109	Probiotics and prevention of Clostridium difficile infection. Anaerobe, 2017, 45, 114-119.	1.0	33
1110	Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes, 2017, 8, 17-32.	4.3	89
1111	Process and Outcome of Fecal Microbiota Transplants in Patients With Recurrent Clostridium difficile Infection. Gastroenterology Nursing, 2017, 40, 411-419.	0.2	3
1113	Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metabolism, 2017, 26, 611-619.e6.	7.2	689
1115	Fecal Transplant in Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2017, 46, 825-837.	1.0	29
1116	Clostridium difficile in Older Adults. Infectious Disease Clinics of North America, 2017, 31, 743-756.	1.9	23
1117	Clostridium difficileinfection: new approaches to prevention, non-antimicrobial treatment, and stewardship. Expert Review of Anti-Infective Therapy, 2017, 15, 1027-1040.	2.0	19

#	Article	IF	Citations
1118	Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology, 2017, 66, 1727-1738.	3.6	454
1121	Ethical Considerations in Microbial Therapeutic Clinical Trials. New Bioethics, 2017, 23, 210-218.	0.5	7
1122	Comparative epidemiology of Clostridium difficile infection: England and the USA. International Journal for Quality in Health Care, 2017, 29, 785-791.	0.9	16
1123	The Microbiota and Energy Balanc. Endocrinology, 2017, , 1-18.	0.1	0
1124	Probiotic species in the modulation of the anticancer immune response. Seminars in Cancer Biology, 2017, 46, 182-190.	4.3	47
1125	Functional amplification and preservation of human gut microbiota. Microbial Ecology in Health and Disease, 2017, 28, 1308070.	3.8	10
1126	Recurrent Reverse Evolution Maintains Polymorphism after Strong Bottlenecks in Commensal Gut Bacteria. Molecular Biology and Evolution, 2017, 34, 2879-2892.	3.5	38
1127	Fecal transplantation for treatment of inflammatory bowel disease. The Cochrane Library, 0, , .	1.5	57
1128	The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1710-1717.	0.9	39
1129	The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. Immunological Reviews, 2017, 279, 90-105.	2.8	490
1130	Encapsulation of the therapeutic microbe Akkermansia muciniphila in a double emulsion enhances survival in simulated gastric conditions. Food Research International, 2017, 102, 372-379.	2.9	56
1131	Role of the gastrointestinal microbiota in small animal health and disease. Veterinary Record, 2017, 181, 370-370.	0.2	54
1132	2. Grundlagen. , 2017, , .		0
1133	Biochemical Mechanisms of Pathogen Restriction by Intestinal Bacteria. Trends in Biochemical Sciences, 2017, 42, 887-898.	3.7	39
1135	Investigation into the stability and culturability of Chinese enterotypes. Scientific Reports, 2017, 7, 7947.	1.6	32
1136	Faecal microbiota transplantation: establishment of a clinical application framework. European Journal of Gastroenterology and Hepatology, 2017, 29, e36-e45.	0.8	33
1137	The intricate connection between diet, microbiota, and cancer: A jigsaw puzzle. Seminars in Immunology, 2017, 32, 35-42.	2.7	19
1138	Clostridium difficile. Medicine, 2017, 45, 634-638.	0.2	1

#	Article	IF	Citations
1139	More than just a gut feeling: constraint-based genome-scale metabolic models for predicting functions of human intestinal microbes. Microbiome, 2017, 5, 78.	4.9	54
1140	Gut microbiota and IBD: causation or correlation?. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 573-584.	8.2	1,099
1141	Potential for Monitoring Gut Microbiota for Diagnosing Infections and Graft-versus-Host Disease in Cancer and Stem Cell Transplant Patients. Clinical Chemistry, 2017, 63, 1685-1694.	1.5	7
1142	The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes, 2017, 8, 574-588.	4.3	102
1143	Antimicrobial resistance in the next 30Âyears, humankind, bugs and drugs: a visionary approach. Intensive Care Medicine, 2017, 43, 1464-1475.	3.9	199
1144	Infection therapy: the problem of drug resistance â€“ and possible solutions. Microbial Biotechnology, 2017, 10, 1041-1046.	2.0	18
1145	Evolution, human-microbe interactions, and life history plasticity. Lancet, The, 2017, 390, 521-530.	6.3	178
1146	Systematic review with metaâ€analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Alimentary Pharmacology and Therapeutics, 2017, 46, 479-493.	1.9	455
1147	Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality. Bone Marrow Transplantation, 2017, 52, 1452-1454.	1.3	27
1148	The microbiota revolution: Excitement and caution. European Journal of Immunology, 2017, 47, 1406-1413.	1.6	30
1149	The human microbiome. Advances in Medical Sciences, 2017, 62, 414-420.	0.9	140
1150	Resultados de la implementaciÃ³n de un programa multidisciplinar de trasplante de microbiota fecal por colonoscopia para el tratamiento de la infecciÃ³n recurrente por Clostridium difficile. GastroenterologÃa Y HepatologÃa, 2017, 40, 605-614.	0.2	7
1151	Fecal Microbial Transplantation in Inflammatory Bowel Disease: A Movement Too Big to Be Ignored. Clinical Pharmacology and Therapeutics, 2017, 102, 588-590.	2.3	9
1152	Experience and Outcomes at a Specialized Clostridium difficile Clinical Practice. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 49-56.	1.2	17
1153	Changes in the Intestinal Microbiota of Gibel Carp (Carassius gibelio) Associated with Cyprinid herpesvirus 2 (CyHV-2) Infection. Current Microbiology, 2017, 74, 1130-1136.	1.0	42
1154	Persistent diarrhea: a persistent infection with enteropathogens or a gut commensal dysbiosis?. Environmental Microbiology, 2017, 19, 3789-3801.	1.8	17
1155	Genetically Engineered Bacteria for Treating Human Disease. Trends in Pharmacological Sciences, 2017, 38, 763-764.	4.0	8
1156	Clostridium difficile infections in young infants: Case presentations and literature review. IDCases, 2017, 10, 7-11.	0.4	17

#	Article	IF	Citations
1157	Therapy for Clostridium difficile infection â€“ any news beyond Metronidazole and Vancomycin?. Expert Review of Clinical Pharmacology, 2017, 10, 1239-1250.	1.3	10
1158	Nonantimicrobial drug targets for Clostridium difficile infections. Future Microbiology, 2017, 12, 975-985.	1.0	6
1159	Fecal Microbiota Transplant in Severe/Complicated Clostridium difficile Infection. Infectious Diseases in Clinical Practice, 2017, 25, 264-267.	0.1	1
1160	Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome. Digestion, 2017, 96, 29-38.	1.2	266
1161	A clinician's guide to microbiome analysis. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 585-595.	8.2	124
1162	Bezlotoxumab for the prevention ofClostridium difficilerecurrence. Expert Opinion on Biological Therapy, 2017, 17, 1-7.	1.4	6
1163	From Expert Protocols to Standardized Management of Infectious Diseases. Clinical Infectious Diseases, 2017, 65, S12-S19.	2.9	8
1164	The Intestinal Microbiome in Infectious Diseases: The Clinical Relevance of a Rapidly Emerging Field. Open Forum Infectious Diseases, 2017, 4, ofx144.	0.4	51
1165	Improving regulation of microbiota transplants. Science, 2017, 358, 1390-1391.	6.0	41
1166	Effect of Oral Capsuleâ€“ vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection. JAMA - Journal of the American Medical Association, 2017, 318, 1985.	3.8	446
1167	Capsules for Fecal Microbiota Transplantation in Recurrent Clostridium difficile Infection. JAMA - Journal of the American Medical Association, 2017, 318, 1979.	3.8	14
1168	Evaluating the effect of Clostridium difficile conditioned medium on fecal microbiota community structure. Scientific Reports, 2017, 7, 16448.	1.6	9
1169	Contemporary Applications of Fecal Microbiota Transplantation to Treat Intestinal Diseases in Humans. Archives of Medical Research, 2017, 48, 766-773.	1.5	37
1170	Enterococci and Their Interactions with the Intestinal Microbiome. Microbiology Spectrum, 2017, 5, .	1.2	131
1171	A Two-Week Fecal Microbiota Transplantation Course in Pediatric Patients with Inflammatory Bowel Disease. Advances in Experimental Medicine and Biology, 2017, 1047, 81-87.	0.8	30
1172	Results of the implementation of a multidisciplinary programme of faecal microbiota transplantation by colonoscopy for the treatment of recurrent Clostridium difficile infection. GastroenterologÃa Y HepatologÃa (English Edition), 2017, 40, 605-614.	0.0	1
1173	Recent Issues in Pediatric Clostridium difficile Infection. Current Infectious Disease Reports, 2017, 19, 49.	1.3	5
1174	Patientsâ€™ views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?. European Journal of Gastroenterology and Hepatology, 2017, 29, 322-330.	0.8	17

#	Article	IF	Citations
1175	The microbiome and big data. Current Opinion in Systems Biology, 2017, 4, 92-96.	1.3	11
1176	Fecal Microbiota Therapy With a Focus on Clostridium difficile Infection. Psychosomatic Medicine, 2017, 79, 868-873.	1.3	10
1177	The gut microbiome and liver cancer: mechanisms and clinical translation. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 527-539.	8.2	401
1179	Amelioration of Clostridium difficile Infection in Mice by Dietary Supplementation With Indole-3-carbinol. Annals of Surgery, 2017, 265, 1183-1191.	2.1	37
1180	The remedy within: will the microbiome fulfill its therapeutic promise?. Journal of Molecular Medicine, 2017, 95, 1021-1027.	1.7	30
1181	The microbiome: current and future view of an ancient paradigm. Future Microbiology, 2017, 12, 831-834.	1.0	1
1182	The Different Drummer: Non-traditional Therapeutic Approaches. Clinical Gastroenterology, 2017, , 205-216.	0.0	0
1183	Fecal Fixation: Fecal Microbiota Transplantation for Clostridium difficile Infection. Clinical Infectious Diseases, 2017, 64, 272-274.	2.9	10
1184	Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study. Intensive Care Medicine, 2017, 43, 59-68.	3.9	183
1185	Complications, effectiveness, and long term followâ€up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United European Gastroenterology Journal, 2017, 5, 868-879.	1.6	64
1186	Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clinical Microbiology Reviews, 2017, 30, 191-231.	5.7	67
1187	The microbiome and human disease pathogenesis: how do you do what you do to me â€¦?. Translational Research, 2017, 179, 1-6.	2.2	4
1188	Gutâ€“lung axis: The microbial contributions and clinical implications. Critical Reviews in Microbiology, 2017, 43, 81-95.	2.7	188
1189	Introducing the Microbiome into Precision Medicine. Trends in Pharmacological Sciences, 2017, 38, 81-91.	4.0	84
1190	The microbiome-metabolome crosstalk in the pathogenesis of respiratory fungal diseases. Virulence, 2017, 8, 673-684.	1.8	25
1191	Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota. Translational Research, 2017, 179, 116-125.	2.2	16
1192	Hypoxia and inflammatory bowel disease. Microbes and Infection, 2017, 19, 210-221.	1.0	53
1193	Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis. Journal of Gastroenterology, 2017, 52, 476-482.	2.3	66

#	Article	IF	Citations
1194	Chronic Diarrhea. , 2017, , 341-350.e1.		0
1195	Clostridium difficile Infections in Hospitals and Community. , 2017, , 351-354.e1.		1
1196	Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 177-185.	1.3	16
1197	Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Applied Microbiology and Biotechnology, 2017, 101, 47-64.	1.7	387
1198	Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial. Clinical Infectious Diseases, 2017, 64, 265-271.	2.9	145
1199	Diagnosis and treatment of Clostridium difficile (C. diff) colitis: Review of the literature and a perspective in gynecologic oncology. Gynecologic Oncology, 2017, 144, 428-437.	0.6	6
1200	Fecal Microbiota Transfer for Multidrug-Resistant Gram-Negatives: A Clinical Success Combined With Microbiological Failure. Open Forum Infectious Diseases, 2017, 4, ofx047.	0.4	34
1201	The Gut Microbiome and Its Marriage to the Immune System: Can We Change It All?. Birkhauser Advances in Infectious Diseases, 2017, , 191-208.	0.3	0
1203	Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches. Gastroenterology Clinics of North America, 2017, 46, 689-729.	1.0	27
1204	Faecal transplantation for IBD managementâ€"pitfalls and promises. British Medical Bulletin, 2017, 124, 1-10.	2.7	4
1205	Lien entre les probiotiques et le microbiote : vision du clinicien. Cahiers De Nutrition Et De Dietetique, 2017, 52, S5-S12.	0.2	1
1206	Impact of Fecal Microbiota Transplantation for Decolonization of Multidrug-Resistant Organisms May Vary According to Donor Microbiota. Clinical Infectious Diseases, 2018, 66, 1316-1317.	2.9	4
1207	Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases. Open Forum Infectious Diseases, 2017, 4, ofx243.	0.4	38
1210	FMT in IBD: What Have We Learned?. Digestive Diseases and Sciences, 2017, 62, 2618-2620.	1.1	2
1211	Characterizing the gut microbiome in trauma: significant changes in microbial diversity occur early after severe injury. Trauma Surgery and Acute Care Open, 2017, 2, e000108.	0.8	83
1212	Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?. MÃ©decine Et Maladies Infectieuses, 2017, 47, 532-539.	5.1	4
1213	Koch Postulate: Why Should we Grow Bacteria?. Archives of Medical Research, 2017, 48, 774-779.	1.5	6
1214	5. Mikrobiom. , 2017, , .		0

#	Article	IF	Citations
1215	8. InfektiÃ¶se Durchfallerkrankungen. , 2017, , .		0
1216	41 Wichtige aktuelle Leitlinien â€“ kurz erlÃutert. , 2017, , 505-514.		0
1217	Novel Concept of a Heart-Gut Axis in the Pathophysiology of Heart Failure. Korean Circulation Journal, 2017, 47, 663.	0.7	47
1218	Identification of the Microbiota in the Aging Process. , 2017, , 37-56.		3
1219	Microbiome in atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 51-56.	0.8	54
1220	Recent Development of Prebiotic Researchâ€"Statement from an Expert Workshop. Nutrients, 2017, 9, 1376.	1.7	24
1221	The Human Gut Phage Community and Its Implications for Health and Disease. Viruses, 2017, 9, 141.	1.5	206
1222	Characterizing and Functionally Defining the Gut Microbiota: Methodology and Implications. , 2017, , 15-25.		3
1223	The Human Microbiome and the Missing Heritability Problem. Frontiers in Genetics, 2017, 8, 80.	1.1	67
1224	Cecal Microbiota in Broilers Fed with Prebiotics. Frontiers in Genetics, 2017, 8, 153.	1.1	10
1225	The Microbiota and Epigenetic Regulation of T Helper 17/Regulatory T Cells: In Search of a Balanced Immune System. Frontiers in Immunology, 2017, 8, 417.	2.2	103
1226	Interactions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease. Frontiers in Immunology, 2017, 8, 942.	2.2	249
1227	Beneficial Microorganisms for Corals (BMC): Proposed Mechanisms for Coral Health and Resilience. Frontiers in Microbiology, 2017, 8, 341.	1.5	425
1228	Drosophila melanogaster as a High-Throughput Model for Hostâ€"Microbiota Interactions. Frontiers in Microbiology, 2017, 8, 751.	1.5	63
1229	Gut Bacteria Missing in Severe Acute Malnutrition, Can We Identify Potential Probiotics by Culturomics?. Frontiers in Microbiology, 2017, 8, 899.	1.5	93
1230	Human Gut Microbiota: Toward an Ecology of Disease. Frontiers in Microbiology, 2017, 8, 1265.	1.5	110
1231	Host-microbial Cross-talk in Inflammatory Bowel Disease. Immune Network, 2017, 17, 1.	1.6	147
1232	Linking Gut Microbiota to Colorectal Cancer. Journal of Cancer, 2017, 8, 3378-3395.	1.2	104

#	Article	IF	Citations
1233	Human Microbiome and Aging. , 2017, , 43-51.		1
1234	The microbiota in inflammatory bowel disease: current and therapeutic insights. Journal of Inflammation Research, 2017, Volume 10, 63-73.	1.6	168
1235	Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders. Journal of Neurogastroenterology and Motility, 2017, 23, 9-19.	0.8	19
1236	The Microbiome: a Key Player in Human Health and Disease. Journal of Healthcare Communications, 2017, 02, .	0.8	6
1237	Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PLoS ONE, 2017, 12, e0170258.	1.1	38
1238	Faecal microbiota transplantation for Clostridium difficile â€associated diarrhoea: a systematic review of randomised controlled trials. Medical Journal of Australia, 2017, 207, 166-172.	0.8	109
1239	Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome. PLoS ONE, 2017, 12, e0189768.	1.1	39
1240	Faecal microbiota transplantation: a regulatory hurdle?. BMC Gastroenterology, 2017, 17, 128.	0.8	28
1241	Biobanking for human microbiome research: promise, risks, and ethics. Asian Bioethics Review, 2017, 9, 311-324.	0.9	10
1242	Â«Mikrobiota-TuningÂ» en vogue: Von der ErnÃhrung Ã¼ber Probiotika bis zur fÃkalen Mikrobiota-Transplantation. Schweizerische Zeitschrift FÃ¼r GanzheitsMedizin, 2017, 29, 144-148.	0.0	1
1243	Reply to Galperine et al and Jansen. Clinical Infectious Diseases, 2017, 64, 1293-1295.	2.9	1
1244	Fecal Microbiota Transplantation and Its Potential Therapeutic Uses in Gastrointestinal Disorders. Ä°stanbul Kuzey Klinikleri, 2017, 5, 79-88.	0.1	16
1245	Safety and effectiveness of fecal microbiota transplantation: a systematic review. Journal of the Korean Medical Association, 2017, 60, 761.	0.1	0
1246	Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients. Intestinal Research, 2017, 15, 68.	1.0	32
1247	Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?. Intestinal Research, 2017, 15, 145.	1.0	0
1248	Effects of Natural and Chemically Defined Nutrients on <I>Candida albicans</I> Water-soluble Fraction (CAWS) Vasculitis in Mice. Medical Mycology Journal, 2017, 58, E47-E62.	0.5	8
1249	Faecal microbiota transplantation for Clostridium difficile infection: a multicentre study of nonâ€responders. Medical Journal of Australia, 2017, 207, 159-160.	0.8	5
1250	Serial Frozen Fecal Microbiota Transplantation in the Treatment of Chronic Intestinal Pseudo-obstruction: A Preliminary Study. Journal of Neurogastroenterology and Motility, 2017, 23, 289-297.	0.8	42

#	Article	IF	Citations
1251	FMT in Clostridium difficile and Other Potential Uses. , 2017, , 315-326.		0
1252	Cost-Effectiveness of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium Difficile Infection: A Literature Review. Cureus, 2017, 9, e1599.	0.2	17
1253	Precision Medicine and Challenges in Research and Clinical Implementation. , 2017, , 717-732.		3
1254	Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review. Infection Control and Hospital Epidemiology, 2018, 39, 412-424.	1.0	30
1255	Clostridioides (Clostridium) difficileinfection: current and alternative therapeutic strategies. Future Microbiology, 2018, 13, 469-482.	1.0	8
1256	Multiscale Evolutionary Dynamics of Host-Associated Microbiomes. Cell, 2018, 172, 1216-1227.	13.5	85
1257	The Human Gut Microbiome: From Association to Modulation. Cell, 2018, 172, 1198-1215.	13.5	558
1258	Concomitant resolution through fecal microbiota transplantation of Clostridium difficile and OXA-48-producing Klebsiella pneumoniae. Infectious Diseases, 2018, 50, 565-566.	1.4	0
1259	Competitively Selected Donor Fecal Microbiota Transplantation. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 185-187.	0.9	23
1260	Treatment of recurrent Clostridium difficile colitis: a narrative review. Gastroenterology Report, 2018, 6, 21-28.	0.6	45
1261	Gut microbiota and its implications in small bowel transplantation. Frontiers of Medicine, 2018, 12, 239-248.	1.5	11
1262	New and emerging therapies in treatment of Clostridium difficile infection. European Journal of Gastroenterology and Hepatology, 2018, 30, 589-597.	0.8	5
1263	Antibiotic treatment and stewardship in the era of microbiota-oriented diagnostics. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 795-798.	1.3	4
1264	Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections. Clinical Infectious Diseases, 2018, 66, 645-650.	2.9	106
1265	Is a Single Fecal Microbiota Transplant a Promising Treatment for Recurrent Clostridium difficile Infection?. Open Forum Infectious Diseases, 2018, 5, ofy045.	0.4	16
1266	Pre-colonization with the commensal fungusCandida albicansreduces murine susceptibility toClostridium difficileinfection. Gut Microbes, 2018, 9, 1-13.	4.3	57
1267	Help, hope and hype: ethical considerations of human microbiome research and applications. Protein and Cell, 2018, 9, 404-415.	4.8	88
1268	Regional variability in fecal microbiota transplantation practices: a survey of the Southern Ontario Fecal Microbiota Transplantation Movement. CMAJ Open, 2018, 6, E184-E190.	1.1	9

#	Article	IF	Citations
1269	Microbiota transplantation: concept, methodology and strategy for its modernization. Protein and Cell, 2018, 9, 462-473.	4.8	201
1270	Harnessing the microbiome for human health. Microbial Biotechnology, 2018, 11, 435-436.	2.0	1
1271	Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe, 2018, 53, 64-73.	1.0	144
1272	The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. Journal of Affective Disorders, 2018, 235, 506-512.	2.0	134
1273	Guided Protocol for Fecal Microbial Characterization by 16S rRNA-Amplicon Sequencing. Journal of Visualized Experiments, 2018, , .	0.2	14
1274	What will it take to understand the ecology of symbiotic microorganisms?. Environmental Microbiology, 2018, 20, 1920-1924.	1.8	9
1275	Successful Fecal Microbiota Transplantation in a Patient with Severe Complicated <i>Clostridium difficile</i> Infection after Liver Transplantation. Case Reports in Gastroenterology, 2018, 12, 76-84.	0.3	24
1276	Recruitment of feces donors among blood donors: Results from an observational cohort study. Gut Microbes, 2018, 9, 1-11.	4.3	27
1277	Invited Commentary: The Microbiome and Population Healthâ€"Considerations for Enhancing Study Design and Data Analysis in Observational and Interventional Epidemiology. American Journal of Epidemiology, 2018, 187, 1291-1294.	1.6	3
1278	Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1281-1288.	1.3	10
1279	Methodological Strategies in Microbiome Research and their Explanatory Implications. Perspectives on Science, 2018, 26, 239-265.	0.3	14
1280	Microbiome and Gut Dysbiosis. Experientia Supplementum (2012), 2018, 109, 459-476.	0.5	121
1281	Complementary medicine for axial spondyloarthritis: is there any scientific evidence?. Current Opinion in Rheumatology, 2018, 30, 310-318.	2.0	14
1282	Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. Infectious Diseases and Therapy, 2018, 7, 71-86.	1.8	45
1283	Tacrolimus concentration to dose ratio in solid organ transplant patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. Transplant Infectious Disease, 2018, 20, e12857.	0.7	2
1284	The mechanistic link between health and gut microbiota diversity. Scientific Reports, 2018, 8, 2183.	1.6	88
1285	Regulation of T cell proliferation with drug-responsive microRNA switches. Nucleic Acids Research, 2018, 46, 1541-1552.	6.5	31
1286	Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. Cell Host and Microbe, 2018, 23, 229-240.e5.	5.1	292

#	Article	IF	Citations
1287	Diagnosis and Treatment of Undifferentiated and Infectious Acute Diarrhea in the Adult Horse. Veterinary Clinics of North America Equine Practice, 2018, 34, 39-53.	0.3	24
1288	The role of gut microbiota in Clostridium difficile infection. European Journal of Internal Medicine, 2018, 50, 28-32.	1.0	58
1289	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 2018, 66, e1-e48.	2.9	1,695
1290	Factors Associated with the Use of Fecal Microbiota Transplant in Patients with Recurrent Clostridium difficile Infections. Infection Control and Hospital Epidemiology, 2018, 39, 302-306.	1.0	2
1291	Faecal Microbiota Transplantation as Emerging Treatment in European Countries. Advances in Experimental Medicine and Biology, 2018, 1050, 177-195.	0.8	7
1292	European Practice for CDI Treatment. Advances in Experimental Medicine and Biology, 2018, 1050, 117-135.	0.8	9
1293	Fecal Microbiota Transplants: Current Knowledge and Future Directions. , 2018, , 279-302.		0
1294	Altered Microbiota and Their Metabolism in Host Metabolic Diseases. , 2018, , 129-165.		1
1295	Adaptive immune education by gut microbiota antigens. Immunology, 2018, 154, 28-37.	2.0	203
1296	Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans. Endocrine Reviews, 2018, 39, 133-153.	8.9	207
1297	Institutional review of the implementation and use of a Clostridium difficile infection bundle and probiotics in adult trauma patients. American Journal of Surgery, 2018, 215, 825-830.	0.9	4
1298	Research Agenda for Microbiome Based Research for Multidrug-resistant Organism Prevention in the Veterans Health Administration System. Infection Control and Hospital Epidemiology, 2018, 39, 202-209.	1.0	2
1299	Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder. Journal of Psychiatric Research, 2018, 99, 50-61.	1.5	151
1300	Gut Microbiota, Inflammation, and Probiotics on Neural Development in Autism Spectrum Disorder. Neuroscience, 2018, 374, 271-286.	1.1	77
1301	Sieving through gut models of colonization resistance. Nature Microbiology, 2018, 3, 132-140.	5.9	54
1302	Clostridium difficile infection is associated with graft loss in solid organ transplant recipients. American Journal of Transplantation, 2018, 18, 1745-1754.	2.6	49
1303	The role of the gut microbiome in systemic inflammatory disease. BMJ: British Medical Journal, 2018, 360, j5145.	2.4	367
1304	Safety, Clinical Response, and Microbiome Findings Following Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 410-421.	0.9	106

#	Article	IF	Citations
1305	Classifying Fecal Microbiota Transplantation Failure: AnÂObservational Study Examining Timing and CharacteristicsÂofÂFecal Microbiota Transplantation Failures. Clinical Gastroenterology and Hepatology, 2018, 16, 1832-1833.	2.4	23
1306	Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. Clinical Microbiology and Infection, 2018, 24, 780.e1-780.e3.	2.8	8
1307	Microbiologic factors affecting Clostridium difficile recurrence. Clinical Microbiology and Infection, 2018, 24, 476-482.	2.8	51
1308	Update of treatment algorithms for Clostridium difficile infection. Clinical Microbiology and Infection, 2018, 24, 452-462.	2.8	103
1309	The Gut Microbiome in Neuromyelitis Optica. Neurotherapeutics, 2018, 15, 92-101.	2.1	54
1310	Gut microbiota in the pathogenesis of inflammatory bowel disease. Clinical Journal of Gastroenterology, 2018, 11, 1-10.	0.4	904
1311	What do we know about the diagnostics, treatment and epidemiology of Clostridioides (Clostridium) difficile infection in Europe?. Journal of Infection and Chemotherapy, 2018, 24, 164-170.	0.8	39
1312	The gut microbiota as a novel regulator of cardiovascular function and disease. Journal of Nutritional Biochemistry, 2018, 56, 1-15.	1.9	122
1313	Enterotypes in the landscape of gut microbial community composition. Nature Microbiology, 2018, 3, 8-16.	5.9	717
1314	The longâ€term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Alimentary Pharmacology and Therapeutics, 2018, 47, 371-379.	1.9	48
1315	Exploring ways to improve CDI outcomes. MÃ©decine Et Maladies Infectieuses, 2018, 48, 10-17.	5.1	2
1316	The germ-organ theory of non-communicable diseases. Nature Reviews Microbiology, 2018, 16, 103-110.	13.6	117
1317	Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection. Anaerobe, 2018, 49, 103-111.	1.0	14
1318	Bacterial Outer Membrane Vesicles from Dextran Sulfate Sodiumâ€“Induced Colitis Differentially Regulate Intestinal UDP-Glucuronosyltransferase 1A1 Partially Through Toll-Like Receptor 4/Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-Kinase Pathway. Drug Metabolism and Disposition, 2018, 46, 292-302.	1.7	28
1319	Minimally Invasive Approaches to Clostridium Difficile Colitis. , 2018, , 107-113.		1
1320	Studying microbial functionality within the gut ecosystem by systems biology. Genes and Nutrition, 2018, 13, 5.	1.2	31
1321	Clostridium difficile cure with fecal microbiota transplantation in a child with Pompe disease: a case report. Journal of Medical Case Reports, 2018, 12, 112.	0.4	4
1323	Role of fecal microbiota transplantation in inflammatory bowel disease. Journal of Digestive Diseases, 2018, 19, 322-334.	0.7	17

#	Article	IF	Citations
1324	Consensus and contentious statements on the use of probiotics in clinical practice: A south east Asian gastroâ€neuro motility association working team report. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1707-1716.	1.4	19
1325	Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. BMJ Open, 2018, 8, e019231.	0.8	51
1326	Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660â€"A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases, 2018, 67, 1198-1204.	2.9	96
1327	Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications. Annual Review of Biomedical Engineering, 2018, 20, 277-300.	5.7	83
1328	Effects of dietary Lactobacillus rhamnosus JCM1136 and Lactococcus lactis subsp. lactis JCM5805 on the growth, intestinal microbiota, morphology, immune response and disease resistance of juvenile Nile tilapia, Oreochromis niloticus. Fish and Shellfish Immunology, 2018, 76, 368-379.	1.6	157
1329	Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?. Expert Opinion on Biological Therapy, 2018, 18, 469-476.	1.4	5
1330	Fecal transplants in spondyloarthritis and uveitis: ready for a clinical trial?. Current Opinion in Rheumatology, 2018, 30, 303-309.	2.0	18
1331	Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	23
1332	Recent Progress for the Effective Prevention and Treatment of Recurrent Clostridium difficile Infection. Infectious Diseases: Research and Treatment, 2018, 11, 117863371875802.	0.7	10
1333	Evolving Treatment Strategies for Severe Clostridium difficile Colitis: Defining the Therapeutic Window. Hot Topics in Acute Care Surgery and Trauma, 2018, , 225-239.	0.1	3
1334	Effect of Vegan Fecal Microbiota Transplantation on Carnitineâ€and Cholineâ€Derived Trimethylamineâ€Nâ€Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome. Journal of the American Heart Association, 2018, 7, .	1.6	164
1335	Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Current Gastroenterology Reports, 2018, 20, 14.	1.1	35
1336	Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clinical Microbiology and Infection, 2018, 24, 1264-1272.	2.8	107
1337	Can Diet Influence Our Health by Altering Intestinal Microbiota-Derived Fecal Metabolites?. MSystems, 2018, 3, .	1.7	10
1338	Non-obese type 2 diabetes patients present intestinal B cell dysregulations associated with hyperactive intestinal Tfh cells. Molecular Immunology, 2018, 97, 27-32.	1.0	14
1339	The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science, 2018, 359, 1366-1370.	6.0	525
1340	Reproducibility and repeatability of six high-throughput 16S rDNA sequencing protocols for microbiota profiling. Journal of Microbiological Methods, 2018, 147, 76-86.	0.7	30
1341	Insights into the human oral microbiome. Archives of Microbiology, 2018, 200, 525-540.	1.0	339

#	Article	IF	Citations
1343	Effect of Faecal Microbiota Transplantation for Treatment of Clostridium difficile Infection in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Cohort Studies. Journal of Crohn's and Colitis, 2018, 12, 710-717.	0.6	51
1344	Equine faecal microbiota transplant: Current knowledge, proposed guidelines and future directions. Equine Veterinary Education, 2018, 30, 151-160.	0.3	29
1345	Microbial Ecology of the Human Skin. Microbial Ecology, 2018, 76, 113-120.	1.4	86
1346	Do the Microbiota Influence Vaccines and Protective Immunity to Pathogens?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029363.	2.3	12
1347	Faecal microbiota transplantation in clinical practice. Gut, 2018, 67, 196.1-196.	6.1	14
1348	Designing fecal microbiota transplant trials that account for differences in donor stool efficacy. Statistical Methods in Medical Research, 2018, 27, 2906-2917.	0.7	13
1349	Clostridium difficile and cystic fibrosis: management strategies and the role of faecal transplantation. Paediatric Respiratory Reviews, 2018, 26, 16-18.	1.2	12
1350	Donor Screening Experience for Fecal Microbiota Transplantation in Patients With Recurrent C. difficile Infection. Journal of Clinical Gastroenterology, 2018, 52, 146-150.	1.1	50
1351	Do checkpoint inhibitors rely on gut microbiota to fight cancer?. Journal of Oncology Pharmacy Practice, 2018, 24, 468-472.	0.5	3
1352	The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointestinal Endoscopy, 2018, 87, 18-29.	0.5	41
1353	Going to the Bank: Fecal Microbiota Transplantation in Pediatrics. Clinical Pediatrics, 2018, 57, 481-483.	0.4	4
1354	The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 67-77.	1.9	154
1355	Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients. Journal of the Pediatric Infectious Diseases Society, 2018, 7, e6-e8.	0.6	31
1356	Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Clinical Infectious Diseases, 2018, 66, 456-457.	2.9	48
1357	Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 17-24.	3.7	325
1358	Microbiota Replacement Therapies: Innovation in Gastrointestinal Care. Clinical Pharmacology and Therapeutics, 2018, 103, 102-111.	2.3	49
1359	Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC. Gut, 2018, 67, 1558-1559.	6.1	46
1360	Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI score. International Journal of Antimicrobial Agents, 2018, 51, 393-398.	1.1	38

#	Article	IF	Citations
1361	Clostridium difficile : What the surgeon needs to know. Seminars in Colon and Rectal Surgery, 2018, 29, 28-36.	0.2	3
1362	Impacts of the Human Gut Microbiome on Therapeutics. Annual Review of Pharmacology and Toxicology, 2018, 58, 253-270.	4.2	74
1363	Antibiotics, gut microbiome and obesity. Clinical Endocrinology, 2018, 88, 185-200.	1.2	70
1364	Review article: the gut microbiome in inflammatory bowel diseaseâ€”avenues for microbial management. Alimentary Pharmacology and Therapeutics, 2018, 47, 26-42.	1.9	147
1365	Marine Mammal Microbiota Yields Novel Antibiotic with Potent Activity Against Clostridium difficile. ACS Infectious Diseases, 2018, 4, 59-67.	1.8	22
1366	JAID/JSC Guidelines for Infection Treatment 2015â˜†Intestinal infections. Journal of Infection and Chemotherapy, 2018, 24, 1-17.	0.8	14
1367	Cryopreservation of artificial gut microbiota produced with inÂvitro fermentation technology. Microbial Biotechnology, 2018, 11, 163-175.	2.0	34
1368	Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection. Chest, 2018, 153, 266-277.	0.4	43
1370	Control of Clostridium difficile Infection by Defined Microbial Communities. Microbiology Spectrum, 2017, 5, .	1.2	26
1371	Ecological Therapeutic Opportunities for Oral Diseases. Microbiology Spectrum, 2017, 5, .	1.2	62
1372	Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond Clostridium difficile. Microbiology Spectrum, 2017, 5, .	1.2	52
1373	C. difficile Microbiome Manipulation. , 2018, , 153-162.		0
1374	Human Gut Microbiome: Function Matters. Trends in Microbiology, 2018, 26, 563-574.	3.5	458
1375	Small Intestinal Bacterial Overgrowth: Should Screening Be Included in the Pre-fecal Microbiota Transplantation Evaluation?. Digestive Diseases and Sciences, 2018, 63, 193-197.	1.1	13
1376	Gut microbiome: a new player in gastrointestinal disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 159-172.	1.4	59
1377	Interplay between the lung microbiome and lung cancer. Cancer Letters, 2018, 415, 40-48.	3.2	188
1378	An Intragastric Fecal Microbiota Transplantation Program for Treatment of Recurrent Clostridium difficile in Children is Efficacious, Safe, and Inexpensive. Journal of Pediatrics, 2018, 194, 123-127.e1.	0.9	31
1379	Commensal Koch's postulates: establishing causation in human microbiota research. Current Opinion in Microbiology, 2018, 42, 47-52.	2.3	84

#	Article	IF	Citations
1380	Meeting update: faecal microbiota transplantationâ€“â€“bench, bedside, courtroom?. Frontline Gastroenterology, 2018, 9, 45-48.	0.9	4
1381	The Revolving (Bathroom) Door. , 2018, , 239-244.		0
1382	Clostridium difficile and Clostridium sordellii toxins, proinflammatory versus anti-inflammatory response. Toxicon, 2018, 149, 54-64.	0.8	15
1383	Recipe for IBD: can we use food to control inflammatory bowel disease?. Seminars in Immunopathology, 2018, 40, 145-156.	2.8	26
1384	Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients. Digestive Diseases and Sciences, 2018, 63, 198-203.	1.1	39
1385	Microbiota and HDL metabolism. Current Opinion in Lipidology, 2018, 29, 18-23.	1.2	19
1386	Parasite metacommunities: Evaluating the roles of host community composition and environmental gradients in structuring symbiont communities within amphibians. Journal of Animal Ecology, 2018, 87, 354-368.	1.3	20
1387	Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence. Gut, 2018, 67, 1836-1844.	6.1	38
1388	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. Gut Microbes, 2018, 9, 55-60.	4.3	85
1389	Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics. Clinical Microbiology and Infection, 2018, 24, 85.e1-85.e4.	2.8	16
1390	Decreasing Clostridium difficile â€“Associated Fatality Rates Among Hospitalized Patients in the United States: 2004-2014. American Journal of Medicine, 2018, 131, 90-96.	0.6	16
1391	Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness. Annals of Gastroenterology, 2018, 32, 30-38.	0.4	58
1392	Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. Journal of Clinical Oncology, 2018, 36, 3162-3171.	0.8	25
1393	Case series of successful treatment with fecal microbiota transplant (FMT) oral capsules mixed from multiple donors even in patients previously treated with FMT enemas for recurrent Clostridium difficile infection. Medicine (United States), 2018, 97, e11706.	0.4	15
1394	Microbiota replacement for Clostridium difficile by capsule is as effective as via colonoscopy. Journal of Thoracic Disease, 2018, 10, S1081-S1083.	0.6	6
1395	Intestinal Microbiome and the Liver. , 2018, , 37-65.e6.		0
1396	Fecal Microbiota Transplants as a Treatment Option for Parkinsonâ€™s Disease. , 2018, , .		3
1397	Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Advances, 2018, 2, 745-753.	2.5	167

#	Article	IF	Citations
1398	Gut microbes as a therapeutic armory. Drug Discovery Today: Disease Models, 2018, 28, 51-59.	1.2	3
1401	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine, 2018, 24, 1804-1808.	15.2	521
1402	Gut microbiome transition across a lifestyle gradient in Himalaya. PLoS Biology, 2018, 16, e2005396.	2.6	128
1403	Current Status of <I>Clostridium Difficile</I> Infection. Nihon Daicho Komonbyo Gakkai Zasshi, 2018, 71, 456-469.	0.1	1
1404	Strategies for the Preservation, Restoration and Modulation of the Human Milk Microbiota. Implications for Human Milk Banks and Neonatal Intensive Care Units. Frontiers in Microbiology, 2018, 9, 2676.	1.5	30
1405	Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation. Frontiers in Microbiology, 2018, 9, 2976.	1.5	105
1406	Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential. MSphere, 2018, 3, .	1.3	17
1407	Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes. International Journal of Molecular Sciences, 2018, 19, 3720.	1.8	138
1408	Manipulating gut microbiota using faecal microbiome transplantation: update on evidence and guide for use. Gastrointestinal Nursing, 2018, 16, 43-49.	0.0	0
1409	Clinical Efficacy and Microbiome Changes Following Fecal Microbiota Transplantation in Children With Recurrent Clostridium Difficile Infection. Frontiers in Microbiology, 2018, 9, 2622.	1.5	27
1410	Efficacy of fecal microbiota transplantation in a patient with chronic intractable constipation. Clinical Case Reports (discontinued), 2018, 6, 2029-2032.	0.2	6
1411	The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLoS ONE, 2018, 13, e0194904.	1.1	59
1412	Modeling the Role of the Microbiome in Evolution. Frontiers in Physiology, 2018, 9, 1836.	1.3	39
1413	Clinical laboratory utilization management and improved healthcare performance. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 535-547.	2.7	4
1414	Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. Mediators of Inflammation, 2018, 2018, 1-12.	1.4	199
1415	Inhibitory Effect of Ursodeoxycholic Acid on Clostridium difficile Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans. Frontiers in Microbiology, 2018, 9, 2849.	1.5	11
1416	Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. Nature Communications, 2018, 9, 5184.	5.8	190
1418	Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota. Gastroenterology, 2018, 155, 1495-1507.e15.	0.6	127

#	Article	IF	Citations
1419	Clinician Guide to Microbiome Testing. Digestive Diseases and Sciences, 2018, 63, 3167-3177.	1.1	22
1421	Introduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines. Journal of Hospital Infection, 2018, 100, 130-132.	1.4	14
1422	Management of inflammatory bowel disease. Medical Journal of Australia, 2018, 209, 318-323.	0.8	58
1423	Gastrointestinal Neuropathies. Gastroenterology Clinics of North America, 2018, 47, 877-894.	1.0	9
1424	Clostridioides difficile Infection. Annals of Internal Medicine, 2018, 169, ITC49-ITC64.	2.0	89
1425	Therapeutic tolerance in autoimmune disease. Seminars in Arthritis and Rheumatism, 2018, 48, 558-562.	1.6	15
1426	Molecular Basis of Resilience. , 2018, , .		1
1427	Bacterial Infectious Disease Threat. , 2018, , 97-122.		0
1428	Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioMed Research International, 2018, 2018, 1-11.	0.9	85
1429	A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-10.	0.8	104
1430	The microbiome and HLA-B27-associated acute anterior uveitis. Nature Reviews Rheumatology, 2018, 14, 704-713.	3.5	106
1431	Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study. Frontiers in Immunology, 2018, 9, 2195.	2.2	97
1432	Diversion colitis and pouchitis: A mini-review. World Journal of Gastroenterology, 2018, 24, 1734-1747.	1.4	58
1434	Current Evidence in Delivery and Therapeutic Uses of Fecal Microbiota Transplantation in Human Diseasesâ€"Clostridium difficile Disease and Beyond. American Journal of the Medical Sciences, 2018, 356, 424-432.	0.4	24
1435	Non-invasive continuous real-time in vivo analysis of microbial hydrogen production shows adaptation to fermentable carbohydrates in mice. Scientific Reports, 2018, 8, 15351.	1.6	29
1436	Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2018, 30, 1309-1317.	0.8	48
1437	Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection. Surgical Infections, 2018, 19, 785-791.	0.7	6
1438	Fecal Microbiota Transplantation Beneficially Regulates Intestinal Mucosal Autophagy and Alleviates Gut Barrier Injury. MSystems, 2018, 3, .	1.7	94

#	Article	IF	Citations
1439	An Impressive Example of Peripheral Tolerance Against Nonself: Tolerance to Commensal Bacterial and Dietary Protein Antigens. , 2018, , 829-835.		0
1440	Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. F1000Research, 2018, 7, 661.	0.8	7
1441	The Safety of Fecal Microbiota Transplantation for Crohnâ€™s Disease: Findings from A Long-Term Study. Advances in Therapy, 2018, 35, 1935-1944.	1.3	64
1442	Fecal microbiota transplant – a new frontier in inflammatory bowel disease. Journal of Inflammation Research, 2018, Volume 11, 321-328.	1.6	50
1443	Clinical review of Clostridium difficile infection: an update on treatment and prevention. Expert Opinion on Pharmacotherapy, 2018, 19, 1759-1769.	0.9	20
1444	Clostridium difficile Infection in Children. Pediatric Annals, 2018, 47, e359-e365.	0.3	10
1445	Fecal microbial transplantation. Current Opinion in Clinical Nutrition and Metabolic Care, 2018, 21, 405-410.	1.3	14
1446	Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. Microbiome, 2018, 6, 166.	4.9	73
1447	Multidrug-resistantKlebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Review of Anti-Infective Therapy, 2018, 16, 749-761.	2.0	123
1448	Is gut microbiota a relevant and competitive dietary target for cardio-metabolic health? Proceedings of an expert workshop. Trends in Food Science and Technology, 2018, 81, 146-154.	7.8	4
1449	Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nature Communications, 2018, 9, 3663.	5.8	177
1450	The role of gut microbiota in lupus: what we know in 2018?. Expert Review of Clinical Immunology, 2018, 14, 787-792.	1.3	11
1451	The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Journal of Hospital Infection, 2018, 100, S1-S31.	1.4	38
1452	Interkingdom Community Interactions in Disease Ecology. Advances in Environmental Microbiology, 2018, , 3-38.	0.1	1
1453	The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms. American Journal of the Medical Sciences, 2018, 356, 433-440.	0.4	17
1454	Transplantation of High Hydrogen-Producing Microbiota Leads to Generation of Large Amounts of Colonic Hydrogen in Recipient Rats Fed High Amylose Maize Starch. Nutrients, 2018, 10, 144.	1.7	18
1455	The hygiene hypothesis at a glance: Early exposures, immune mechanism and novel therapies. Acta Tropica, 2018, 188, 16-26.	0.9	44
1456	Carbapenems and alternative Î²-lactams for the treatment of infections due to extended-spectrum Î²-lactamase-producing Enterobacteriaceae: What impact on intestinal colonisation resistance?. International Journal of Antimicrobial Agents, 2018, 52, 762-770.	1.1	48

#	Article	IF	Citations
1457	Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection. BMC Gastroenterology, 2018, 18, 131.	0.8	67
1458	Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond Clostridium difficile. , 2018, , 291-308.		2
1459	Enterococci and Their Interactions with the Intestinal Microbiome. , 2018, , 309-330.		7
1460	Ecological Therapeutic Opportunities for Oral Diseases. , 2018, , 235-265.		0
1461	Control ofClostridium difficileInfection by Defined Microbial Communities. , 0, , 267-289.		1
1462	Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation. Current Infectious Disease Reports, 2018, 20, 21.	1.3	32
1463	Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infectionâ€"single versus multiple infusions. Alimentary Pharmacology and Therapeutics, 2018, 48, 152-159.	1.9	117
1464	Gut Microbiota in Health and Disease. , 2018, , 57-90.		0
1465	Classification and Reclassification of Inflammatory Bowel Diseases. , 2018, , 17-34.		4
1466	Fecal Microbiota Transplantation as Therapy for Inflammatory Bowel Disease. , 2018, , 319-327.		2
1467	BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection. PLoS ONE, 2018, 13, e0196977.	1.1	34
1468	Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection. Jammi, 2018, 3, 71-92.	0.3	9
1469	Refractory ulcerative proctitis: How to treat it?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 32-33, 49-57.	1.0	24
1471	Gastrointestinal Microbial Ecology With Perspectives on Health and Disease. , 2018, , 737-753.		3
1472	Prevention and Treatment of Clostridium difficile Enterocolitis. Advances in Surgery, 2018, 52, 29-42.	0.6	2
1473	Microbiota, Obesity and NAFLD. Advances in Experimental Medicine and Biology, 2018, 1061, 111-125.	0.8	63
1474	Obesity, Fatty Liver and Liver Cancer. Advances in Experimental Medicine and Biology, 2018, , .	0.8	17
1475	All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance. International Journal of Pharmaceutics, 2018, 548, 408-422.	2.6	49

#	Article	IF	Citations
1477	AMPs and Mechanisms of Antimicrobial Action. , 2018, , 97-131.		6
1478	Fungi as Part of the Microbiota and Interactions with Intestinal Bacteria. Current Topics in Microbiology and Immunology, 2018, 422, 265-301.	0.7	51
1479	Fecal Transplantation. , 2018, , 327-339.		0
1481	From hairballs to hypothesesâ€“biological insights from microbial networks. FEMS Microbiology Reviews, 2018, 42, 761-780.	3.9	374
1482	Conducting metagenomic studies in microbiology and clinical research. Applied Microbiology and Biotechnology, 2018, 102, 8629-8646.	1.7	26
1483	Management of Primary and Recurrent Clostridium difficile Infection: An Update. Antibiotics, 2018, 7, 54.	1.5	11
1484	Fecal microbiota transplantation for recurrentClostridium difficileinfection in a patient with ulcerative colitis. Intestinal Research, 2018, 16, 142.	1.0	6
1485	Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection. PLoS ONE, 2018, 13, e0201539.	1.1	10
1486	The Human Gut Microbiome â€“ A Potential Controller of Wellness and Disease. Frontiers in Microbiology, 2018, 9, 1835.	1.5	681
1487	Microbiome and Diseases: Metabolic Disorders. , 2018, , 251-277.		3
1488	Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?. Intestinal Research, 2018, 16, 209.	1.0	12
1489	Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity. Cell Systems, 2018, 7, 5-16.	2.9	107
1490	The Potential for Topical Probiotic Treatment of Chronic Rhinosinusitis, a Personal Perspective. Frontiers in Cellular and Infection Microbiology, 2017, 7, 530.	1.8	27
1491	Commentary: Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Frontiers in Cellular and Infection Microbiology, 2018, 8, 104.	1.8	8
1492	Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy. Frontiers in Immunology, 2018, 9, 595.	2.2	119
1493	Exogenous Fecal Microbiota Transplantation from Local Adult Pigs to Crossbred Newborn Piglets. Frontiers in Microbiology, 2017, 8, 2663.	1.5	79
1494	Clostridium difficile â€“ From Colonization to Infection. Frontiers in Microbiology, 2018, 9, 646.	1.5	118
1495	Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections. Frontiers in Microbiology, 2018, 9, 1242.	1.5	69

#	Article	IF	Citations
1496	Standardized Preparation for Fecal Microbiota Transplantation in Pigs. Frontiers in Microbiology, 2018, 9, 1328.	1.5	42
1497	Neurogenic Bowel. , 2018, , 143-149.e7.		2
1498	Microbial Regulation of Glucose Metabolism and Insulin Resistance. Genes, 2018, 9, 10.	1.0	38
1499	Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut, 2018, 67, 2107-2115.	6.1	250
1500	Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2018, 6, 1232-1244.	1.6	137
1501	A Retrospective Study Analyzing the Appropriateness of Initial Treatment of Clostridium difficile in Patients with Active Malignancy. Gastroenterology Research and Practice, 2018, 2018, 1-8.	0.7	3
1502	Gut microbial and metabolomic profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients. FEMS Microbiology Ecology, 2018, 94, .	1.3	73
1503	Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Current Opinion in Microbiology, 2018, 44, 34-40.	2.3	262
1504	Gutâ€“kidney crosstalk in septic acute kidney injury. Critical Care, 2018, 22, 117.	2.5	52
1505	Engineering microbes for targeted strikes against human pathogens. Cellular and Molecular Life Sciences, 2018, 75, 2719-2733.	2.4	24
1506	The rhizosphere microbiome: Significance in rhizoremediation of polyaromatic hydrocarbon contaminated soil. Journal of Environmental Management, 2018, 217, 858-870.	3.8	86
1507	Fecal microbiota transplantation against intestinal colonization by extended spectrum beta-lactamase producing Enterobacteriaceae: a proof of principle study. BMC Research Notes, 2018, 11, 190.	0.6	76
1508	Human microbiome restoration and safety. International Journal of Medical Microbiology, 2018, 308, 487-497.	1.5	46
1509	Safety and efficacy of encapsulated fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review. European Journal of Gastroenterology and Hepatology, 2018, 30, 730-734.	0.8	31
1510	Microbial taxonomic and metabolic alterations during faecal microbiota transplantation to treat infection. Journal of Infection, 2018, 77, 107-118.	1.7	39
1511	Current, experimental, and future treatments in inflammatory bowel disease: a clinical review. Immunopharmacology and Immunotoxicology, 2018, 40, 446-460.	1.1	30
1512	The â€˜ins and outsâ€™ of faecal microbiota transplant for recurrent Clostridium difficile diarrhoea at Wits Donald Gordon Medical Centre, Johannesburg, South Africa. South African Medical Journal, 2018, 108, 403.	0.2	3
1513	The Microbial Composition of Bacteroidetes Species in Ulcerative Colitis Is Effectively Improved by Combination Therapy With Fecal Microbiota Transplantation and Antibiotics. Inflammatory Bowel Diseases, 2018, 24, 2590-2598.	0.9	27

#	Article	IF	Citations
1514	Immunomodulation as Therapy for Fungal Infection: Are We Closer?. Frontiers in Microbiology, 2018, 9, 1612.	1.5	43
1515	Does the Internet promote the unregulated use of fecal microbiota transplantation: a potential public health issue?. Clinical and Experimental Gastroenterology, 2018, Volume 11, 179-183.	1.0	6
1516	Development of the Pediatric Gut Microbiome: Impact on Health and Disease. American Journal of the Medical Sciences, 2018, 356, 413-423.	0.4	109
1517	Prevention and Treatment of Clostridium difficile-Associated Diarrhea in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America, 2018, 32, 733-748.	1.9	9
1518	An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection. Frontiers in Microbiology, 2018, 9, 2080.	1.5	24
1519	The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut, 2018, 67, 1920-1941.	6.1	248
1520	Fecal microbiota transplantation as a potential way to eradicate multiresistant microorganisms. IDCases, 2018, 13, e00432.	0.4	6
1521	Gut microbiota ndash architects of small intestinal capillaries. Frontiers in Bioscience - Landmark, 2018, 23, 752-766.	3.0	9
1522	CLOUD: a non-parametric detection test for microbiome outliers. Microbiome, 2018, 6, 137.	4.9	16
1523	Microbiome: Focus on Causation and Mechanism. Cell, 2018, 174, 785-790.	13.5	188
1524	Phylogeny-corrected identification of microbial gene families relevant to human gut colonization. PLoS Computational Biology, 2018, 14, e1006242.	1.5	39
1525	A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. Nature Communications, 2018, 9, 3347.	5.8	192
1526	Clostridium difficile infection and antibiotic-associated diarrhoea. Clinical Medicine, 2018, 18, 237-241.	0.8	114
1527	Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota. Cell Metabolism, 2018, 27, 1222-1235.e6.	7.2	352
1528	Emerging Trends in Clinical Research With Implications for Population Health and Health Policy. Milbank Quarterly, 2018, 96, 369-401.	2.1	5
1529	Microbiota and immune cell crosstalk: dialogues driving health and disease. Clinical and Translational Immunology, 2018, 7, e1020.	1.7	9
1530	What's new in restoring the gut microbiota in ICU patients? Potential role of faecalÂmicrobiota transplantation. Clinical Microbiology and Infection, 2018, 24, 803-805.	2.8	10
1531	Transient Osmotic Perturbation Causes Long-Term Alteration to the Gut Microbiota. Cell, 2018, 173, 1742-1754.e17.	13.5	171

#	Article	IF	Citations
1532	The biodiversity hypothesis and immunotolerance in allergy. Allergo Journal International, 2018, 27, 140-146.	0.9	4
1534	Technical Aspects of Fecal Microbial Transplantation (FMT). Current Gastroenterology Reports, 2018, 20, 30.	1.1	21
1535	The Intersection Between Colonization Resistance, Antimicrobial Stewardship, and Clostridium difficile. Current Infectious Disease Reports, 2018, 20, 27.	1.3	8
1536	Which experimental systems should we use for human microbiome science?. PLoS Biology, 2018, 16, e2005245.	2.6	25
1537	Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?. American Journal of Gastroenterology, 2018, 113, 1125-1136.	0.2	35
1538	Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation. , 2018, , 197-288.		0
1539	Dysbiosis of the Microbiota: Therapeutic Strategies Utilizing Dietary Modification, Pro- and Prebiotics and Fecal Transplant Therapies in Promoting Normal Balance and Local GI Functions. , 2018, , 381-419.		3
1540	Serial Microbiota Analysis after Fecal Microbiota Transplantation in a Child with Down's Syndrome. Journal of Pediatric Infectious Diseases, 2019, 14, 136-139.	0.1	0
1541	Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota. Human Vaccines and Immunotherapeutics, 2019, 15, 1453-1456.	1.4	7
1542	Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for RecurrentClostridium difficileInfection: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2019, 68, 1351-1358.	2.9	137
1543	Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them. Mucosal Immunology, 2019, 12, 1-9.	2.7	177
1544	Surveillance and control of asymptomatic carriers of drugâ€resistant bacteria. Bioethics, 2019, 33, 766-775.	0.7	9
1545	Gut Microbiota Modulation for Multidrug-Resistant Organism Decolonization: Present and Future Perspectives. Frontiers in Microbiology, 2019, 10, 1704.	1.5	54
1546	Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens, 2019, 8, 126.	1.2	464
1547	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory Intestinal Diseases, 2019, 4, 79-96.	0.8	53
1548	Clostridioides difficile: diagnosis and treatments. BMJ: British Medical Journal, 2019, 366, l4609.	2.4	70
1549	Clostridioides difficile therapeutics: guidelines and beyond. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611986854.	1.1	6
1550	The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet, The, 2019, 394, 420-431.	6.3	234

#	Article	IF	Citations
1551	Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nature Biomedical Engineering, 2019, 3, 717-728.	11.6	229
1552	Microbiota-derived lantibiotic restores resistance against vancomycin-resistant Enterococcus. Nature, 2019, 572, 665-669.	13.7	176
1553	Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	35
1554	Recent advances in the treatment of C. difficile using biotherapeutic agents . Infection and Drug Resistance, 2019, Volume 12, 1597-1615.	1.1	11
1555	Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 605-616.	8.2	951
1556	Universal membrane-labeling combined with expression of Katushka far-red fluorescent protein enables non-invasive dynamic and longitudinal quantitative 3D dual-color fluorescent imaging of multiple bacterial strains in mouse intestine. BMC Microbiology, 2019, 19, 167.	1.3	5
1557	Outcomes of a Multidisciplinary Clinic in Evaluating Recurrent Clostridioides difficile Infection Patients for Fecal Microbiota Transplant: A Retrospective Cohort Analysis. Journal of Clinical Medicine, 2019, 8, 1036.	1.0	10
1558	Potential relevance of pig gut content transplantation for production and research. Journal of Animal Science and Biotechnology, 2019, 10, 55.	2.1	25
1559	Establishing a donor stool bank for faecal microbiota transplantation: methods and feasibility. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1837-1847.	1.3	16
1560	Epigenetic Regulation at the Interplay Between Gut Microbiota and Host Metabolism. Frontiers in Genetics, 2019, 10, 638.	1.1	116
1562	Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. Nature Medicine, 2019, 25, 1234-1242.	15.2	352
1564	Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection. Gastroenterology, 2019, 157, 624-636.	0.6	76
1565	Nutrition, Immunity, and Cancer. , 2019, , 209-281.		2
1566	Microbiota-Immune Interaction in the Pathogenesis of Gut-Derived Infection. Frontiers in Immunology, 2019, 10, 1873.	2.2	91
1567	Banking feces: a new frontier for public blood banks?. Transfusion, 2019, 59, 2776-2782.	0.8	13
1568	Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?. Current Diabetes Reports, 2019, 19, 51.	1.7	91
1569	Fresh Ideas Bloom in Gut Healthcare to Cross-Fertilize Lake Management. Environmental Science & Technology, 2019, 53, 14099-14112.	4.6	2
1570	A single faecal microbiota transplantation modulates the microbiome and improves clinical manifestations in a rat model of colitis. EBioMedicine, 2019, 48, 630-641.	2.7	53

#	Article	IF	Citations
1571	Fecal microbiota transplant for C.Âdifficile infection: Just say yes. Anaerobe, 2019, 60, 102109.	1.0	8
1572	Successful Fecal Microbiota Transplantation in a Patient Suffering From Irritable Bowel Syndrome and Recurrent Urinary Tract Infections. Open Forum Infectious Diseases, 2019, 6, ofz398.	0.4	20
1573	FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2019, 10, 1021.	1.1	48
1574	Framework for rational donor selection in fecal microbiota transplant clinical trials. PLoS ONE, 2019, 14, e0222881.	1.1	36
1575	Emerging Frontiers in Microbiome Engineering. Trends in Immunology, 2019, 40, 952-973.	2.9	47
1576	Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduction and Targeted Therapy, 2019, 4, 41.	7.1	150
1577	Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: Establishment and implementation. Journal of Microbiology, Immunology and Infection, 2019, 52, 841-850.	1.5	15
1578	The microbiota and infectious diseases. , 2019, , 445-457.		0
1579	Updates in Treatment of Recurrent Clostridium difficile Infection. Journal of Clinical Medicine Research, 2019, 11, 465-471.	0.6	44
1580	Microbiote intestinal, lipides alimentaires et maladies mÃ©taboliques. Cahiers De Nutrition Et De Dietetique, 2019, 54, 347-353.	0.2	0
1581	Minor Effect of Antibiotic Pre-treatment on the Engraftment of Donor Microbiota in Fecal Transplantation in Mice. Frontiers in Microbiology, 2019, 10, 2685.	1.5	41
1582	Microbiota transplant therapy and autism: lessons for the clinic. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1033-1037.	1.4	24
1583	How Oxygen Availability Affects the Antimicrobial Efficacy of Host Defense Peptides: Lessons Learned from Studying the Copper-Binding Peptides Piscidins 1 and 3. International Journal of Molecular Sciences, 2019, 20, 5289.	1.8	17
1584	Recovery of the Gut Microbiota after Antibiotics Depends on Host Diet, Community Context, and Environmental Reservoirs. Cell Host and Microbe, 2019, 26, 650-665.e4.	5.1	166
1585	Dietâ€“microbiomeâ€“disease: Investigating dietâ€™s influence on infectious disease resistance through alteration of the gut microbiome. PLoS Pathogens, 2019, 15, e1007891.	2.1	49
1586	Timescales of gut microbiome dynamics. Current Opinion in Microbiology, 2019, 50, 56-63.	2.3	27
1587	Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases. Gastroenterology, 2019, 157, 1530-1543.e4.	0.6	24
1588	Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Alimentary Pharmacology and Therapeutics, 2019, 50, 1094-1099.	1.9	29

#	Article	IF	Citations
1589	Fecal Microbiota Transplantation for Dysbiosis â€" Predictable Risks. New England Journal of Medicine, 2019, 381, 2064-2066.	13.9	59
1590	Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. New England Journal of Medicine, 2019, 381, 2043-2050.	13.9	767
1591	Systematic review with metaâ€analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Alimentary Pharmacology and Therapeutics, 2019, 49, 354-363.	1.9	87
1592	COMPARISON OF RADIATION DOSE AND IMAGE QUALITY IN CTA OF THE PERIPHERAL ARTERIES. Radiation Protection Dosimetry, 2019, 186, 437-442.	0.4	1
1593	Impact of infection on transplantation tolerance. Immunological Reviews, 2019, 292, 243-263.	2.8	6
1594	Vulnerability of the industrialized microbiota. Science, 2019, 366, .	6.0	177
1595	The Microbiota-Gut-Brain Axis. Physiological Reviews, 2019, 99, 1877-2013.	13.1	2,304
1596	Manipulation of Biodiversity to Steer and Optimize Microbial Community Function. , 2019, , 29-41.		0
1597	The altered gut virome community in rhesus monkeys is correlated with the gut bacterial microbiome and associated metabolites. Virology Journal, 2019, 16, 105.	1.4	9
1598	Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?. BioMed Research International, 2019, 2019, 1-11.	0.9	21
1599	Fungal Physiology and Immunopathogenesis. Current Topics in Microbiology and Immunology, 2019, , .	0.7	4
1600	Metagenomic and culturomic analysis of gut microbiota dysbiosis during Clostridium difficile infection. Scientific Reports, 2019, 9, 12807.	1.6	46
1601	Fecal microbiota transplantation (FMT) for C.Âdifficile infection, just say â€˜Noâ€™. Anaerobe, 2019, 60, 102092.	1.0	29
1602	A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research. Nature Medicine, 2019, 25, 1442-1452.	15.2	255
1603	Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection. Annals of Medicine, 2019, 51, 379-389.	1.5	20
1604	Evolutionary and Ecological Consequences of Gut Microbial Communities. Annual Review of Ecology, Evolution, and Systematics, 2019, 50, 451-475.	3.8	175
1605	Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis. Mucosal Immunology, 2019, 12, 1336-1347.	2.7	21
1606	Fecal microbiota transplantation for refractory diarrhea in immunocompromised diseases: a pediatric case report. Italian Journal of Pediatrics, 2019, 45, 116.	1.0	16

#	Article	IF	Citations
1607	The Potential Role of Gut Mycobiome in Irritable Bowel Syndrome. Frontiers in Microbiology, 2019, 10, 1894.	1.5	54
1608	Murine Fecal Microbiota Transplantation Alleviates Intestinal and Systemic Immune Responses in Campylobacter jejuni Infected Mice Harboring a Human Gut Microbiota. Frontiers in Immunology, 2019, 10, 2272.	2.2	29
1609	Fecal Microbiota Transplantation: An Update on Clinical Practice. Clinical Endoscopy, 2019, 52, 137-143.	0.6	128
1610	Conceptual Design of a Universal Donor Screening Approach for Vaginal Microbiota Transplant. Frontiers in Cellular and Infection Microbiology, 2019, 9, 306.	1.8	29
1611	Microbial Metabolism Modulates Antibiotic Susceptibility within the Murine Gut Microbiome. Cell Metabolism, 2019, 30, 800-823.e7.	7.2	70
1612	Faecal Microbiota Transplantation Eradicated Extended-Spectrum Beta-Lactamase-Producing <i>Klebsiella pneumoniae</i> from a Renal Transplant Recipient with Recurrent Urinary Tract Infections. Case Reports in Nephrology and Dialysis, 2019, 9, 102-107.	0.3	27
1613	Microbiome dysbiosis and alcoholic liver disease. Liver Research, 2019, 3, 218-226.	0.5	28
1614	Fecal Transplant in Children With Clostridioides difficile Gives Sustained Reduction in Antimicrobial Resistance and Potential Pathogen Burden. Open Forum Infectious Diseases, 2019, 6, ofz379.	0.4	32
1615	Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. Expert Opinion on Biological Therapy, 2019, 19, 1343-1355.	1.4	11
1616	Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 690-704.	8.2	686
1617	An Infectious Diseases Perspective on Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 580-584.	0.6	3
1618	Translating the gut microbiome: ready for the clinic?. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 656-661.	8.2	33
1619	New concepts in C. difficile management. British Medical Bulletin, 2019, 131, 109-118.	2.7	2
1620	The role of the gut microbiota in the treatment of inflammatory bowel diseases. Microbial Pathogenesis, 2019, 137, 103774.	1.3	62
1621	Microbiome and Allogeneic Hematopoietic Stem Cell Transplantation. , 2019, , 141-154.		0
1622	Impact of antimicrobial therapy on the gut microbiome. Journal of Antimicrobial Chemotherapy, 2019, 74, i6-i15.	1.3	145
1623	Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infectious Diseases, The, 2019, 19, 265-274.	4.6	41
1624	Transforming medicine with the microbiome. Science Translational Medicine, 2019, 11, .	5.8	50

#	Article	IF	Citations
1625	Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncology, The, 2019, 20, e77-e91.	5.1	249
1626	Oral faecal microbiota transplantation for the treatment of Clostridium difficile-associated diarrhoea in a dog: a case report. BMC Veterinary Research, 2019, 15, 11.	0.7	29
1627	The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Frontiers in Cellular and Infection Microbiology, 2019, 9, 2.	1.8	262
1628	Gut microbiota affects development and olfactory behavior in Drosophila melanogaster. Journal of Experimental Biology, 2019, 222, .	0.8	68
1629	Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. PLoS ONE, 2019, 14, e0210016.	1.1	100
1630	Gut microbiome and cancer immunotherapy. Cancer Letters, 2019, 447, 41-47.	3.2	159
1631	Fecal microbiota transplantation in recurrent Clostridium difficile infection: A retrospective singleâ€center chart review. JGH Open, 2019, 3, 4-9.	0.7	16
1632	Pathophysiology of the irritable bowel syndrome â€“ Reflections of today. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 40-41, 101620.	1.0	19
1633	Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential. Molecular Aspects of Medicine, 2019, 69, 93-106.	2.7	212
1634	Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population. Infectious Disease Clinics of North America, 2019, 33, 447-466.	1.9	17
1635	Regulating microbiome manipulation. Nature Medicine, 2019, 25, 874-876.	15.2	8
1636	Community ecology as a framework for human microbiome research. Nature Medicine, 2019, 25, 884-889.	15.2	96
1637	Initial experience of fecal microbiota transplantation in gastrointestinal disease: A case series. Kaohsiung Journal of Medical Sciences, 2019, 35, 566-571.	0.8	21
1638	Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine, 2019, 44, 716-729.	2.7	95
1639	Role of Microbiome in Modulating Immune Responses in Cancer. Mediators of Inflammation, 2019, 2019, 1-7.	1.4	25
1640	Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome. Frontiers in Immunology, 2019, 10, 1341.	2.2	63
1641	Fecal microbiota transplantation for recurrent Clostridioides difficile infection. American Journal of Health-System Pharmacy, 2019, 76, 935-942.	0.5	6
1642	Gut Mycobiota in Immunity and Inflammatory Disease. Immunity, 2019, 50, 1365-1379.	6.6	158

#	Article	IF	Citations
1643	IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection. Nature Communications, 2019, 10, 2712.	5.8	93
1644	The Role of Fecal Microbiota Transplantation in Reducing Intestinal Colonization With Antibiotic-Resistant Organisms: The Current Landscape and Future Directions. Open Forum Infectious Diseases, 2019, 6, .	0.4	38
1645	Skin microbiome modulation induced by probiotic solutions. Microbiome, 2019, 7, 95.	4.9	74
1646	Gut flora â€œthe second brainâ€•connects Eastern and Western medicine: intestinal hyper-permeability or Qi deficiency can affect brain, mind, and whole body. Longhua Chinese Medicine, 2019, 2, 6-6.	0.5	1
1648	The microbiome and cancer for clinicians. Critical Reviews in Oncology/Hematology, 2019, 141, 1-12.	2.0	84
1649	Cryopreservation of the human gut microbiota: Current state and perspectives. International Journal of Medical Microbiology, 2019, 309, 259-269.	1.5	11
1650	Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia. Lancet Respiratory Medicine,the, 2019, 7, 710-720.	5.2	66
1651	Enterotoxic Clostridia:Clostridioides difficileInfections. Microbiology Spectrum, 2019, 7, .	1.2	12
1652	Metaâ€Omicsâ€•and Metabolic Modelingâ€Assisted Deciphering of Human Microbiota Metabolism. Biotechnology Journal, 2019, 14, 1800445.	1.8	7
1653	A network metaâ€analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection. United European Gastroenterology Journal, 2019, 7, 1051-1063.	1.6	35
1654	Fecal Microbiota Transplantation Controls Murine Chronic Intestinal Inflammation by Modulating Immune Cell Functions and Gut Microbiota Composition. Cells, 2019, 8, 517.	1.8	50
1655	Fecal microbiota transplantation: great potential with many challenges. Translational Gastroenterology and Hepatology, 2019, 4, 40-40.	1.5	32
1656	Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection. Advances in Therapy, 2019, 36, 2052-2061.	1.3	13
1657	Dysbiosis of the intestinal microbiota in neurocritically ill patients and the risk for death. Critical Care, 2019, 23, 195.	2.5	84
1658	Therapeutic potential of an anaerobic cultured human intestinal microbiota, ACHIM, for treatment of IBS. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 40-41, 101607.	1.0	7
1659	Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments. International Journal of Molecular Sciences, 2019, 20, 2699.	1.8	26
1660	Composition of the gut microbiota transcends genetic determinants of malaria infection severity and influences pregnancy outcome. EBioMedicine, 2019, 44, 639-655.	2.7	23
1661	Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scandinavian Journal of Gastroenterology, 2019, 54, 690-699.	0.6	29

#	Article	IF	Citations
1662	Relationship between the microbiome and ocular health. Ocular Surface, 2019, 17, 384-392.	2.2	60
1663	Management ofClostridioides difficilecolitis: insights for the gastroenterologist. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481984765.	1.4	18
1664	Pathogen Colonization Resistance in the Gut and Its Manipulation for Improved Health. American Journal of Pathology, 2019, 189, 1300-1310.	1.9	31
1665	The Conceptual Ecology of the Human Microbiome. Quarterly Review of Biology, 2019, 94, 149-175.	0.0	23
1666	Reconceptualizing anorexia nervosa. Psychiatry and Clinical Neurosciences, 2019, 73, 518-525.	1.0	48
1667	Microbiota-Dependent Regulation of Antimicrobial Immunity in the Lung. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 284-289.	1.4	14
1668	Fecal microbiota transplantation donation: the gift that keeps on giving. Current Opinion in Pharmacology, 2019, 49, 24-28.	1.7	9
1669	The ancestral and industrialized gut microbiota and implications for human health. Nature Reviews Microbiology, 2019, 17, 383-390.	13.6	255
1670	Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. Journal of Digestive Diseases, 2019, 20, 401-408.	0.7	62
1671	Fermented foods and preterm birth risk from a prospective large cohort study: the Japan Environment and Childrenâ€™s study. Environmental Health and Preventive Medicine, 2019, 24, 25.	1.4	9
1672	Current applications of fecal microbiota transplantation in intestinal disorders. Kaohsiung Journal of Medical Sciences, 2019, 35, 327-331.	0.8	6
1673	Butyrate Protects Mice from Clostridium difficile-Induced Colitis through an HIF-1-Dependent Mechanism. Cell Reports, 2019, 27, 750-761.e7.	2.9	212
1674	The efficacy of fecal microbiota transplantation for patients with chronic pouchitis: A case series. Clinical Case Reports (discontinued), 2019, 7, 782-788.	0.2	16
1675	Issues and current standards of controls in microbiome research. FEMS Microbiology Ecology, 2019, 95, .	1.3	152
1676	Updates in the epidemiology and management of candidemia and Clostridioides difficilecoinfection. Expert Review of Anti-Infective Therapy, 2019, 17, 375-382.	2.0	2
1677	Protocol for the Gut Bugs Trial: a randomised double-blind placebo-controlled trial of gut microbiome transfer for the treatment of obesity in adolescents. BMJ Open, 2019, 9, e026174.	0.8	16
1678	Current and future trends in clostridioides (clostridium) difficile infection management. Anaerobe, 2019, 58, 95-102.	1.0	20
1679	Evolution of fecal microbiota transplantation in methodology and ethical issues. Current Opinion in Pharmacology, 2019, 49, 11-16.	1.7	40

#	Article	IF	Citations
1680	Infectious diarrhoea. Medicine, 2019, 47, 341-346.	0.2	4
1681	Microbial evolutionary medicine: from theory to clinical practice. Lancet Infectious Diseases, The, 2019, 19, e273-e283.	4.6	11
1682	HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration. Current HIV/AIDS Reports, 2019, 16, 204-213.	1.1	92
1683	Why Does Clostridium difficile Infection Recur?. Journal of Osteopathic Medicine, 2019, 119, 322-326.	0.4	8
1684	Towards a rational design of faecal transplant analogues. Scientific Reports, 2019, 9, 5558.	1.6	3
1685	Gut microbiome interventions in human health and diseases. Medicinal Research Reviews, 2019, 39, 2286-2313.	5.0	52
1686	Impact of the microbiome on cancer progression and response to anti-cancer therapies. Advances in Cancer Research, 2019, 143, 255-294.	1.9	23
1687	Structural shifts in the intestinal microbiota of rats treated with cyclosporine A after orthotropic liver transplantation. Frontiers of Medicine, 2019, 13, 451-460.	1.5	16
1688	Cost savings following faecal microbiota transplantation for recurrent Clostridium difficile infection. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481984300.	1.4	17
1689	Future Antibacterial Strategies: From Basic Concepts to Clinical Challenges. Journal of Infectious Diseases, 2019, 220, 350-360.	1.9	87
1690	Emerging drugs for the treatment of clostridium difficile. Expert Opinion on Emerging Drugs, 2019, 24, 17-28.	1.0	11
1691	Identification of the microbial diversity after fecal microbiota transplantation therapy for chronic intractable constipation using 16s rRNA amplicon sequencing. PLoS ONE, 2019, 14, e0214085.	1.1	36
1692	Saccharomyces boulardii CNCM I-745 Modulates the Fecal Bile Acids Metabolism During Antimicrobial Therapy in Healthy Volunteers. Frontiers in Microbiology, 2019, 10, 336.	1.5	18
1693	The microbiome, cancer, and cancer therapy. Nature Medicine, 2019, 25, 377-388.	15.2	712
1694	Critical illness and the role of the microbiome. Acute Medicine & Surgery, 2019, 6, 91-94.	0.5	15
1695	Gut Microbiota and Healthy Aging. , 2019, , .		0
1696	The rise ofClostridioides difficileinfections and fall of associated mortality in hospitalized advanced cirrhotics. Liver International, 2019, 39, 1263-1270.	1.9	10
1697	2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World Journal of Emergency Surgery, 2019, 14, 8.	2.1	102

#	Article	IF	Citations
1698	Faecal microbiota transplantation for the decolonization of antibiotic-resistant bacteria in the gut: a systematic review and meta-analysis. Journal of Hospital Infection, 2019, 102, 174-188.	1.4	38
1699	Clinical metagenomics. Nature Reviews Genetics, 2019, 20, 341-355.	7.7	793
1700	Fecal microbiota transplantation prevents Candida albicans from colonizing the gastrointestinal tract. Microbiology and Immunology, 2019, 63, 155-163.	0.7	22
1701	Fecal Microbiota Transplantation. , 2019, , 249-261.		3
1702	Mining the microbiota for microbial and metabolite-based immunotherapies. Nature Reviews Immunology, 2019, 19, 305-323.	10.6	211
1703	Fifty shades of graft: How to improve the efficacy of faecal microbiota transplantation for decolonization of antibiotic-resistant bacteria. International Journal of Antimicrobial Agents, 2019, 53, 553-556.	1.1	11
1704	Intestinal microbiome as a novel therapeutic target for local and systemic inflammation. , 2019, 199, 164-172.		49
1705	Domestic canines do not display evidence of gut microbial dysbiosis in the presence of Clostridioides (Clostridium) difficile, despite cellular susceptibility to its toxins. Anaerobe, 2019, 58, 53-72.	1.0	20
1706	Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis. Drug Safety, 2019, 42, 869-880.	1.4	115
1707	A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults. Vaccine, 2019, 37, 2600-2607.	1.7	5
1708	The direct and indirect effects of vancomycin-resistant enterococci colonization in liver transplant candidates and recipients. Expert Review of Anti-Infective Therapy, 2019, 17, 363-373.	2.0	7
1709	Safety and efficacy of fecal microbiota transplant in 9 critically ill patients with severe and complicated <scp>Clostridium difficile</scp> infection with impending colectomy. Journal of Digestive Diseases, 2019, 20, 301-307.	0.7	15
1710	Intestinal Microbiota in Early Life and Its Implications on Childhood Health. Genomics, Proteomics and Bioinformatics, 2019, 17, 13-25.	3.0	159
1711	Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1297-1305.	1.3	8
1713	Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients. EBioMedicine, 2019, 44, 730-740.	2.7	45
1714	The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany. United European Gastroenterology Journal, 2019, 7, 716-722.	1.6	24
1715	Clostridium difficile infection: review. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1211-1221.	1.3	391
1716	Midbiotics: conjugative plasmids for genetic engineering of natural gut flora. Gut Microbes, 2019, 10, 643-653.	4.3	30

#	Article	IF	Citations
1717	Gut Microbiome in Health and Disease. Gastroenterology Clinics of North America, 2019, 48, 221-235.	1.0	23
1718	Bacterial viability in faecal transplants: Which bacteria survive?. EBioMedicine, 2019, 41, 509-516.	2.7	84
1719	Pharmacologic Approach to Management of Clostridium difficile Infection. Critical Care Nursing Quarterly, 2019, 42, 2-11.	0.4	1
1720	Two Strains of Lactobacilli Effectively Decrease the Colonization of VRE in a Mouse Model. Frontiers in Cellular and Infection Microbiology, 2019, 9, 6.	1.8	18
1721	Current Status of Fecal Microbiota Transplantation. , 2019, , 155-165.		1
1722	Current Options for Fecal Transplantation in Clostridium difficile Infection. , 2019, , 177-184.		0
1723	The Lung Microbiome, Metabolome, and Breath Volatolome in the Diagnosis of Pulmonary Disease. , 2019, , 297-305.		0
1724	Fecal Microbiota Transfer and Inflammatory Bowel Disease. , 2019, , 425-434.		2
1725	Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent Clostridioides difficile infection. Digestive and Liver Disease, 2019, 51, 944-951.	0.4	13
1726	Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 130-143.	0.9	92
1727	A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clinical Microbiology and Infection, 2019, 25, 830-838.	2.8	106
1729	Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Gastroenterology, 2019, 156, 1324-1332.e3.	0.6	236
1730	Histopathological Features and Composition of Gut Microbiota in Rhesus Monkey of Alcoholic Liver Disease. Frontiers in Microbiology, 2019, 10, 165.	1.5	15
1731	Faecal microbiota transplantation in Australia: bogged down in regulatory uncertainty. Internal Medicine Journal, 2019, 49, 148-151.	0.5	9
1732	Gut Microbiota and Its Mysteries. Indian Journal of Medical Microbiology, 2019, 37, 268-277.	0.3	75
1733	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With RecurrentClostridioides difficileInfection Treated With Fecal Microbiota Transplantation or Antibiotics. Annals of Internal Medicine, 2019, 171, 695.	2.0	81
1734	The Therapeutic Potential of the â€œYin-Yangâ€•Garden in Our Gut. , 2019, , .		2
1735	Clinical application of bacteriophages in Europe. Microbiology Australia, 2019, 40, 8.	0.1	16

#	Article	IF	Citations
1736	The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation. Journal of Law, Medicine and Ethics, 2019, 47, 482-504.	0.4	15
1737	The Ethics of Fecal Microbiota Transplant as a Tool for Antimicrobial Stewardship Programs. Journal of Law, Medicine and Ethics, 2019, 47, 541-554.	0.4	2
1738	Vaginal Microbiota Transplantation: The Next Frontier. Journal of Law, Medicine and Ethics, 2019, 47, 555-567.	0.4	21
1739	Consortium of Probiotics Attenuates Colonization of Clostridioides difficile. Frontiers in Microbiology, 2019, 10, 2871.	1.5	19
1740	FMT and Microbial Medical Products: Generating High-Quality Evidence through Good Governance. Journal of Law, Medicine and Ethics, 2019, 47, 505-523.	0.4	6
1741	Where Stool is a Drug: International Approaches to Regulating the use of Fecal Microbiota for Transplantation. Journal of Law, Medicine and Ethics, 2019, 47, 524-540.	0.4	15
1742	Intestinal Microbiome Changes in Fecal Microbiota Transplant (FMT) vs. FMT Enriched with Lactobacillus in the Treatment of Recurrent Clostridioides difficile Infection. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-7.	0.8	16
1743	Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials. BMJ Open, 2019, 9, e031145.	0.8	13
1744	Mesenchymal stem cellâ€“gut microbiota interaction in the repair of inflammatory bowel disease: an enhanced therapeutic effect. Clinical and Translational Medicine, 2019, 8, 31.	1.7	50
1745	Type 3 Immunity during Clostridioides difficile Infection: Too Much of a Good Thing?. Infection and Immunity, 2019, 88, .	1.0	12
1746	Enterotoxic Clostridia:Clostridioides difficileInfections. , 2019, , 991-1011.		0
1747	Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. United European Gastroenterology Journal, 2019, 7, 1408-1410.	1.6	15
1749	Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for Clostridium difficile. Vaccines, 2019, 7, 180.	2.1	5
1750	High-fat diet-mediated dysbiosis exacerbates NSAID-induced small intestinal damage through the induction of interleukin-17A. Scientific Reports, 2019, 9, 16796.	1.6	15
1751	Human Gut Microbiome Transplantation in Ileitis Prone Mice: A Tool for the Functional Characterization of the Microbiota in Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2020, 26, 347-359.	0.9	12
1752	Oral Administration of miR-30d from Feces of MS Patients Suppresses MS-like Symptoms in Mice by Expanding Akkermansia muciniphila. Cell Host and Microbe, 2019, 26, 779-794.e8.	5.1	118
1753	How causal are microbiomes? A comparison with the Helicobacter pylori explanation of ulcers. Biology and Philosophy, 2019, 34, 1.	0.7	45
1754	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators of Inflammation, 2019, 2019, 1-10.	1.4	39

#	Article	IF	Citations
1755	Food allergy and the microbiome: Current understandings and future directions. Journal of Allergy and Clinical Immunology, 2019, 144, 1468-1477.	1.5	118
1756	Fecal Microbiota Transplantation After Oral Vancomycin for Recurrent Clostridium difficile Infection. Infectious Diseases in Clinical Practice, 2019, 27, 356-359.	0.1	0
1757	Faecal microbiota transplantation for refractory Clostridiumdifficile infection. BMJ Case Reports, 2019, 12, e231027.	0.2	2
1758	UEG Week 2019 Oral Presentations. United European Gastroenterology Journal, 2019, 7, 10-188.	1.6	7
1759	Transfer of skin microbiota between two dissimilar autologous microenvironments: A pilot study. PLoS ONE, 2019, 14, e0226857.	1.1	18
1760	Use of the microbiome in the management of children with type 2 diabetes mellitus. Current Opinion in Pediatrics, 2019, 31, 524-530.	1.0	7
1761	Fecal microbiota transplantation in children: current concepts. Current Opinion in Pediatrics, 2019, 31, 623-629.	1.0	14
1762	The current novel therapeutic regimens forClostridium difficileinfection (CDI) and the potentials of Traditional Chinese Medicine in treatment of CDI. Critical Reviews in Microbiology, 2019, 45, 729-742.	2.7	7
1763	The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study. Clinical and Translational Gastroenterology, 2019, 10, e00034.	1.3	70
1764	The Microbiome and Its Potential for Pharmacology. Handbook of Experimental Pharmacology, 2019, 260, 301-326.	0.9	14
1765	The Importance of the Microbiome in Critically Ill Patients: Role of Nutrition. Nutrients, 2019, 11, 3002.	1.7	43
1766	Prevention and treatment of recurrent Clostridioides difficile infection. Current Opinion in Infectious Diseases, 2019, 32, 482-489.	1.3	11
1767	Growing consumption of antibiotics and epidemiology of Clostridioides difficile infections in Poland: A need to develop new solutions. Acta Microbiologica Et Immunologica Hungarica, 2020, 67, 79-86.	0.4	0
1768	The origins of gut microbiome research in Europe: From Escherich to Nissle. Human Microbiome Journal, 2019, 14, 100065.	3.8	28
1769	Impact of the microbiota on solid organ transplant rejection. Current Opinion in Organ Transplantation, 2019, 24, 679-686.	0.8	21
1770	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 2019, 68, 2111-2121.	6.1	290
1771	Rethinking antimicrobial stewardship paradigms in the context of the gut microbiome. JAC-Antimicrobial Resistance, 2019, 1, dlz015.	0.9	10
1772	Investigations of Bacteroides spp. towards next-generation probiotics. Food Research International, 2019, 116, 637-644.	2.9	121

#	Article	IF	Citations
1773	The Role of Autologous Fecal Microbiota Transplantation in Diversion Colitis: A Case Report. Inflammatory Bowel Diseases, 2019, 25, e29-e30.	0.9	6
1774	Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis. FEMS Microbiology Reviews, 2019, 43, 1-18.	3.9	86
1775	Fecal microbiota transplantation: Review and update. Journal of the Formosan Medical Association, 2019, 118, S23-S31.	0.8	263
1776	The gut microbiome in food allergy. Annals of Allergy, Asthma and Immunology, 2019, 122, 276-282.	0.5	99
1777	Influence of the microbiota on epigenetics in colorectal cancer. National Science Review, 2019, 6, 1138-1148.	4.6	25
1778	Fecal Microbiota Transplantation for the Critically Ill Patient. Nutrition in Clinical Practice, 2019, 34, 73-79.	1.1	26
1779	Optimisation of a propidium monoazide based method to determine the viability of microbes in faecal slurries for transplantation. Journal of Microbiological Methods, 2019, 156, 40-45.	0.7	15
1780	Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients. European Journal of Gastroenterology and Hepatology, 2019, 31, 128-134.	0.8	13
1781	Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e17-e22.	2.0	44
1782	Nuts and Bolts of Fecal Microbiota Transplantation. Clinical Gastroenterology and Hepatology, 2019, 17, 345-352.	2.4	38
1783	Clinical Application and Potential of Fecal Microbiota Transplantation. Annual Review of Medicine, 2019, 70, 335-351.	5.0	184
1784	An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila. Digestion, 2019, 100, 127-138.	1.2	44
1785	Effects of Lactococcus lactis subsp. lactis JCM5805 on colonization dynamics of gut microbiota and regulation of immunity in early ontogenetic stages of tilapia. Fish and Shellfish Immunology, 2019, 86, 53-63.	1.6	34
1786	Faecal microbiota transplantation shortens the colonisation period and allows re-entry of patients carrying carbapenamase-producing bacteria into medical care facilities. International Journal of Antimicrobial Agents, 2019, 53, 355-361.	1.1	32
1787	Fecal microbiota transplantation in cancer management: Current status and perspectives. International Journal of Cancer, 2019, 145, 2021-2031.	2.3	195
1788	Influence of Early Life, Diet, and the Environment on the Microbiome. Clinical Gastroenterology and Hepatology, 2019, 17, 231-242.	2.4	130
1789	Synthetic consortia of nanobodyâ€coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosisâ€associated diseases and coâ€morbidities. Microbial Biotechnology, 2019, 12, 58-65.	2.0	17
1790	Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers, 2019, 11, 38.	1.7	378

#	Article	IF	Citations
1791	Microbial regulation of organismal energy homeostasis. Nature Metabolism, 2019, 1, 34-46.	5.1	354
1792	The Microbiota and Energy Balance. Endocrinology, 2019, , 109-126.	0.1	2
1793	Ecological dynamics of the vaginal microbiome in relation to health and disease. American Journal of Obstetrics and Gynecology, 2019, 220, 324-335.	0.7	129
1794	Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). Zeitschrift Fur Gastroenterologie, 2019, 57, 162-241.	0.2	41
1795	Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis. JAMA - Journal of the American Medical Association, 2019, 321, 156.	3.8	548
1796	An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Science Translational Medicine, 2019, 11, .	5.8	242
1797	Bile Acid 7Î±-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids. Cell Chemical Biology, 2019, 26, 27-34.e4.	2.5	134
1798	Small-Molecule Allosteric Triggers of Clostridium difficile Toxin B Auto-proteolysis as a Therapeutic Strategy. Cell Chemical Biology, 2019, 26, 17-26.e13.	2.5	11
1799	Current and future targets for faecal microbiota transplantation. Human Microbiome Journal, 2019, 11, 100045.	3.8	7
1800	Enlisting commensal microbes to resist antibiotic-resistant pathogens. Journal of Experimental Medicine, 2019, 216, 10-19.	4.2	51
1801	The gut microbiome: Relationships with disease and opportunities for therapy. Journal of Experimental Medicine, 2019, 216, 20-40.	4.2	547
1802	Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT). Diabetes, Obesity and Metabolism, 2019, 21, 479-490.	2.2	101
1803	Probiotics in the treatment of otitis media. The past, the present and the future. International Journal of Pediatric Otorhinolaryngology, 2019, 116, 135-140.	0.4	12
1804	Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease. Digestive Diseases and Sciences, 2019, 64, 669-677.	1.1	17
1805	Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review. Anaerobe, 2019, 55, 112-116.	1.0	6
1806	The role of the microbiota in infectious diseases. Nature Microbiology, 2019, 4, 35-45.	5.9	244
1807	The Human Microbiome in Health and Disease. , 2019, , 607-618.		8
1808	Management of adult Clostridium difficile digestive contaminations: a literature review. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 209-231.	1.3	11

#	Article	IF	Citations
1809	Current Medical Therapies for Ulcerative Colitis. , 2019, , 1-15.		0
1810	Prevention of Clostridium difficile Infection in Critically Ill Adults. Pharmacotherapy, 2019, 39, 399-407.	1.2	4
1811	Science in Focus: The Microbiome and Cancer Therapy. Clinical Oncology, 2019, 31, 1-4.	0.6	7
1812	Human Microbiome: Composition and Role in Inflammatory Skin Diseases. Archivum Immunologiae Et Therapiae Experimentalis, 2019, 67, 1-18.	1.0	66
1813	Mapping the Environmental Microbiome. , 2019, , 17-28.		1
1814	Exploring Human Bacterial Diversity Toward Prevention of Infectious Disease and Health Promotion. , 2019, , 519-533.		4
1815	The Gut Microbiota and Hematopoietic Stem Cell Transplantation: Challenges and Potentials. Journal of Innate Immunity, 2019, 11, 405-415.	1.8	33
1816	Successful treatment by fecal microbiota transplantation for Japanese patients with refractory Clostridium difficile infection: AÂprospective case series. Journal of Microbiology, Immunology and Infection, 2019, 52, 663-666.	1.5	15
1817	Optimization of fecal sample processing for microbiome study â€" The journey from bathroom to bench. Journal of the Formosan Medical Association, 2019, 118, 545-555.	0.8	107
1818	Faecal microbiota transplantation for Clostridium difficile infection using a lyophilized inoculum from non-related donors: A case series involving 19 patients. Acta Microbiologica Et Immunologica Hungarica, 2017, 66, 69-78.	0.4	9
1819	C. difficile Infection and Antibiotic Associated Diarrhea. , 2020, , 404-417.		0
1820	A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years. Clinical Infectious Diseases, 2020, 70, 1-10.	2.9	32
1821	Fecal Microbiota Transplant. , 2020, , 431-435.		0
1822	Recent Advancements in the Development of Modern Probiotics for Restoring Human Gut Microbiome Dysbiosis. Indian Journal of Microbiology, 2020, 60, 12-25.	1.5	70
1823	From the Pipeline to the Bedside: Advances and Challenges in Clinical Metagenomics. Journal of Infectious Diseases, 2020, 221, S331-S340.	1.9	69
1824	Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews. Inflammatory Bowel Diseases, 2020, 26, 843-851.	0.9	9
1825	The impact of lung microbiota dysbiosis on inflammation. Immunology, 2020, 159, 156-166.	2.0	45
1826	Diversification of host bile acids by members of the gut microbiota. Gut Microbes, 2020, 11, 158-171.	4.3	278

#	Article	IF	Citations
1827	Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohnâ€™s Disease. Digestive Diseases and Sciences, 2020, 65, 150-157.	1.1	33
1828	Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials. Anaerobe, 2020, 61, 102098.	1.0	42
1829	Effects of dietary probiotic supplementation on the growth, gut health and disease resistance of juvenile Nile tilapia (Oreochromis niloticus). Animal Nutrition, 2020, 6, 69-79.	2.1	85
1830	Expert opinion on fecal microbiota transplantation for the treatment of Clostridioides difficile infection and beyond. Expert Opinion on Biological Therapy, 2020, 20, 73-81.	1.4	21
1831	Influence of prior appendectomy and cholecystectomy on Clostridioides difficile infection recurrence and mortality. American Journal of Surgery, 2020, 220, 203-207.	0.9	5
1832	Preâ€•and postâ€•serial metagenomic analysis of gut microbiota as a prognostic factor in patients undergoing haematopoietic stem cell transplantation. British Journal of Haematology, 2020, 188, 438-449.	1.2	45
1833	Mucosal microbial load in Crohn's disease: A potential predictor of response to faecal microbiota transplantation. EBioMedicine, 2020, 51, 102611.	2.7	21
1834	Differential Composition of Vaginal Microbiome, but Not of Seminal Microbiome, Is Associated With Successful Intrauterine Insemination in Couples With Idiopathic Infertility: A Prospective Observational Study. Open Forum Infectious Diseases, 2020, 7, ofz525.	0.4	31
1835	Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules. Journal of Hospital Infection, 2020, 105, 319-324.	1.4	19
1836	Manipulating the Human Microbiome to Manage Disease. JAMA - Journal of the American Medical Association, 2020, 323, 303.	3.8	22
1837	Avoiding infections in transplant recipients: does the gut microbiota have a key role?. Expert Review of Clinical Immunology, 2020, 16, 113-115.	1.3	0
1838	Proton pump inhibitor in upper gastrointestinal fecal microbiota transplant: A systematic review and analysis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 932-940.	1.4	8
1839	Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1415-1420.	0.9	31
1840	Novel Therapies for Treatment of Food Allergy. Immunology and Allergy Clinics of North America, 2020, 40, 175-186.	0.7	24
1841	The role of the microbiome in precision medicine. , 2020, , 13-18.		0
1842	Infection in the Patient With Cancer. , 2020, , 544-564.e6.		4
1843	Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 613-627.	1.3	33
1844	Understanding immuneâ€“microbiota interactions in the intestine. Immunology, 2020, 159, 4-14.	2.0	62

#	Article	IF	Citations
1845	Bile salt metabolism is not the only factor contributing toClostridioides(Clostridiumdifficiledisease severity in the murine model of disease. Gut Microbes, 2020, 11, 481-496.	4.3	12
1846	Carbapenemase-producing Enterobacteriaceae â€“ once positive always positive?. Current Opinion in Gastroenterology, 2020, 36, 9-16.	1.0	11
1847	Harnessing the microbiota for therapeutic purposes. American Journal of Transplantation, 2020, 20, 1482-1488.	2.6	14
1848	Engineering microbial living therapeutics. , 2020, , 71-82.		3
1850	Roles of microbiota in response to cancer immunotherapy. Seminars in Cancer Biology, 2020, 65, 164-175.	4.3	36
1851	Efficacy and safety of fecal microbiota transplantation by washed preparation in patients with moderate to severely active ulcerative colitis. Journal of Digestive Diseases, 2020, 21, 621-628.	0.7	17
1852	Composition of â€œgold juiceâ€•using an ancient method based on intestinal microecology. Journal of International Medical Research, 2020, 48, 030006052093128.	0.4	2
1853	Faecal microbiota transplantation for Clostridioides difficile infection: Four yearsâ€™ experience of the Netherlands Donor Feces Bank. United European Gastroenterology Journal, 2020, 8, 1236-1247.	1.6	35
1854	Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease . Journal of Inflammation Research, 2020, Volume 13, 563-570.	1.6	9
1855	Gut Microbiota and Epilepsy: A Systematic Review on Their Relationship and Possible Therapeutics. ACS Chemical Neuroscience, 2020, 11, 3488-3498.	1.7	26
1856	Is it unethical to conduct placebo-controlled trials of faecal microbiota transplantation for recurrent Clostridioides difficile infection?. The Lancet Gastroenterology and Hepatology, 2020, 5, 432-433.	3.7	0
1857	Oral delivery of bacteria: Basic principles and biomedical applications. Journal of Controlled Release, 2020, 327, 801-833.	4.8	55
1858	Another Step in the Journeyâ€”From Feces to Regulated Microbial Therapeutics. Clinical Infectious Diseases, 2021, 73, e1621-e1623.	2.9	0
1859	Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With Clostridioides difficile Infection. Clinical Infectious Diseases, 2021, 73, e1706-e1712.	2.9	8
1860	Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1453-1468.	1.9	36
1861	Gut microbiota and old age: Modulating factors and interventions for healthy longevity. Experimental Gerontology, 2020, 141, 111095.	1.2	61
1862	Infusion of donor feces affects the gutâ€“brain axis in humans with metabolic syndrome. Molecular Metabolism, 2020, 42, 101076.	3.0	50
1863	Rational design of a microbial consortium of mucosal sugar utilizers reduces Clostridiodes difficile colonization. Nature Communications, 2020, 11, 5104.	5.8	177

#	Article	IF	Citations
1864	Dietary and Microbial Determinants in Food Allergy. Immunity, 2020, 53, 277-289.	6.6	49
1865	Streptococcus pneumoniae Endopeptidase O Promotes the Clearance of Staphylococcus aureus and Streptococcus pneumoniae via SH2 Domain-Containing Inositol Phosphatase 1-Mediated Complement Receptor 3 Upregulation. Frontiers in Cellular and Infection Microbiology, 2020, 10, 358.	1.8	4
1867	Onâ€Ðemand Bacterial Reactivation by Restraining within a Triggerable Nanocoating. Advanced Materials, 2020, 32, e2002406.	11.1	76
1868	Fecal microbiota transplantation for treatment of irritable bowel syndrome. The Cochrane Library, 0, , .	1.5	1
1869	Uso de las tecnologÃas de secuenciaciÃ³n masiva para el diagnÃ³stico y epidemiologÃa de enfermedades infecciosas. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 32-38.	0.3	1
1870	Microbiota Transplant in the Treatment of Obesity and Diabetes: Current and Future Perspectives. Frontiers in Microbiology, 2020, 11, 590370.	1.5	40
1871	Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope?. Current Gastroenterology Reports, 2020, 22, 60.	1.1	4
1872	Anti-virulence strategies for Clostridioides difficile infection: advances and roadblocks. Gut Microbes, 2020, 12, 1802865.	4.3	10
1874	Metagenomic Information Recovery from Human Stool Samples Is Influenced by Sequencing Depth and Profiling Method. Genes, 2020, 11, 1380.	1.0	11
1875	Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantation treatment and the efficacy of re-FMT: a case series. BMC Gastroenterology, 2020, 20, 401.	0.8	10
1876	Clinical outcomes after faecal microbiota transplant by retention enema in both immunocompetent and immunocompromised patients with recurrent Clostridioides difficile infections at an academic medical centre. Journal of Hospital Infection, 2020, 106, 643-648.	1.4	5
1877	Fecal microbiota transplantation: Uses, questions, and ethics. Medicine in Microecology, 2020, 6, 100027.	0.7	20
1878	British HIV Association guidelines on the management of opportunistic infection in people living with HIV: the clinical management of gastrointestinal opportunistic infections 2020. HIV Medicine, 2020, 21, 1-19.	1.0	3
1879	The Effectiveness of Multi-Session FMT Treatment in Active Ulcerative Colitis Patients: A Pilot Study. Biomedicines, 2020, 8, 268.	1.4	20
1880	Multidrug-Resistant Gram-Negative Bacteria Decolonization in Immunocompromised Patients: A Focus on Fecal Microbiota Transplantation. International Journal of Molecular Sciences, 2020, 21, 5619.	1.8	13
1881	Engineered Live Biotherapeutics: Progress and Challenges. Biotechnology Journal, 2020, 15, e2000155.	1.8	13
1882	Gut Microbiota Modulation: Implications for Infection Control and Antimicrobial Stewardship. Advances in Therapy, 2020, 37, 4054-4067.	1.3	13
1883	Probiotics, prebiotics, antibiotic, Chinese herbal medicine, and fecal microbiota transplantation in irritable bowel syndrome. Medicine (United States), 2020, 99, e21502.	0.4	9

#	Article	IF	Citations
1884	Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093431.	1.4	6
1885	Microbiome and food allergy. , 2020, , 145-156.		0
1886	Prebiotics, Probiotics, and Bacterial Infections. , 0, , .		0
1887	The influence of oxygen on the metabolites of phenolic blueberry extract and the mouse microflora during in vitro fermentation. Food Research International, 2020, 136, 109610.	2.9	10
1888	Effects of Antibiotic Treatment on Gut Microbiota and How to Overcome Its Negative Impacts on Human Health. ACS Infectious Diseases, 2020, 6, 2544-2559.	1.8	57
1889	Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis. Microbiome, 2020, 8, 112.	4.9	62
1890	Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. Science Translational Medicine, 2020, 12, .	5.8	97
1891	Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent Clostridioides difficile infection. EClinicalMedicine, 2020, 24, 100420.	3.2	11
1892	Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection. Journal of Infection, 2020, 81, 758-765.	1.7	9
1893	The gut microbiome and potential implications for early-onset colorectal cancer. Colorectal Cancer, 2020, 9, .	0.8	9
1894	Acetate coordinates neutrophil and ILC3 responses against C. difficile through FFAR2. Journal of Experimental Medicine, 2020, 217, .	4.2	116
1895	The trans-kingdom battle between donor and recipient gut microbiome influences fecal microbiota transplantation outcome. Scientific Reports, 2020, 10, 18349.	1.6	25
1896	Prevention of Clostridium difficile Infection and Associated Diarrhea: An Unsolved Problem. Microorganisms, 2020, 8, 1640.	1.6	8
1897	Septic shock due to refractory severe clostridioides difficile colitis rapidly resolving after faecal microbiota transplantation. BMJ Case Reports, 2020, 13, e234329.	0.2	2
1898	Protocol for a pilot randomised, double-blind, placebo-controlled trial for assessing the feasibility and efficacy of faecal microbiota transplantation in adolescents with refractory irritable bowel syndrome: FAIS Trial. BMJ Paediatrics Open, 2020, 4, e000689.	0.6	2
1899	Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?. European Respiratory Review, 2020, 29, 200023.	3.0	23
1900	Fecal Microbiota Transplantation for multidrug-resistant organism: Efficacy and Response prediction. Journal of Infection, 2020, 81, 719-725.	1.7	29
1901	The ethicolegal framework relevant to human faecal microbiota transplants in South Africa: Part 1. A legal vacuum. South African Medical Journal, 2020, 110, 812.	0.2	2

#	Article	IF	Citations
1902	Physician and patient perceptions of fecal microbiota transplant for recurrent or refractory Clostridioides difficile in the first 6â€‰years of a central stool bank. JGH Open, 2020, 4, 950-957.	0.7	8
1905	Computational and Methodological Statistics and Biostatistics. Emerging Topics in Statistics and Biostatistics, 2020, , .	0.1	1
1907	Drinking Refined Deep-Sea Water Improves the Gut Ecosystem with Beneficial Effects on Intestinal Health in Humans: A Randomized Double-Blind Controlled Trial. Nutrients, 2020, 12, 2646.	1.7	5
1908	Of men in mice: the development and application of a humanized gnotobiotic mouse model for microbiome therapeutics. Experimental and Molecular Medicine, 2020, 52, 1383-1396.	3.2	87
1909	Clostridioides difficile Spore Formation and Germination: New Insights and Opportunities for Intervention. Annual Review of Microbiology, 2020, 74, 545-566.	2.9	42
1910	Diagnostic and therapy of severe Clostridioides difficile infections in the ICU. Current Opinion in Critical Care, 2020, 26, 450-458.	1.6	4
1911	Defined microbiota transplant restores Th17/RORÎ³t⁺regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21536-21545.	3.3	58
1912	A Summary of the Fifth Annual Virology Education HIV Microbiome Workshop. AIDS Research and Human Retroviruses, 2020, 36, 886-895.	0.5	2
1913	Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. International Journal of Molecular Sciences, 2020, 21, 5999.	1.8	13
1914	Expert centres for faecal microbiota transplantation: The guarantee for safe and effective use of faecal transplants. United European Gastroenterology Journal, 2020, 8, 1145-1146.	1.6	1
1915	Microbiome-based interventions: therapeutic strategies in cancer immunotherapy. Immuno-Oncology Technology, 2020, 8, 12-20.	0.2	9
1916	Metagenomic Systems Biology. , 2020, , .		0
1917	Culture-Independent Omics-Techniques for Microbiome-Based Molecular Therapeutics Against Infectious Diseases. , 2020, , 95-114.		0
1918	Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine, 2020, 29-30, 100642.	3.2	111
1919	The Link between Oral and Gut Microbiota in Inflammatory Bowel Disease and a Synopsis of Potential Salivary Biomarkers. Applied Sciences (Switzerland), 2020, 10, 6421.	1.3	12
1920	Exploring the Preventive Effect and Mechanism of Senile Sarcopenia Based on â€œGutâ€“Muscle Axisâ€• Frontiers in Bioengineering and Biotechnology, 2020, 8, 590869.	2.0	22
1921	Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microbial Cell Factories, 2020, 19, 203.	1.9	202
1922	Pulmonary infections complicating ARDS. Intensive Care Medicine, 2020, 46, 2168-2183.	3.9	69

#	Article	IF	Citations
1923	Airway Microbiota as a Modulator of Lung Cancer. International Journal of Molecular Sciences, 2020, 21, 3044.	1.8	35
1924	Faecal microbiota transplantation as a home therapy to frail older people. Age and Ageing, 2020, 49, 1093-1096.	0.7	11
1925	The Bacterial Microbiota of Gastrointestinal Cancers: Role in Cancer Pathogenesis and Therapeutic Perspectives . Clinical and Experimental Gastroenterology, 2020, Volume 13, 151-185.	1.0	18
1926	Intervention strategies for microbial therapeutics in cancer immunotherapy. Immuno-Oncology Technology, 2020, 6, 9-17.	0.2	8
1927	Clinical remission of ulcerative colitis after different modes of faecal microbiota transplantation: a meta-analysis. International Journal of Colorectal Disease, 2020, 35, 1025-1034.	1.0	15
1928	Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity. Nature Communications, 2020, 11, 2354.	5.8	75
1929	Delivery routes for faecal microbiota transplants: Available, anticipated and aspired. Pharmacological Research, 2020, 159, 104954.	3.1	41
1930	The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI. Cell Reports Medicine, 2020, 1, 100005.	3.3	26
1931	Gut Microbiota Dysbiosis Associated with Bile Acid Metabolism in Neonatal Cholestasis Disease. Scientific Reports, 2020, 10, 7686.	1.6	21
1932	The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridiumdifficile Infection: Current Understanding and Gap Analysis. Open Forum Infectious Diseases, 2020, 7, ofaa114.	0.4	31
1933	New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection. MBio, 2020, 11, .	1.8	8
1934	Relief of hypersaline stress in Nile tilapia Oreochromis niloticus by dietary supplementation of a host-derived Bacillus subtilis strain. Aquaculture, 2020, 528, 735542.	1.7	22
1935	How do I establish a stool bank for fecal microbiota transplantation within the bloodâ€•and tissue transplant service?. Transfusion, 2020, 60, 1135-1141.	0.8	13
1936	Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial. BMJ Open, 2020, 10, e038847.	0.8	4
1937	Computational Approaches for Unraveling the Effects of Variation in the Human Genome and Microbiome. Annual Review of Biomedical Data Science, 2020, 3, 411-432.	2.8	5
1938	Oral vancomycin prophylaxis against recurrentClostridioides difficileinfection: Efficacy and side effects in two hospitals. Infection Control and Hospital Epidemiology, 2020, 41, 908-913.	1.0	3
1939	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. OncoImmunology, 2020, 9, 1774298.	2.1	22
1940	The Microbiome and Hepatocellular Carcinoma. Liver Transplantation, 2020, 26, 1316-1327.	1.3	24

#	Article	IF	Citations
1941	Net release and uptake of xenometabolites across intestinal, hepatic, muscle, and renal tissue beds in healthy conscious pigs. American Journal of Physiology - Renal Physiology, 2020, 319, G133-G141.	1.6	4
1942	Bacteriophage-mediated manipulation of the gut microbiome â€“ promises and presents limitations. FEMS Microbiology Reviews, 2020, 44, 507-521.	3.9	65
1943	Matching between Donors and Ulcerative Colitis Patients Is Important for Long-Term Maintenance after Fecal Microbiota Transplantation. Journal of Clinical Medicine, 2020, 9, 1650.	1.0	32
1944	Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials, 2020, 21, 455.	0.7	4
1945	Freeze-dried fecal samples are biologically active after long-lasting storage and suited to fecal microbiota transplantation in a preclinical murine model of Clostridioides difficile infection. Gut Microbes, 2020, 11, 1405-1422.	4.3	24
1946	Microbiome in health and disease. Journal of Paediatrics and Child Health, 2020, 56, 1735-1738.	0.4	11
1947	Role of the Microbiome in Allergic Disease Development. Current Allergy and Asthma Reports, 2020, 20, 44.	2.4	21
1948	Adapting with Microbial Help: Microbiome Flexibility Facilitates Rapid Responses to Environmental Change. BioEssays, 2020, 42, e2000004.	1.2	146
1949	Protonâ€pump inhibitor use before fecal microbiota transplant: A wonder drug, a necessary evil, or a needless prescription?. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 913-914.	1.4	2
1950	Xenometabolite signatures in the UC Davis type 2 diabetes mellitus rat model revealed using a metabolomics platform enriched with microbe-derived metabolites. American Journal of Physiology - Renal Physiology, 2020, 319, G157-G169.	1.6	13
1951	Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. Journal of Clinical Medicine, 2020, 9, 1757.	1.0	65
1952	Regulation, risk and safety of Faecal Microbiota Transplant. Infection Prevention in Practice, 2020, 2, 100069.	0.6	51
1953	Links between Nutrition, Infectious Diseases, and Microbiota: Emerging Technologies and Opportunities for Human-Focused Research. Nutrients, 2020, 12, 1827.	1.7	20
1954	Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0228846.	1.1	49
1955	Altering Routine Intensive Care Unit Practices to Support Commensalism. Nutrition in Clinical Practice, 2020, 35, 433-441.	1.1	4
1956	Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection. Trends in Molecular Medicine, 2020, 26, 496-507.	3.5	25
1957	Host microbiomes and disease. , 2020, , 122-153.		1
1958	Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. Microbiology and Molecular Biology Reviews, 2020, 84, .	2.9	37

#	Article	IF	Citations
1959	The gut microbiome and thromboembolism. Thrombosis Research, 2020, 189, 77-87.	0.8	41
1960	Changes in Microbiota Profiles After Prolonged Frozen Storage of Stool Suspensions. Frontiers in Cellular and Infection Microbiology, 2020, 10, 77.	1.8	19
1961	Fecal Microbiota Transplantation in Neurological Disorders. Frontiers in Cellular and Infection Microbiology, 2020, 10, 98.	1.8	221
1962	A new protectant medium preserving bacterial viability after freeze drying. Microbiological Research, 2020, 236, 126454.	2.5	33
1963	Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease. Translational Research, 2020, 226, 1-11.	2.2	34
1964	Rapid improvement in Alzheimerâ€™s disease symptoms following fecal microbiota transplantation: a case report. Journal of International Medical Research, 2020, 48, 030006052092593.	0.4	98
1965	The Gutâ€“CNS Axis in Multiple Sclerosis. Trends in Neurosciences, 2020, 43, 622-634.	4.2	64
1966	Impact of Case Definitions on Efficacy Estimation in Clinical Trialsâ€”A Proof-of-Principle Based on Historical Examples. Antibiotics, 2020, 9, 379.	1.5	4
1967	Challenges and emerging systems biology approaches to discover how the human gut microbiome impact host physiology. Biophysical Reviews, 2020, 12, 851-863.	1.5	8
1968	The use of fecal microbiota transplant in sepsis. Translational Research, 2020, 226, 12-25.	2.2	25
1969	Microbiome therapeutics and patent protection. Nature Biotechnology, 2020, 38, 806-810.	9.4	10
1970	Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Current Oncology Reports, 2020, 22, 74.	1.8	34
1971	Fecal transplants as a microbiome-based therapeutic. Current Opinion in Microbiology, 2020, 56, 16-23.	2.3	14
1972	An ecological framework to understand the efficacy of fecal microbiota transplantation. Nature Communications, 2020, 11, 3329.	5.8	59
1973	Diagnosis and treatment of Clostridioides difficile infection. Medicina ClÃ¬nica (English Edition), 2020, 155, 30-35.	0.1	0
1974	The Current Hepatic Encephalopathy Pipeline. Journal of Clinical and Experimental Hepatology, 2020, 10, 377-385.	0.4	9
1975	Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?. Gastroenterology, 2020, 158, 1881-1898.	0.6	123
1976	Abnormal Uroguanylin Immunoreactive Cells Density in the Duodenum of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Changes following Fecal Microbiota Transplantation. Gastroenterology Research and Practice, 2020, 2020, 1-9.	0.7	6

#	Article	IF	Citations
1977	Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 223-237.	8.2	893
1978	Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opinion on Biological Therapy, 2020, 20, 343-351.	1.4	29
1979	Strategies to prevent adverse outcomes following Clostridioides difficile infection in the elderly. Expert Review of Anti-Infective Therapy, 2020, 18, 203-217.	2.0	3
1980	Editorial: faecal microbiota transplantationâ€"the silver bullet for severe and fulminant Clostridioides difficile infection?. Alimentary Pharmacology and Therapeutics, 2020, 51, 180-181.	1.9	0
1981	The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases. Nutrients, 2020, 12, 605.	1.7	109
1982	Nonpharmacologic Management of Hepatic Encephalopathy. Clinics in Liver Disease, 2020, 24, 243-261.	1.0	5
1983	From role of gut microbiota to microbial-based therapies in type 2-diabetes. Infection, Genetics and Evolution, 2020, 81, 104268.	1.0	53
1984	Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease. International Journal of Hepatology, 2020, 2020, 1-6.	0.4	13
1985	Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. Gut, 2020, 69, 801-810.	6.1	52
1986	Faecal microbiota transplantation in the treatment of Clostridioides difficile infection. Human Microbiome Journal, 2020, 16, 100070.	3.8	1
1987	Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan. Journal of Microbiology, Immunology and Infection, 2020, 53, 191-208.	1.5	20
1988	Improving Riskâ€"Benefit in Faecal Transplantation through Microbiome Screening. Trends in Microbiology, 2020, 28, 331-339.	3.5	19
1989	Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 386.	1.8	112
1990	A systematic review of economic evaluation in fecal microbiota transplantation. Infection Control and Hospital Epidemiology, 2020, 41, 458-466.	1.0	6
1991	The gut microbiota and its interactions with cardiovascular disease. Microbial Biotechnology, 2020, 13, 637-656.	2.0	97
1992	Microbiome Anomalies in Allogeneic Hematopoietic Cell Transplantation. Annual Review of Medicine, 2020, 71, 137-148.	5.0	16
1993	The microbiota and immuneâ€mediated diseases: Opportunities for therapeutic intervention. European Journal of Immunology, 2020, 50, 326-337.	1.6	39
1994	Le transfert de microbiote fÃ©calÂ: quel potentiel thÃ©rapeutique dans le traitement des maladies mÃ©taboliquesÂ?. Nutrition Clinique Et Metabolisme, 2020, 34, 108-115.	0.2	1

#	Article	IF	Citations
1995	Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2020, 65, 757-788.	1.1	97
1996	Fecal microbiota transplantation in disease therapy. Clinica Chimica Acta, 2020, 503, 90-98.	0.5	107
1997	Klebsiella michiganensis transmission enhances resistance to Enterobacteriaceae gut invasion by nutrition competition. Nature Microbiology, 2020, 5, 630-641.	5.9	67
1998	Fecal microbiota transplantation improves metabolism and gut microbiome composition in db/db mice. Acta Pharmacologica Sinica, 2020, 41, 678-685.	2.8	61
1999	AlGaN Deep-Ultraviolet Light-Emitting Diodes Grown on SiC Substrates. ACS Photonics, 2020, 7, 554-561.	3.2	59
2000	Winning with poo? Fecal microbiome transplantation as an emerging strategy for the management of recurrent Clostridioides difficile infection in children. Pediatric Transplantation, 2020, 24, e13651.	0.5	0
2001	Insights into the Role of Human Gut Microbiota in Clostridioides difficile Infection. Microorganisms, 2020, 8, 200.	1.6	40
2002	Fecal Microbiota Transplantation for Clostridioides difficile in High-Risk Older Adults: Treat Early, Treat Often. Digestive Diseases and Sciences, 2020, 65, 3425-3427.	1.1	2
2003	Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia. Translational Research, 2020, 220, 167-181.	2.2	9
2004	Microbiota-Orientated Treatments for Major Depression and Schizophrenia. Nutrients, 2020, 12, 1024.	1.7	38
2005	Problems with using stability, specificity, and proportionality as criteria for evaluating strength of scientific causal explanations: commentary on Lynch et al. (2019). Biology and Philosophy, 2020, 35, 1.	0.7	5
2006	From Association to Causality: the Role of the Gut Microbiota and Its Functional Products on Host Metabolism. Molecular Cell, 2020, 78, 584-596.	4.5	177
2007	Alcohol pretreatment of stools effect on culturomics. Scientific Reports, 2020, 10, 5190.	1.6	7
2008	Screening of Natural Products and Approved Oncology Drug Libraries for Activity against Clostridioides difficile. Scientific Reports, 2020, 10, 5966.	1.6	9
2009	Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection. Expert Review of Anti-Infective Therapy, 2020, 18, 669-676.	2.0	15
2010	Management of difficult-to-treatClostridioides difficilein a patient with chronic osteomyelitis. BMJ Case Reports, 2020, 13, e233095.	0.2	1
2011	From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation. Diseases (Basel, Switzerland), 2020, 8, 9.	1.0	31
2012	Guidelines for Clostridium difficile infection in adults. Przeglad Gastroenterologiczny, 2020, 15, 1-21.	0.3	20

#	Article	IF	Citations
2013	The microbiome in rheumatology: Where are we and where should we go?. Annals of the Rheumatic Diseases, 2020, 79, 727-733.	0.5	55
2014	Phages and Their Role in Gastrointestinal Disease: Focus on Inflammatory Bowel Disease. Cells, 2020, 9, 1013.	1.8	33
2015	Gut Microbiota and Pathogenesis of Organ Injury. Advances in Experimental Medicine and Biology, 2020, , .	0.8	7
2016	Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. Cell Host and Microbe, 2020, 27, 823-829.e3.	5.1	110
2017	Results from the first English stool bank using faecal microbiota transplant as a medicinal product for the treatment of Clostridioides difficile infection. EClinicalMedicine, 2020, 20, 100301.	3.2	16
2018	The Route to Palatable Fecal Microbiota Transplantation. AAPS PharmSciTech, 2020, 21, 114.	1.5	16
2019	Ulcerative Proctitis in a Patient With a History of Fecal Microbiota Transplant for Clostridioides difficile Infection. ACG Case Reports Journal, 2020, 7, e00364.	0.2	0
2020	Saccharomyces boulardii for the Prevention of Hospital Onset Clostridium difficile Infection. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 21-24.	0.5	22
2021	Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study. Digestive Diseases and Sciences, 2021, 66, 873-880.	1.1	34
2022	Fecal Microbiota Transplantation (FMT) with Colonoscopy Is Superior to Enema and Nasogastric Tube While Comparable to Capsule for the Treatment of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2021, 66, 369-380.	1.1	52
2023	Risk Factors that Predict the Failure of Multiple Fecal Microbiota Transplantations for Clostridioides difficile Infection. Digestive Diseases and Sciences, 2021, 66, 213-217.	1.1	15
2024	Human microbiome and homeostasis: insights into the key role of prebiotics, probiotics, and symbiotics. Critical Reviews in Food Science and Nutrition, 2021, 61, 1415-1428.	5.4	20
2025	The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein and Cell, 2021, 12, 331-345.	4.8	133
2026	Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. Seminars in Cancer Biology, 2021, 70, 11-23.	4.3	26
2027	Superiority of Higher-Volume Fresh Feces Compared to Lower-Volume Frozen Feces in Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Colitis. Digestive Diseases and Sciences, 2021, 66, 2000-2004.	1.1	4
2028	Classical methods and perspectives for manipulating the human gut microbial ecosystem. Critical Reviews in Food Science and Nutrition, 2021, 61, 234-258.	5.4	13
2029	Fecal Microbiota Transplant in a Patient Infected with Multidrug-Resistant Bacteria: A Case Report. GE Portuguese Journal of Gastroenterology, 2021, 28, 56-61.	0.3	5
2030	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. United European Gastroenterology Journal, 2021, 9, 229-247.	1.6	66

#	Article	IF	Citations
2031	Gut-brain axis: A matter of concern in neuropsychiatric disordersâ€¦!. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110051.	2.5	42
2032	Fecal microbiota transplantation for ulcerative colitis. Immunological Medicine, 2021, 44, 30-34.	1.4	15
2033	Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology, 2021, 160, 145-157.e8.	0.6	109
2034	Challenges of Screening Prospective Stool Donors for Fecal Microbiota Transplantation. Biological Research for Nursing, 2021, 23, 21-30.	1.0	10
2035	Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms. Clinical Infectious Diseases, 2021, 72, 1444-1447.	2.9	40
2036	Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology, 2021, 160, 183-192.e3.	0.6	113
2037	Gut microbes in cardiovascular diseases and their potential therapeutic applications. Protein and Cell, 2021, 12, 346-359.	4.8	62
2038	Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health. Gut, 2021, 70, 595-605.	6.1	265
2039	Bacteriome Structure, Function, and Probiotics in Fish Larviculture: The Good, the Bad, and the Gaps. Annual Review of Animal Biosciences, 2021, 9, 423-452.	3.6	31
2040	Bile Acid Signaling in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, 66, 674-693.	1.1	102
2041	Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study. Lancet Infectious Diseases, The, 2021, 21, 711-721.	4.6	21
2042	Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy. Translational Research, 2021, 230, 197-207.	2.2	5
2043	The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumorâ€“immuneâ€“microbiome interaction. Human Genetics, 2021, 140, 725-746.	1.8	32
2044	Cancer and the Microbiomeâ€”Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology, 2021, 160, 600-613.	0.6	167
2045	Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metabolism, 2021, 33, 21-32.	7.2	98
2046	Introduction to host microbiome symbiosis in health and disease. Mucosal Immunology, 2021, 14, 547-554.	2.7	95
2047	Gut mycobiome: A promising target for colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188489.	3.3	21
2048	SelecciÃ³n del donante para la transferencia de microbiota fecal. Documento de posicionamiento de la Societat Catalana de Digestologia y de la Societat Catalana de Malalties Infeccioses i Microbiologia ClÃnica. GastroenterologÃa Y HepatologÃa, 2021, 44, 175-180.	0.2	5

#	Article	IF	Citations
2049	Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis. Infectious Diseases and Therapy, 2021, 10, 201-211.	1.8	8
2050	Gut microbiota in human metabolic health and disease. Nature Reviews Microbiology, 2021, 19, 55-71.	13.6	1,960
2051	Phages and their potential to modulate the microbiome and immunity. Cellular and Molecular Immunology, 2021, 18, 889-904.	4.8	83
2052	Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 67-80.	8.2	91
2053	Gut Microbiome and Gastrointestinal Disorders. The Microbiomes of Humans, Animals, Plants, and the Environment, 2021, , 41-91.	0.2	0
2054	Infectious Diarrhea. , 2021, , 398-415.e5.		0
2055	Fecal microbiota transplantation via colonoscopy in a dog with Clostridioides (Clostridium) difficile infection. Ciencia Rural, 2021, 51, .	0.3	4
2056	Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience â˜’ effective, safe, yet room for improvement. Internal Medicine Journal, 2021, 51, 106-110.	0.5	1
2057	Successful Experience of Fecal Transplantation in a Patient with Severe Pseudomembranous Colitis. Acta Biomedica Scientifica, 2021, 5, 248-253.	0.1	0
2058	Clostridioides difficile Infection in Chronic Kidney Diseaseâ€"An Overview for Clinicians. Journal of Clinical Medicine, 2021, 10, 196.	1.0	6
2059	Bacteriotherapy for inflammatory bowel disease. Inflammation and Regeneration, 2021, 41, 3.	1.5	21
2060	Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection. Gut and Liver, 2021, 15, 61-69.	1.4	6
2061	Treatment of CDI. , 2021, , 69-78.		0
2062	Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110096.	1.4	10
2064	Application of Next Generation Sequencing in Laboratory Medicine. Annals of Laboratory Medicine, 2021, 41, 25-43.	1.2	99
2065	Biologically Inspired Design: A Primer. Synthesis Lectures on Engineering Science and Technology, 2021, 3, 1-115.	0.2	0
2067	External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482097738.	1.4	10
2068	Skin microbiome transplantation and manipulation: Current state of the art. Computational and Structural Biotechnology Journal, 2021, 19, 624-631.	1.9	52

#	Article	IF	Citations
2069	Clostridioides difficile Infection, Still a Long Way to Go. Journal of Clinical Medicine, 2021, 10, 389.	1.0	25
2070	Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review. Health Economics Review, 2021, 11, 3.	0.8	10
2071	Management of Severe and Severe/Complicated Clostridoides difficile Infection Using Sequential Fecal Microbiota Transplant by Retention Enema. Clinical Infectious Diseases, 2021, 73, 716-719.	2.9	2
2072	Healthcare providersâ€™ perception of faecal microbiota transplantation with clostridium difficile infection and inflammatory bowel disease: a quantitative systematic review. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110426.	1.4	2
2073	Role of the Microbiome in Interstitial Lung Diseases. Frontiers in Medicine, 2021, 8, 595522.	1.2	29
2074	Fecal Transplant. , 2021, , 1039-1042.e2.		0
2075	The role of faecal microbiota transplantation: looking beyondClostridioides difficileinfection. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612098152.	1.1	13
2076	Longitudinal dynamics of gut bacteriome, mycobiome and virome after fecal microbiota transplantation in graft-versus-host disease. Nature Communications, 2021, 12, 65.	5.8	51
2077	Crosstalk between gut microbiota and sepsis. Burns and Trauma, 2021, 9, tkab036.	2.3	24
2078	Assessment of clinical and microbiota responses to fecal microbial transplantation in adult horses with diarrhea. PLoS ONE, 2021, 16, e0244381.	1.1	18
2079	Strategies for Prevention and Containment of Antimicrobial Resistance. Sustainable Agriculture Reviews, 2021, , 1-31.	0.6	1
2080	A metagenomics approach to investigate microbiome sociobiology. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	2
2081	Future Directions in Reducing Gastrointestinal Disorders in Children With ASD Using Fecal Microbiota Transplantation. Frontiers in Cellular and Infection Microbiology, 2021, 11, 630052.	1.8	11
2082	The Butyrate-Producing Bacterium Clostridium butyricum Suppresses Clostridioides difficile Infection via Neutrophil- and Antimicrobial Cytokineâ€“Dependent but GPR43/109a-Independent Mechanisms. Journal of Immunology, 2021, 206, 1576-1585.	0.4	47
2085	Opportunities and Challenges in Development of Live Biotherapeutic Products to Fight Infections. Journal of Infectious Diseases, 2021, 223, S283-S289.	1.9	9
2086	Ocular Surface Microbiome Alterations Are Found in Both Eyes of Individuals With Unilateral Infectious Keratitis. Translational Vision Science and Technology, 2021, 10, 19.	1.1	7
2087	The Human Gut Microbe Bacteroides thetaiotaomicron Suppresses Toxin Release from Clostridium difficile by Inhibiting Autolysis. Antibiotics, 2021, 10, 187.	1.5	5
2088	FECAL MICROBIOTES TRANSPLANTATION TECHNOLOGIES: MEDICAL, BIOTECHNOLOGICAL AND REGULATORY ASPECTS. Biotechnologia Acta, 2021, 14, 46-56.	0.3	0

#	Article	IF	Citations
2089	Stool banking for fecal microbiota transplantation: ready for prime time?. Hepatobiliary Surgery and Nutrition, 2021, 10, 110-112.	0.7	6
2090	Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection. Nature Communications, 2021, 12, 755.	5.8	40
2091	Fecal Microbiota Transplantation Is a Promising Method to Restore Gut Microbiota Dysbiosis and Relieve Neurological Deficits after Traumatic Brain Injury. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-21.	1.9	54
2092	Fecal microbiota transplantation: donor selection criteria, storage and preparation of biomaterials (review of current recommendations). Terapevticheskii Arkhiv, 2021, 93, 215-221.	0.2	6
2093	Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile. Microorganisms, 2021, 9, 306.	1.6	6
2094	Donor selection for faecal microbiota transplantation. Consensus document of the Catalan Society of Gastroenterology and the Catalan Society of Infectious Diseases and Clinical Microbiology. GastroenterologÃa Y HepatologÃa (English Edition), 2021, 44, 175-180.	0.0	2
2095	Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. Biomedicines, 2021, 9, 145.	1.4	20
2096	Modulating gut microbiota to treat cancer. Science, 2021, 371, 573-574.	6.0	25
2097	Impact on the Gut Microbiota of Intensive and Prolonged Antimicrobial Therapy in Patients With Bone and Joint Infection. Frontiers in Medicine, 2021, 8, 586875.	1.2	7
2098	Primary Human Dendritic Cells and Whole-Blood Based Assays to Evaluate Immuno-Modulatory Properties of Heat-Killed Commensal Bacteria. Vaccines, 2021, 9, 225.	2.1	2
2099	Ten-Year Follow-Up of Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection from a Randomized Controlled Trial and Review of the Literature. Microorganisms, 2021, 9, 548.	1.6	9
2100	When is it biological control? A framework of definitions, mechanisms, and classifications. Journal of Pest Science, 2021, 94, 665-676.	1.9	86
2101	The microbiome and human cancer. Science, 2021, 371, .	6.0	506
2102	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Diseases of the Colon and Rectum, 2021, 64, 650-668.	0.7	7
2103	InÂVitro Evaluation of the Effect of Storage atÂâ^'20Â°C and Proximal Gastrointestinal Conditions on Viability of Equine Fecal Microbiota Transplant. Journal of Equine Veterinary Science, 2021, 98, 103360.	0.4	3
2104	A Systematic Review of Fecal Microbiota Transplantation Versus Vancomycin for Treatment of Recurrent Clostridioides difficile Infection. Gastroenterology Nursing, 2021, 44, 106-115.	0.2	0
2105	Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy. Advanced Science, 2021, 8, 2003542.	5.6	26
2106	Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination. International Journal of Antimicrobial Agents, 2021, 57, 106277.	1.1	27

#	Article	IF	Citations
2107	What Makes a Successful Donor? Fecal Transplant from Anxious-Like Rats Does Not Prevent Spinal Cord Injury-Induced Dysbiosis. Biology, 2021, 10, 254.	1.3	5
2108	Faecalibacterium prausnitzii: A Next-Generation Probiotic in Gut Disease Improvement. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-10.	0.7	37
2109	Phage Therapy for Mycobacterium Abscessus and Strategies to Improve Outcomes. Microorganisms, 2021, 9, 596.	1.6	11
2110	Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 147-163.	0.5	0
2111	Microbiota, Inflammation, and Gut Barrier Dysfunction in HCC. , 0, , .		1
2113	Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic. International Journal of Molecular Sciences, 2021, 22, 3004.	1.8	25
2114	A Novel and Reliable Rat Model of Autism. Frontiers in Psychiatry, 2021, 12, 549810.	1.3	13
2115	Fecal microbiota transplantation for Crohnâ€™s disease: a systematic review and meta-analysis. Techniques in Coloproctology, 2021, 25, 495-504.	0.8	28
2117	Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank. Frontiers in Cellular and Infection Microbiology, 2021, 11, 622949.	1.8	21
2118	Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice, 2021, 2021, 1-13.	0.7	23
2119	Advances in Microbiome Detection Technologies and Application in Antirheumatic Drug Design. Current Pharmaceutical Design, 2021, 27, 891-899.	0.9	0
2120	Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!. Journal of Internal Medicine, 2021, 290, 294-309.	2.7	10
2121	Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 1158-1167.	0.5	40
2122	Isolation, Identification and Function of Pichia anomala AR2016 and Its Effects on the Growth and Health of Weaned Pigs. Animals, 2021, 11, 1179.	1.0	2
2123	Tandem fecal microbiota transplantation cycles in an allogeneic hematopoietic stem cell transplant recipient targeting carbapenem-resistant Enterobacteriaceae colonization: a case report and literature review. European Journal of Medical Research, 2021, 26, 37.	0.9	10
2124	Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection. PLoS ONE, 2021, 16, e0249861.	1.1	8
2125	Successful use of early, repeat fecal microbiota transplantation for initial treatment of severe, refractory Clostridioides difficile colitis. American Journal of Health-System Pharmacy, 2021, 78, 1374-1381.	0.5	1
2126	Altered Gut Microbiota Taxonomic Compositions of Patients With Sepsis in a Pediatric Intensive Care Unit. Frontiers in Pediatrics, 2021, 9, 645060.	0.9	15

#	Article	IF	Citations
2127	A Triple Threat? The Role of Diet, Nutrition, and the Microbiota in T1D Pathogenesis. Frontiers in Nutrition, 2021, 8, 600756.	1.6	11
2128	The alterations of microbiota and pathological conditions in the gut of patients with colorectal cancer undergoing chemotherapy. Anaerobe, 2021, 68, 102361.	1.0	15
2129	The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 282-291.	3.7	45
2130	Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study. Clinical Cancer Research, 2021, 27, 3784-3792.	3.2	30
2131	Current status, complications and prospects of fecal microbiota transplantation therapy. Archives of Pathology and Clinical Research, 2021, 5, 004-009.	0.3	0
2132	Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 503-513.	8.2	74
2133	Nanobiosystems for Antimicrobial Drug-Resistant Infections. Nanomaterials, 2021, 11, 1075.	1.9	13
2134	Potential Application of Combined Therapy with Lectins as a Therapeutic Strategy for the Treatment of Bacterial Infections. Antibiotics, 2021, 10, 520.	1.5	4
2135	Microbiota-mediated protection against antibiotic-resistant pathogens. Genes and Immunity, 2021, 22, 255-267.	2.2	19
2136	Biologics and Novel Therapies for Food Allergy. Immunology and Allergy Clinics of North America, 2021, 41, 271-283.	0.7	11
2137	Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101504.	2.2	16
2138	Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation. Microbial Cell Factories, 2021, 20, 98.	1.9	79
2139	ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. American Journal of Gastroenterology, 2021, 116, 1124-1147.	0.2	218
2140	Listeria monocytogenes Establishes Commensalism in Germ-Free Mice Through the Reversible Downregulation of Virulence Gene Expression. Frontiers in Immunology, 2021, 12, 666088.	2.2	6
2141	Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e997.	3.1	15
2142	Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation. Gastroenterology, 2021, 160, 2089-2102.e12.	0.6	45
2143	Acute Radiation Syndrome and the Microbiome: Impact and Review. Frontiers in Pharmacology, 2021, 12, 643283.	1.6	21
2144	Multi-modality detection of SARS-CoV-2 in faecal donor samples for transplantation and in asymptomatic emergency surgical admissions. F1000Research, 2021, 10, 373.	0.8	5

#	Article	IF	Citations
2145	The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Frontiers in Cellular and Infection Microbiology, 2021, 11, 524851.	1.8	10
2146	Establishment of an In Vitro System of the Human Intestinal Microbiota: Effect of Cultivation Conditions and Influence of Three Donor Stool Samples. Microorganisms, 2021, 9, 1049.	1.6	5
2147	Binding and neutralization of C. difficile toxins A and B by purified clinoptilolite-tuff. PLoS ONE, 2021, 16, e0252211.	1.1	6
2148	Bile Acids Activated Receptors in Inflammatory Bowel Disease. Cells, 2021, 10, 1281.	1.8	39
2149	Bile Salt Hydrolases: At the Crossroads of Microbiota and Human Health. Microorganisms, 2021, 9, 1122.	1.6	33
2150	The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review. Cancers, 2021, 13, 2353.	1.7	15
2151	Unravelling the involvement of gut microbiota in type 2 diabetes mellitus. Life Sciences, 2021, 273, 119311.	2.0	73
2152	The Role of the Microbiome in Liver Cancer. Cancers, 2021, 13, 2330.	1.7	16
2153	Gut Microbiota and Chemical-Induced Acute Liver Injury. Frontiers in Physiology, 2021, 12, 688780.	1.3	23
2154	Ecological Adaptations of Gut Microbiota Members and Their Consequences for Use as a New Generation of Probiotics. International Journal of Molecular Sciences, 2021, 22, 5471.	1.8	11
2155	Faecal microbiota transplantation in endocrine diseases and obesity. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101483.	2.2	6
2156	Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?. Signal Transduction and Targeted Therapy, 2021, 6, 178.	7.1	3
2157	The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. Frontiers in Immunology, 2021, 12, 670286.	2.2	16
2158	Inflammatory bowel disease and the gut microbiota. Proceedings of the Nutrition Society, 2021, , 1-11.	0.4	6
2159	Standardized Nursing Procedures for Fecal Microbiota Transplantation via Upper Endoscopy. Gastroenterology Nursing, 2021, 44, 227-232.	0.2	0
2161	Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Medicine, 2021, 13, 107.	3.6	74
2162	Gut Microbiota Prevents Sugar Alcohol-Induced Diarrhea. Nutrients, 2021, 13, 2029.	1.7	10
2163	Fecal Microbiota Transplantation Is Safe for Clostridiodies difficile Infection in Patients with Solid Tumors Undergoing Chemotherapy. Digestive Diseases and Sciences, 2022, 67, 2503-2509.	1.1	7

#	Article	IF	Citations
2164	Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases. GastroenterologÃa Y HepatologÃa, 2021, 45, 223-223.	0.2	3
2165	Microbiota or placebo after antimicrobial therapy for recurrent Clostridioides difficile at home: A clinical trial with novel home-based enrollment. Clinical Trials, 2021, 18, 622-629.	0.7	3
2166	Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitisâ€"Results of a Randomized Controlled Trial. Journal of Clinical Medicine, 2021, 10, 2753.	1.0	24
2167	Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?. World Journal of Gastroenterology, 2021, 27, 3317-3326.	1.4	25
2168	Skin and Gut Microbiota in Psoriasis: A Systematic Review. Biochemistry, 0, , .	0.8	1
2169	Yearly changes in the composition of gut microbiota in the elderly, and the effect of lactobacilli intake on these changes. Scientific Reports, 2021, 11, 12765.	1.6	12
2171	The maintenance of microbial community in human fecal samples by a cost effective preservation buffer. Scientific Reports, 2021, 11, 13453.	1.6	5
2172	Engraftment of Bacteria after Fecal Microbiota Transplantation Is Dependent on Both Frequency of Dosing and Duration of Preparative Antibiotic Regimen. Microorganisms, 2021, 9, 1399.	1.6	12
2173	Mycobiome and Cancer: What Is the Evidence?. Cancers, 2021, 13, 3149.	1.7	39
2174	Icariin enhances youth-like features by attenuating the declined gut microbiota in the aged mice. Pharmacological Research, 2021, 168, 105587.	3.1	25
2175	Fecal microbiota transfer for refractory intestinal graftâ€versusâ€host disease â€" Experience from two German tertiary centers. European Journal of Haematology, 2021, 107, 229-245.	1.1	20
2176	Microbiome: Insulin signaling shapes gut community composition. Current Biology, 2021, 31, R803-R806.	1.8	0
2177	Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future?. Cell Metabolism, 2021, 33, 1098-1110.	7.2	93
2178	Analysis of gut microbiota alteration and application as an auxiliary prognostic marker for sepsis in children: a pilot study. Translational Pediatrics, 2021, 10, 1647-1657.	0.5	15
2179	Focus on gut microbiota in age-associated body changes. Medical Alphabet, 2021, , 44-51.	0.0	0
2180	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. BMJ Open, 2021, 11, e048541.	0.8	7
2181	Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients. Journal of Clinical Microbiology, 2021, , JCM0016121.	1.8	7
2183	Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial. Frontiers in Immunology, 2021, 12, 678476.	2.2	35

#	Article	IF	Citations
2184	Danish national guideline for the treatment of Clostridioides difficile infection and use of faecal microbiota transplantation (FMT). Scandinavian Journal of Gastroenterology, 2021, 56, 1056-1077.	0.6	12
2185	Microbiota and epigenetics: promising therapeutic approaches?. Environmental Science and Pollution Research, 2021, 28, 49343-49361.	2.7	15
2186	The need for a holistic view on management of Clostridioides difficile infection. Clinical Microbiology and Infection, 2021, 27, 1383-1385.	2.8	2
2187	Review: The Nose as a Route for Therapy. Part 2 Immunotherapy. Frontiers in Allergy, 2021, 2, 668781.	1.2	5
2188	Ageing of the gut microbiome: Potential influences on immune senescence and inflammageing. Ageing Research Reviews, 2021, 68, 101323.	5.0	62
2189	Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases. FEBS Journal, 2022, 289, 4758-4772.	2.2	6
2190	Effects of Different Treatment of Fecal Microbiota Transplantation Techniques on Treatment of Ulcerative Colitis in Rats. Frontiers in Microbiology, 2021, 12, 683234.	1.5	8
2191	Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection. Digestive Diseases and Sciences, 2022, 67, 2763-2770.	1.1	15
2193	Exploring the Gut Microbiota and Cardiovascular Disease. Metabolites, 2021, 11, 493.	1.3	22
2194	Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. BMC Gastroenterology, 2021, 21, 281.	0.8	61
2195	Amadis: A Comprehensive Database for Association Between Microbiota and Disease. Frontiers in Physiology, 2021, 12, 697059.	1.3	12
2196	The gut microbiome: what the oncologist ought to know. British Journal of Cancer, 2021, 125, 1197-1209.	2.9	74
2197	Antimicrobial peptides and proteins: Interaction with the skin microbiota. Experimental Dermatology, 2021, 30, 1496-1508.	1.4	15
2198	Fecal Microbiota Transplantation: A Microbiome Modulation Technique for Alzheimerâ€™s Disease. Cureus, 2021, 13, e16503.	0.2	8
2199	Long-Term Follow-Up Results of Fecal Microbiota Transplantation for Irritable Bowel Syndrome: A Single-Center, Retrospective Study. Frontiers in Medicine, 2021, 8, 710452.	1.2	19
2201	Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204. Frontiers in Oncology, 2021, 11, 685320.	1.3	3
2202	Geographic differences in gut microbiota composition impact susceptibility to enteric infection. Cell Reports, 2021, 36, 109457.	2.9	33
2203	Recent advancements in the exploitation of the gut microbiome in the diagnosis and treatment of colorectal cancer. Bioscience Reports, 2021, 41, .	1.1	5

#	Article	IF	Citations
2205	How to: prophylactic interventions for prevention of Clostridioides difficile infection. Clinical Microbiology and Infection, 2021, 27, 1777-1783.	2.8	15
2206	Toward the development of defined microbial therapeutics. International Immunology, 2021, 33, 761-766.	1.8	8
2207	â€˜Gut healthâ€™ and the microbiome in the popular press: a content analysis. BMJ Open, 2021, 11, e052446.	0.8	8
2208	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Regional Health - Europe, The, 2021, 9, 100181.	3.0	43
2209	Microbiome therapeutics for hepatic encephalopathy. Journal of Hepatology, 2021, 75, 1452-1464.	1.8	37
2210	Microbiota intestinal y salud. GastroenterologÃa Y HepatologÃa, 2021, 44, 519-535.	0.2	21
2211	Solutions in microbiome engineering: prioritizing barriers to organism establishment. ISME Journal, 2022, 16, 331-338.	4.4	58
2212	Microbiome Management for the 21st Century and Beyond. MSystems, 2021, 6, e0076021.	1.7	2
2213	Causative Microbes in Host-Microbiome Interactions. Annual Review of Microbiology, 2021, 75, 223-242.	2.9	9
2214	An omics-based framework for assessing the health risk of antimicrobial resistance genes. Nature Communications, 2021, 12, 4765.	5.8	248
2216	Gut microbes and health. GastroenterologÃa Y HepatologÃa (English Edition), 2021, 44, 519-535.	0.0	8
2217	Restoration of dysbiotic human gut microbiome for homeostasis. Life Sciences, 2021, 278, 119622.	2.0	41
2218	Significance of the Gut Microbiome for Viral Diarrheal and Extra-Intestinal Diseases. Viruses, 2021, 13, 1601.	1.5	6
2219	Giardia duodenalis: Biology and Pathogenesis. Clinical Microbiology Reviews, 2021, 34, e0002419.	5.7	55
2221	Direct Modulation of the Gut Microbiota as a Therapeutic Approach for Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2022, 21, 14-25.	0.8	4
2222	The Gut Microbiome, Metformin, and Aging. Annual Review of Pharmacology and Toxicology, 2022, 62, 85-108.	4.2	28
2224	Bacteria and Sepsis: Microbiome to the Rescue?. Journal of Clinical Medicine, 2021, 10, 3578.	1.0	6
2225	Towards the Characterization and Engineering of Bacteriophages in the Gut Microbiome. MSystems, 2021, 6, e0073521.	1.7	1

#	Article	IF	Citations
2226	Maternal cecal microbiota transfer rescues early-life antibiotic-induced enhancement of type 1 diabetes in mice. Cell Host and Microbe, 2021, 29, 1249-1265.e9.	5.1	32
2227	Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe, 2021, 70, 102387.	1.0	8
2228	Dynamic Colonization of Microbes and Their Functions after Fecal Microbiota Transplantation for Inflammatory Bowel Disease. MBio, 2021, 12, e0097521.	1.8	26
2229	Microbiome and Cancer Immunotherapy. Korean Journal of Medicine, 2021, 96, 312-317.	0.1	0
2230	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2021, 11, 684659.	1.8	14
2231	Role of the gut microbiome in chronic diseases: a narrative review. European Journal of Clinical Nutrition, 2022, 76, 489-501.	1.3	168
2232	Fecal Microbiota Transplantation as a Tool for Therapeutic Modulation of Non-gastrointestinal Disorders. Frontiers in Medicine, 2021, 8, 665520.	1.2	9
2233	Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes. Nature Microbiology, 2021, 6, 1309-1318.	5.9	60
2234	Incongruence between dominant commensal donor microbes in recipient feces post fecal transplant and response to anti-PD-1 immunotherapy. BMC Microbiology, 2021, 21, 251.	1.3	7
2236	Microbiome and cancer. Cancer Cell, 2021, 39, 1317-1341.	7.7	199
2237	Fecal Microbiota Transplantation and Medical Therapy for Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2022, 56, 881-888.	1.1	8
2238	An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides difficile Colonization and Hinders Clearance. MSphere, 2021, 6, e0062921.	1.3	9
2239	Effects of obesity and weight-loss surgery shift the microbiome and impact alloimmune responses. Current Opinion in Organ Transplantation, 2021, Publish Ahead of Print, 603-608.	0.8	0
2240	The oesophageal microbiome and cancer: hope or hype?. Trends in Microbiology, 2022, 30, 322-329.	3.5	2
2241	Bacteriophage-mediated modulation of microbiota for diseases treatment. Advanced Drug Delivery Reviews, 2021, 176, 113856.	6.6	18
2242	Controlled Complexity: Optimized Systems to Study the Role of the Gut Microbiome in Host Physiology. Frontiers in Microbiology, 2021, 12, 735562.	1.5	2
2243	Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50â€“85 years. Vaccine, 2021, 39, 5991-6003.	1.7	2
2245	The Role of Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease. Journal of Clinical Medicine, 2021, 10, 4055.	1.0	16

#	Article	IF	Citations
2246	Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation. Microbiology Spectrum, 2021, 9, e0070821.	1.2	38
2247	Fecal Microbiota Transplantation to Prevent and Treat Chronic Disease: Implications for Dietetics Practice. Journal of the Academy of Nutrition and Dietetics, 2022, 122, 33-37.	0.4	2
2248	Faecal microbiota transplants: towards a healthy disgust scepticism. Medical Humanities, 2021, 47, 407-416.	0.6	2
2249	Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. Future Microbiology, 2021, 16, 1215-1227.	1.0	9
2250	The Case against Antibiotics and for Anti-Virulence Therapeutics. Microorganisms, 2021, 9, 2049.	1.6	25
2252	Nutrition and Cancer Risk from the Viewpoint of the Intestinal Microbiome. Nutrients, 2021, 13, 3326.	1.7	7
2253	Fecal Microbiota Transplantation Influences Procarcinogenic Escherichia coli in Recipient Recurrent Clostridioides difficile Patients. Gastroenterology, 2021, 161, 1218-1228.e5.	0.6	18
2254	Clostridioides (Clostridium) difficile. Medicine, 2021, 49, 643-647.	0.2	0
2255	Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2021, 123, 154844.	1.5	20
2256	The impact of the gut microbiome on toxigenic bacteria. Microbial Pathogenesis, 2021, 160, 105188.	1.3	1
2257	Fecal Microbiome Transplantation: An Offhand Recipe for Microbiome Therapeutics. , 2022, , 246-256.		1
2258	Microbiota Based Management of the Gastrointestinal Disorders. , 2022, , .		0
2260	Adverse events of fecal microbiota transplantation: a metaanalysis of high-quality studies. Annals of Gastroenterology, 2021, 34, 802-814.	0.4	8
2261	Fecal microbiota transplantation as a new treatment for canine inflammatory bowel disease. Bioscience of Microbiota, Food and Health, 2021, 40, 98-104.	0.8	20
2262	Systematic review with meta-analysis: encapsulated faecal microbiota transplantation â€“ evidence for clinical efficacy. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110410.	1.4	18
2263	OUP accepted manuscript. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S58-S63.	0.6	3
2264	The role of microbiota in allogeneic hematopoietic stem cell transplantation. Expert Opinion on Biological Therapy, 2021, 21, 1121-1131.	1.4	5
2265	Hospitalized Older Patients with Clostridioides difficile Infection Refractory to Conventional Antibiotic Therapy Benefit from Fecal Microbiota Transplant. Advances in Geriatric Medicine and Research, 2021, 3, .	0.6	0

#	Article	IF	Citations
2266	Development of the gut microbiota and dysbiosis in children. Bioscience of Microbiota, Food and Health, 2021, 40, 12-18.	0.8	10
2267	Microbiota-Gut-Brain Axis. , 2021, , 423-423.		0
2268	Microbiomes in Medicine and Agriculture. The Microbiomes of Humans, Animals, Plants, and the Environment, 2021, , 353-412.	0.2	0
2269	Gut Microbial Dysbiosis and Cardiovascular Diseases. , 2021, , .		0
2270	Enhancing Pathogen Resistance: The Gut Microbiota and Malaria. , 2022, , 143-167.		2
2271	Fecal transplantation for treatment of inflammatory bowel disease. The Cochrane Library, 2018, 2018, CD012774.	1.5	119
2272	Our Microbiome: On the Challenges, Promises, and Hype. Results and Problems in Cell Differentiation, 2020, 69, 539-557.	0.2	4
2273	Gastrointestinal Tract Commensal Bacteria and Probiotics: Influence on End-Organ Physiology. Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques, 2015, 70, 1-33.	0.6	4
2274	Microbiotas are Transmitted Between Holobiont Generations. , 2013, , 41-54.		1
2275	Fecal Microbial Transplant: For Whom, How, and When. , 2016, , 405-413.		1
2276	Infection Prevention and Control Issues After Solid Organ Transplantation. , 2016, , 843-867.		3
2277	Gut Microbiota and Heart, Vascular Injury. Advances in Experimental Medicine and Biology, 2020, 1238, 107-141.	0.8	13
2278	Prebiotics, Probiotics, and Synbiotics. , 2015, , 19-25.e1.		5
2279	Innate (General or Nonspecific) Host Defense Mechanisms. , 2015, , 26-33.e2.		4
2280	Invasions of Host-Associated Microbiome Networks. Advances in Ecological Research, 2017, , 201-281.	1.4	19
2281	Update on Treatment of Clostridioides difficile Infection. Mayo Clinic Proceedings, 2020, 95, 758-769.	1.4	31
2282	The Soil-Borne Identity and Microbiome-Assisted Agriculture: Looking Back to the Future. Molecular Plant, 2020, 13, 1394-1401.	3.9	80
2284	The Human Microbiota, Infectious Disease, and Global Health: Challenges and Opportunities. ACS Infectious Diseases, 2018, 4, 14-26.	1.8	34

#	Article	IF	Citations
2285	Hostâ€“microbiota interactions in inflammatory bowel disease. Nature Reviews Immunology, 2020, 20, 411-426.	10.6	407
2286	Effects of defined gut microbial ecosystem components on virulence determinants of Clostridioides difficile. Scientific Reports, 2019, 9, 885.	1.6	19
2287	Probiotics and fecal microbiota transplantation in surgical disorders. Seminars in Colon and Rectal Surgery, 2018, 29, 37-43.	0.2	4
2290	Pathophysiology of Inflammatory Bowel Diseases. New England Journal of Medicine, 2020, 383, 2652-2664.	13.9	522
2291	Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection. Gut Microbes, 2021, 13, 1-12.	4.3	10
2292	Clostridium difficile in paediatric populations. Paediatrics and Child Health, 2014, 19, 43-48.	0.3	6
2293	Clinical care is evolving: The microbiome for advanced practice nurses. Journal of the American Association of Nurse Practitioners, 2020, 32, 290-292.	0.5	3
2294	Predictors and Management of Failed Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Journal of Clinical Gastroenterology, 2021, 55, 542-547.	1.1	18
2295	Faecal microbiota transplantation: whatâ€™s beyond Clostridium difficile infection?. European Journal of Gastroenterology and Hepatology, 2021, 33, 487-494.	0.8	3
2296	The importance of the microbiome in pediatrics and pediatric infectious diseases. Current Opinion in Pediatrics, 2018, 30, 117-124.	1.0	45
2297	Fecal Microbiota Transplantation. Journal of Pediatric Gastroenterology and Nutrition, 2015, 61, 4-7.	0.9	7
2298	Fecal Microbiota Transplantation and Hydrocortisone Ameliorate Intestinal Barrier Dysfunction and Improve Survival in a Rat Model of Cecal Ligation and Puncture-Induced Sepsis. Shock, 2021, 55, 666-675.	1.0	23
2311	Editorial: The microbiome as a source of new enterprises and job creation. Microbial Biotechnology, 2018, 11, 145-148.	2.0	2
2312	Systematic review: the global incidence of faecal microbiota transplantationâ€related adverse events from 2000 to 2020. Alimentary Pharmacology and Therapeutics, 2021, 53, 33-42.	1.9	115
2313	Randomised clinical trial: a 12â€strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections. Alimentary Pharmacology and Therapeutics, 2021, 53, 999-1009.	1.9	25
2314	The gut microbiome in solid organ transplantation. Pediatric Transplantation, 2020, 24, e13866.	0.5	17
2316	Microbiome studies in the medical sciences and the need for closer multidisciplinary interplay. Science Signaling, 2020, 13, .	1.6	4
2317	The Gut Microbiome, Its Metabolome, and Their Relationship to Health and Disease. Nestle Nutrition Institute Workshop Series, 2016, 84, 103-110.	1.5	20

#	Article	IF	Citations
2318	Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile. JCI Insight, 2019, 4, .	2.3	32
2319	Intestinal alkaline phosphatase targets the gut barrier to prevent aging. JCI Insight, 2020, 5, .	2.3	66
2321	Does the Gut Microbiota Modulate Host Physiology through Polymicrobial Biofilms?. Microbes and Environments, 2020, 35, n/a.	0.7	13
2322	Recent Advances in the Diagnosis and Treatment of Clostridium Difficile Infection. F1000Research, 2016, 5, 118.	0.8	9
2323	The skin microbiome: potential for novel diagnostic and therapeutic approaches to cutaneous disease. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 98-103.	1.6	193
2324	Fecal Transplants: What Is Being Transferred?. PLoS Biology, 2016, 14, e1002503.	2.6	128
2325	How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient. PLoS Biology, 2017, 15, e2001110.	2.6	103
2326	How can computation advance microbiome research?. PLoS Computational Biology, 2017, 13, e1005547.	1.5	4
2327	Muricholic Acids Inhibit Clostridium difficile Spore Germination and Growth. PLoS ONE, 2013, 8, e73653.	1.1	64
2328	Development of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile. PLoS ONE, 2015, 10, e0135039.	1.1	23
2329	Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0137252.	1.1	25
2330	Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection. PLoS ONE, 2016, 11, e0149521.	1.1	55
2331	Dietary Regulation of the Gut Microbiota Engineered by a Minimal Defined Bacterial Consortium. PLoS ONE, 2016, 11, e0155620.	1.1	16
2332	Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0157259.	1.1	87
2333	Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. PLoS ONE, 2016, 11, e0157970.	1.1	19
2334	Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS ONE, 2016, 11, e0161174.	1.1	294
2335	Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations. PLoS ONE, 2017, 12, e0170922.	1.1	68
2336	Fructo-oligosaccharides and intestinal barrier function in a methionineâ€“choline-deficient mouse model of nonalcoholic steatohepatitis. PLoS ONE, 2017, 12, e0175406.	1.1	58

#	Article	IF	Citations
2337	Long-term taxonomic and functional divergence from donor bacterial strains following fecal microbiota transplantation in immunocompromised patients. PLoS ONE, 2017, 12, e0182585.	1.1	59
2338	Determinants of community membersâ€™ willingness to donate stool for faecal microbiota transplantation. PLoS ONE, 2020, 15, e0243751.	1.1	6
2339	A Gut Odyssey: The Impact of the Microbiota on Clostridium difficile Spore Formation and Germination. PLoS Pathogens, 2015, 11, e1005157.	2.1	53
2340	The Janus-Face of Bacteriophages across Human Body Habitats. PLoS Pathogens, 2016, 12, e1005634.	2.1	21
2341	Organic and Symbiotic Fertilization of Tomato Plants Monitored by Litterbag-NIRS and Foliar-NIRS Rapid Spectroscopic Methods. Journal of Agronomy Research, 2020, 3, 9-26.	0.5	10
2342	Using bugs as drugs: Microbial ecosystem therapeutics. Canada Communicable Disease Report, 2015, 41, 3-6.	0.6	3
2343	Role of Microbiome in Rheumatic Diseases. Hong Kong Bulletin on Rheumatic Diseases, 2017, 17, 58-63.	0.1	2
2344	Experiences with fecal microbiota transplantation in Clostridium difficile infections via upper gastrointestinal tract. Acta Microbiologica Et Immunologica Hungarica, 2018, 66, 179-188.	0.4	6
2346	Initial experience with fecal microbiota transplantation in Clostridium difficile Infection Â– Transplant protocol and preliminary results. Revista Espanola De Enfermedades Digestivas, 2015, 107, 402-7.	0.1	16
2347	Fecal microbiota transplantation in refractory or recurrent Clostridium difficile infection: a real-life experience in a non-academic center. Revista Espanola De Enfermedades Digestivas, 2018, 110, 311-315.	0.1	8
2348	â€œInfectious Supercarelessnessâ€•in Discussing Antibiotic-Resistant Bacteria. Pathogens and Immunity, 2016, 1, 304.	1.4	1
2349	Perceptions of fecal microbiota transplantation for Clostridium difficile infection: factors that predict acceptance. Annals of Gastroenterology, 2016, 30, 83-88.	0.4	13
2350	Recovery of the Gut Microbiota after Antibiotics Depends on Host Diet and Environmental Reservoirs. SSRN Electronic Journal, 0, , .	0.4	4
2351	Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence. Current Pharmaceutical Design, 2020, 26, 2620-2629.	0.9	8
2352	Implication of Gut Microbiota in Human Health. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1325-1333.	0.8	18
2353	Fecal Microbiota Transplantation: Past, Present and Future. Sklifosovsky Journal Emergency Medical Care, 2019, 8, 160-165.	0.3	1
2354	æ•æ²³çŒ´å'ŒéŁŸèŸ¹çŒ´ç›´è‚¾ä¾®ç”Ÿç‰©èŒç¾¤çš„å®åŸºå›„æ¯”è¾ƒ. Zoological Research, 2019, 40, 89-93.	0.9	14
2355	Interaction between gut microbiota and host immune cells. Inflammation and Regeneration, 2015, 35, 140-147.	1.5	1

#	Article	IF	Citations
2356	Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease. Clinical Hematology International, 2019, 1, 28.	0.7	20
2357	Fecal microbiota transplantation: a modern, effective, safe method for the treatment of Clostridium difficile infection. Modern Gastroenterology, 2019, .	0.1	1
2358	Harnessing the microbiota to treat neurological diseases. Dialogues in Clinical Neuroscience, 2019, 21, 159-165.	1.8	4
2359	Antibiotics, cancer risk and oncologic treatment efficacy: a practical review of the literature. Ecancermedicalscience, 2020, 17, 1106.	0.6	8
2360	Bacterial, Gut Microbiome-Modifying Therapies to Defend against Multidrug Resistant Organisms. Microorganisms, 2020, 8, 166.	1.6	16
2362	Altered Gut Microbiome in Autism Spectrum Disorder: Potential Mechanism and Implications for Clinical Intervention. Global Clinical and Translational Research, 2019, , 45-52.	0.4	6
2363	Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spaish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). Revista Espanola De Quimioterapia, 2020, 33, 151-175.	0.5	13
2364	Stool therapy may become a preferred treatment of recurrentClostridium difficile?. World Journal of Gastroenterology, 2013, 19, 4635.	1.4	7
2365	Fecal transplant policy and legislation. World Journal of Gastroenterology, 2015, 21, 6.	1.4	29
2366	Gastroenterologist perceptions of faecal microbiota transplantation. World Journal of Gastroenterology, 2015, 21, 10907.	1.4	33
2367	Chinese physiciansâ€™ perceptions of fecal microbiota transplantation. World Journal of Gastroenterology, 2016, 22, 4757.	1.4	18
2368	Management of inflammatory bowel disease withClostridium difficileinfection. World Journal of Gastroenterology, 2017, 23, 4986.	1.4	62
2369	Therapies to modulate gut microbiota: Past, present and future. World Journal of Gastroenterology, 2020, 26, 777-788.	1.4	52
2370	Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors (Review). Oncology Letters, 2020, 20, 1-1.	0.8	11
2371	Diet, microbiota, and inflammatory bowel disease: lessons from Japanese foods. Korean Journal of Internal Medicine, 2014, 29, 409.	0.7	36
2372	On the mechanism of antibiotic resistance and fecal microbiota transplantation. Mathematical Biosciences and Engineering, 2019, 16, 7057-7084.	1.0	2
2373	Recurrent Clostridioides difficile infection: Recognition, management, prevention. Cleveland Clinic Journal of Medicine, 2020, 87, 347-359.	0.6	11
2374	Current update and future directions on gut microbiome and nephrolithiasis. Indian Journal of Urology, 2020, 36, 262.	0.2	4

#	Article	IF	Citations
2375	Early results of fecal microbial transplantation protocol implementation at a community-based university hospital. Journal of Global Infectious Diseases, 2018, 10, 47.	0.2	14
2376	New and promising anti-bacterials: Can this promise be sustained?. Journal of Anaesthesiology Clinical Pharmacology, 2020, 36, 13.	0.2	1
2377	The Antimicrobial Therapy of the Future: Combating Resistances. Journal of Infectious Disease and Therapy, 2014, 02, .	0.1	2
2378	Causes of Big Bushfires in Australia: Higher Temperatures and Rainfall or More Fuel?. Journal of Geoscience and Environment Protection, 2020, 08, 79-94.	0.2	5
2379	Identification of a Native Novel Oncolytic Immunoglobulin on Exfoliated Colon Epithelial Cells: A Bispecific Heterodimeric Chimera of IgA/IgG*. Open Journal of Preventive Medicine, 2020, 10, 126-150.	0.2	4
2380	Human microbiome: From the bathroom to the bedside. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 79.	0.5	8
2381	Gastrointestinal dysbiosis and the use of fecal microbial transplantation inClostridium difficileinfection. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 169.	0.5	12
2382	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 387.	0.6	6
2383	Gastro-intestinal tract: The leading role of mucosal immunity. Swiss Medical Weekly, 2016, 146, w14293.	0.8	12
2384	RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention. Gut and Liver, 2019, 13, 16-24.	1.4	106
2385	Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut and Liver, 2019, 13, 604-616.	1.4	90
2386	RefractoryClostridium difficileInfection Cured With Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient. Intestinal Research, 2015, 13, 80.	1.0	24
2387	Refractory pseudomembranous colitis that was treated successfully with colonoscopic fecal microbial transplantation. Intestinal Research, 2016, 14, 83.	1.0	9
2388	Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings. Intestinal Research, 2019, 17, 434-437.	1.0	4
2389	Metabolite exchange between microbiome members produces compounds that influence Drosophila behavior. ELife, 2017, 6, .	2.8	152
2390	Computer-guided design of optimal microbial consortia for immune system modulation. ELife, 2018, 7, .	2.8	65
2391	Cancer systems immunology. ELife, 2020, 9, .	2.8	14
2392	Fecal microbiota transplantation research output from 2004 to 2017: a bibliometric analysis. PeerJ, 2019, 7, e6411.	0.9	10

#	Article	IF	Citations
2393	Factors affecting the composition of the gut microbiota, and its modulation. PeerJ, 2019, 7, e7502.	0.9	360
2394	A clinical primer of the role of gut microbiome in health and disease. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2015, 36, 1-13.	0.0	9
2395	Faecal transplantation and Clostridioides difficile infection. Scripta Medica, 2021, 52, 215-223.	0.0	0
2396	Research Progress on the Relationship between Intestinal Flora, Immune System and Glioma. Advances in Clinical Medicine, 2021, 11, 4357-4364.	0.0	0
2397	High prevalence of extendedâ€spectrum betaâ€lactamase organisms and the COVIDâ€19 pandemic impact on donor recruitment for fecal microbiota transplantation in HongÂKong. United European Gastroenterology Journal, 2021, 9, 1027-1038.	1.6	11
2398	Fecal microbiota transplantation mitigates bone loss by improving gut microbiome composition and gut barrier function in aged rats. PeerJ, 2021, 9, e12293.	0.9	21
2399	The gut microbiota and gut disease. Internal Medicine Journal, 2021, 51, 1594-1604.	0.5	6
2400	European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical Microbiology and Infection, 2021, 27, S1-S21.	2.8	242
2401	Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management?. Folia Microbiologica, 2021, 66, 897-916.	1.1	5
2404	A short chain fatty acidâ€“centric view of Clostridioides difficile pathogenesis. PLoS Pathogens, 2021, 17, e1009959.	2.1	23
2405	Transferable Immunoglobulin Aâ€“Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation. Gastroenterology, 2022, 162, 166-178.	0.6	60
2406	Stool preparation under anaerobic conditions contributes to retention of obligate anaerobes: potential improvement for fecal microbiota transplantation. BMC Microbiology, 2021, 21, 275.	1.3	13
2407	Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. Frontiers in Oncology, 2021, 11, 722436.	1.3	6
2408	Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome. Advanced Drug Delivery Reviews, 2021, 179, 114021.	6.6	44
2409	Microbiotaâ€“Gutâ€“Brain Axis and Epilepsy: A Review on Mechanisms and Potential Therapeutics. Frontiers in Immunology, 2021, 12, 742449.	2.2	52
2410	Gut Microbiota for Esophageal Cancer: Role in Carcinogenesis and Clinical Implications. Frontiers in Oncology, 2021, 11, 717242.	1.3	14
2411	Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clinical Microbiology and Infection, 2022, 28, 321-331.	2.8	22
2412	The potential of microbiome replacement therapies for Clostridium difficile infection. Current Opinion in Gastroenterology, 2022, 38, 1-6.	1.0	10

#	Article	IF	Citations
2413	The intestinal 3M (microbiota, metabolism, metabolome) zeitgeist â€“ from fundamentals to future challenges. Free Radical Biology and Medicine, 2021, 176, 265-285.	1.3	27
2414	New Treatment Option for RecurrentClostridium difficileInfection. Intestinal Research, 2013, 11, 149.	1.0	0
2415	Managing Microbe-associated Health Problems in Primary Care. General Medicine, 2013, 14, 4-6.	0.1	0
2416	Prebiotics, Probiotics, Synbiotics, and Phage Therapy. , 2013, , 151-167.		0
2417	Clostridium Difficile Infection - A Review of Current Treatment Strategies. , 2013, 03, .		0
2418	Role of altered gut microbiota in the development of obesity, insulin resistance and type 2 diabetes mellitus. Orthodontic Journal of Nepal, 2013, 2, 1-2.	0.0	0
2419	A five patientâ€™s case study on the influence of two different probiotics on individual intestinal microbiota. Functional Foods in Health and Disease, 2013, 3, 122.	0.3	0
2422	ControllingÂClostridium difficile. Australian Prescriber, 2013, 36, 121-124.	0.5	0
2423	Successful Fecal Transplantation by Enema for Recurrent and Refractory Clostridium difficile Infection. Journal of the Korean Geriatrics Society, 2013, 17, 152-156.	0.3	3
2424	Fecestransplantasjon â€“ ny vidundermedisin?. Tidsskrift for Den Norske Laegeforening, 2014, 134, 2233-2233.	0.2	0
2425	Innate Immunity of Epidermis (1). Nishinihon Journal of Dermatology, 2014, 76, 366-371.	0.0	0
2426	Le Clostridium difficile dans les populations dâ€™Ã¢ge pÃ©diatrique. Paediatrics and Child Health, 2014, 19, 49-54.	0.3	0
2427	Akute infektiÃ¶se Diarrhoe. , 2014, , 1-13.		0
2428	Gastrointestinal Complications. Respiratory Medicine, 2014, , 105-134.	0.1	0
2429	Human Intestinal Microbiome. , 2014, , 1-7.		0
2430	Perioperative Care of the Orthopedic Patient with Gastrointestinal and Liver Issues. , 2014, , 177-184.		0
2431	Upper Versus Lower Gastrointestinal Route of Fecal Microbiota Transplantation in the Treatment of Clostridium Difficile Infection. , 2014, 04, .		0
2434	Severe Clostridium difficile infection. , 2014, , 217-226.		0

#	Article	IF	Citations
2436	Clostridium-difficile-Infektion (CDI): PrÃvention, Diagnostik, Therapie. Intrinsic Activity, 2014, 2, e3.	0.0	0
2437	Commensal Bugs from the Gut-Shaping Human Health and Disease. Journal of Investigative Genomics, 2014, 1, .	0.2	0
2438	Hostâ€“microbe interactions in the gut: lessons learned from models of inflammatory bowel diseases. LymphoSign Journal, 2014, 1, 61-76.	0.1	0
2439	Nosokomiale Infektionen â€“ Epidemiologie, Diagnostik, Therapie und PrÃvention. , 2015, , 949-970.		0
2440	Bacteriotherapy reintroduces â€œold friendsâ€•in IBD. Inflammation and Regeneration, 2015, 35, 122-128.	1.5	0
2441	Clostridium difficile infection: an Australian clinical perspective. Microbiology Australia, 2015, 36, 106.	0.1	0
2442	Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives. Juntendo Medical Journal, 2015, 61, 588-596.	0.1	1
2443	Persontilpasset tarmfloramedisin?. Tidsskrift for Den Norske Laegeforening, 2015, 135, 624-624.	0.2	1
2444	Cost-effectiveness inClostridium difficiletreatment decision-making. World Journal of Clinical Cases, 2015, 3, 935.	0.3	1
2445	Fecal microbiota transplantation: why, who, how?. Pamukkale Medical Journal, 2015, 8, 148-154.	0.2	0
2446	Advances in Gastrointestinal Surgery. GI Surgery Annual, 2015, , 179-237.	0.0	0
2447	Fecal microbiota transplantation - something more than merely a therapeutic curiosity. Revista Espanola De Enfermedades Digestivas, 2015, 107, 399-401.	0.1	2
2448	Clostridium difficile Infection. , 2015, , 2744-2756.e3.		2
2449	Nosokomiale Infektionen auf der Intensivstation. , 2015, , 1-38.		0
2450	ANTIBIOTIC-ASSOCIATED DIARRHEA AND CL. DIFFICILE-INFECTION IN CHILDREN: RISK FACTORS. Detskie Infekcii (Moskva), 2015, 14, 29-34.	0.1	2
2452	Bacterial Inflammatory Enteritides. , 2015, , 1263-1269.e3.		1
2453	ProbiÃ³ticos: una alternativa para la industria de alimentos. IngenierÃa Industrial, 2015, .	0.1	0
2454	Healthcare Analytics Use in Population Health. , 2015, , 108-115.		0

#	Article	IF	Citations
2455	Social Media Use in Health. , 2015, , 94-99.		3
2456	Duodenal Application Is the Method of Choice. Deutsches Ärzteblatt International, 2015, 112, 345-6.	0.6	2
2458	Feces transplantation for recurrentClostridium difficileinfection: US experience and recommendations. Microbial Ecology in Health and Disease, 2015, 26, 27657.	3.8	5
2459	Anaerobically cultivated human intestinal microbiota as first-line treatment forClostridium difficileinfection. Microbial Ecology in Health and Disease, 2015, 26, 27710.	3.8	1
2460	Fecal microbiota transplantation is an effective rescue therapy for refractory inflammatory bowel disease. Inflammation and Cell Signaling, 0, , .	1.6	1
2462	Clostridia Bacteria in the GI Tract Affecting Dopamine and Norepinephrine Metabolism. , 2015, , 31-48.		0
2464	Fecal Microbiota Transplantation in Recurrent Clostridium Difficile Infections: Our Experience in Patients with and without Inflammatory Bowel Disease. Gastroenterology & Hepatology (Bartlesville,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0	0
2465	Clinical Utility and Alterations in Bacterial Flora in Fecal Microbiome Transplantation. International Journal of Medical Students, 2015, 3, 140-150.	0.2	0
2466	*Clostridium difficile*. , 2016, , 422-427.		0
2467	Voeding bij dunnedarmaandoeningen. , 2016, , 107-141.		0
2468	Non-antibiotic management for Clostridium difficile infection. Journal of Gastrointestinal Infections, 2016, 6, 3-11.	0.1	0
2469	Infecties van het maag-darmkanaal. , 2016, , 107-121.		0
2470	Supplements/Diet/Other Integrative Method Vernacular and Controversies from A to Z: What is the Latest or Greatest, or Not So Great?!. , 2016, , 343-383.		0
2471	Physiologische Bakterienflora: Regulation und Wirkungen, iatrogene StÃ¶rungen und Probiotika. Springer-Lehrbuch, 2016, , 27-33.	0.1	0
2472	JAID/JSC æ„ŸæŸ“ç—‡æ²»ç™‚ã‚¬ã‚¤ãƒ‰ã‚¯ã‚¤ãƒ³2015 â€•è…¸ç®¡æ„ŸæŸ“ç—‡â€•. Journal of the Japanese Association for Infectious Disea	0.6	0
2473	2016, 105, 111a-111a.	0.0	0
2474	ClostridiumdifficileInfection. , 0, , 265-294.		1
2476	The Intestinal Microbiome, the Immune System and Spondyloarthropathy. , 2017, , 145-165.		0

#	Article	IF	Citations
2477	Transplantation of fecal microbiota or probiotics?. Russian Journal of Evidence-Based Gastroenterology, 2017, 6, 19.	0.3	0
2478	Diagnosis and Management of Clostridium Difficile Infection (CDI). , 2017, , 569-573.		0
2481	Gastrointestinal Infections: Travelers' Diarrhea and Clostridioides Difficile Infection. , 2017, , .		0
2482	Bacterioterapia preventiva de la obesidad en la comunidad de los indios Pima: evidencias cientÃficas. Duazary, 2017, 14, 188.	0.0	1
2483	Clostridium difficile Infection: Considerations in the Geriatric Population. , 2018, , 291-297.		0
2484	Decolonization in Infection Control of Gram-Negative Bacilli. , 2018, , 235-242.		0
2486	Supportive (Maintenance) Therapy in Hematopoietic Stem Cell Transplantation: Main Principles and New Perspectives. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2017, 10, 501-513.	0.1	0
2487	Immunotherapy Approaches to Breast Cancer. Current Breast Cancer Reports, 2017, 9, 227-235.	0.5	0
2488	The Microbiota and Energy Balance. Endocrinology, 2018, , 1-18.	0.1	0
2489	-Infektion. , 2018, , 187-199.		0
2490	Modern approach to the therapy of infections caused by Clostridium difficile. Racionalna Terapija, 2018, 10, 25-31.	0.1	0
2492	Successful faecal microbiota transplant for recurrentClostridium difficileinfection delivered by colonoscopy through a diverted ileostomy in a patient with severe perianal Crohnâ€™s disease. BMJ Case Reports, 2018, 2018, bcr-2017-222958.	0.2	2
2493	Possibilities of therapeutic manipulation of the gut microbiota. Vnitrni Lekarstvi, 2018, 64, 665-671.	0.1	4
2495	Fecal transplant is superior to oral vancomycin for treatment of recurrent Clostridium difficile. Clinical Research in Practice the Journal of Team Hippocrates, 2018, 4, .	0.0	0
2496	Research progress on human microecology and infectious diseases. Infection International, 2018, 7, 94-100.	0.1	0
2499	Current Status and Future Perspective of Fecal Microbiota Transplantation. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 2176-2182.	0.0	0
2500	V. Clostridioides Difficile Infection. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 2261-2268.	0.0	1
2501	Other Proctitides. , 2019, , 555-570.		0

#	Article	IF	Citations
2502	Altered Gut Microbiome in Autism Spectrum Disorder: Potential Mechanism and Implications for Clinical Intervention. , 2019, , .		2
2503	Characteristics of Faecal Microbiota in Korean Patients withClostridioides difficile-associated Diarrhea. Infection and Chemotherapy, 2019, 51, 365.	1.0	5
2504	â€œWe Are What We Eatâ€: How Diet Impacts the Gut Microbiota in Adulthood. , 2019, , 259-283.		1
2505	Microbes in the Pathogenesis of Inflammatory Bowel Disease: A Review. , 2019, , 399-410.		0
2506	Microbiota, immunity and immunologically-mediated diseases. Vnitrni Lekarstvi, 2019, 65, 98-107.	0.1	4
2507	2019, 108, 401-407.	0.0	0
2509	Prospects of Using Microbiota Correction Methods in the Treatment of Inflammatory Bowel Disease. Russian Journal of Gastroenterology Hepatology Coloproctology, 2019, 29, 12-22.	0.2	3
2510	12. Microbiota and Digestive Diseases. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1939-1945.	0.0	0
2511	Organ-Preserving Strategies in theÂManagement of Fulminant Clostridium difficile Colitis. , 2020, , 563-576.		0
2514	Effectiveness of fecal microbiota transplantation inÂdiseases, notÂassociated withÂecurrent infection ofÂClostridium difficile. Modern Gastroenterology, 2019, .	0.1	0
2515	Physiologische Mikrobiota: Regulation und Wirkungen, iatrogene StÃ¶rungen und Probiotika. , 2020, , 33-43.		0
2518	Place de la transplantation de microbiote fÃ©cal dans lâ€™infection Ã Clostridium difficile. Colon and Rectum, 2020, 14, 88-93.	0.0	0
2519	Clostridium difficile infection in patients after solid organ transplantations. Postepy Higieny I Medycyny Doswiadczalnej, 2020, 74, 198-204.	0.1	0
2520	Donor Screening for Fecal Microbiota Transplantation. Korean Journal of Medicine, 2020, 95, 181-187.	0.1	0
2521	Influence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy. Pharmacological Research, 2021, 174, 105966.	3.1	22
2522	Fecal Microbiota Transplantation Commonly Failed in Children With Coâ€Morbidities. Journal of Pediatric Gastroenterology and Nutrition, 2022, 74, 227-235.	0.9	4
2523	Ecological Approaches to Periodontal Therapy. , 2020, , 195-205.		0
2524	Topological Data Analysis of Clostridioides difficile Infection and Fecal Microbiota Transplantation. Emerging Topics in Statistics and Biostatistics, 2020, , 427-446.	0.1	0

#	Article	IF	Citations
2525	FEKAL MÄ°KROBÄ°YOTA TRANSPLANTASYONU VE HEMÅžÄ°RELÄ°K. Journal of Anatolia Nursing and Health Sciences, 0, , 534-539.	0.3	0
2526	EMNÄ°YET YÃ–NETÄ°M SÄ°STEMÄ°NÄ°N (SMS) Ä°YÄ°LEÅžTÄ°RÄ°LMESÄ° Ä°LE SÄ°VÄ°L HAVACILIK KAZA ORANLARI ARASINDAKÄ° Ä°L Gaziosmanpasa Universitesi Sosyal Bilimler Arastirmalari Dergisi, 2020, 15, 599-610.	0.3	1
2527	The hardware method of biomaterial preparation for fecal transplantation. AlÊ¹manah KliniÄeskoj Mediciny, 2020, 48, 403-411.	0.2	0
2528	STRUCTURING A FECAL MICROBIOTA TRANSPLANTATION CENTER IN A UNIVERSITY HOSPITAL IN BRAZIL. Arquivos De Gastroenterologia, 2020, 57, 434-458.	0.3	3
2531	Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital. Gastroenterology Research, 2020, 13, 138-145.	0.4	0
2532	Faecal microbiota transplantation: a review. Microbiology Australia, 2020, 41, 65.	0.1	0
2533	Dietâ€"microbiome interaction in colorectal cancer: a potentially discriminatory role for Fusobacterium nucleatum. , 2020, , 211-241.		0
2534	Surveillance and Control of Asymptomatic Carriers of Drug-Resistant Bacteria. Public Health Ethics Analysis, 2020, , 183-201.	0.1	0
2535	Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians. Journal of Gastrointestinal Infections, 2020, 10, 16-25.	0.1	0
2536	Diagnosis and Management of Clostridium difficile Infection (CDI). , 2020, , 539-543.		0
2537	Perioperative Care of the Orthopedic Patient with Gastrointestinal and Liver Issues. , 2020, , 223-231.		0
2538	è…‚å†…ç´°èŒåˆ¤ã‚³ãƒ³ãƒˆãƒãƒ¼ãƒ«ã•è……ç®¡ãƒªãƒãƒ“リテーã‚·ãƒ§ãƒ³. The Japanese Journal of SURGICAL METABOLISM and NUTRI	0.1	0
2539	Clostridium difficile. , 2020, , 1115-1120.		0
2540	Ethical, Patent, and Regulatory Issues in Microbial Engineering. , 2020, , 133-142.		2
2541	Pathogenese chronisch-entzÃ¼ndlicher Darmerkrankungen. , 2020, , 51-69.		0
2542	Utilization of Faecal Microbiota in Humans and Animals. Journal of Agriculture & Life Science, 2020, 54, 1-18.	0.1	0
2543	Faecal microbiota transplantation: Application in treatment of some digestive diseases and safety concerns. World Chinese Journal of Digestology, 2020, 28, 135-143.	0.0	0
2544	Effects of fecal microbiota transplant on DNA methylation in subjects with metabolic syndrome. Gut Microbes, 2021, 13, 1993513.	4.3	25

#	Article	IF	Citations
2545	Atopobiosis and Dysbiosis in Ocular Diseases: Is Fecal Microbiota Transplant and Probiotics a Promising Solution?. Journal of Ophthalmic and Vision Research, 2021, 16, 631-643.	0.7	3
2546	Therapeutic Potential of Butyrate for Treatment of Type 2 Diabetes. Frontiers in Endocrinology, 2021, 12, 761834.	1.5	40
2547	Management of uncomplicated recurrent urinary tract infections. BJU International, 2022, 129, 668-678.	1.3	15
2548	Sex Differences in Cardiovascular Impact of Early Metabolic Impairment: Interplay between Dysbiosis and Adipose Inflammation. Molecular Pharmacology, 2022, 102, 60-79.	1.0	2
2549	An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 246-255.	1.4	22
2550	What is unknown in using microbiota as a therapeutic?. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 39-44.	1.4	11
2551	Role of the Gut Microbiota in Parenteral Nutritionâ€“Associated Liver Disease: From Current Knowledge to Future Opportunities. Journal of Nutrition, 2022, 152, 377-385.	1.3	7
2552	How I manage infection risk and prevention in patients with lymphoid cancer. Blood, 2022, 139, 1517-1528.	0.6	3
2553	DiagnÃ³stico y tratamiento de la infecciÃ³n por Clostridioides difficile. Medicina ClÃnica, 2020, 155, 30-35.	0.3	3
2554	Prebiotics, Probiotics, Synbiotics, and Phage Therapy. , 2013, , 151-167.		0
2555	Microbiotas are Transmitted Between Holobiont Generations. , 2013, , 41-54.		1
2558	Fecal transplantation: clinical realities and prospects in the treatment of metabolic syndrome. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, 183, 102-112.	0.1	0
2559	South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. Southern African Journal of Infectious Diseases, 2020, 35, 219.	0.3	3
2560	Gut Microbiota and Cancer Correlates. , 2021, , 1-27.		0
2563	Critical care medicine 2013: a review and prospect. Journal of Thoracic Disease, 2013, 5, 815-23.	0.6	0
2564	Clostridium difficile in paediatric populations. Paediatrics and Child Health, 2014, 19, 43-54.	0.3	2
2566	Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. Gastroenterology and Hepatology, 2014, 10, 230-7.	0.2	20
2567	Fecal Microbiota Transplantation for Clostridium difficile Infection: The Ochsner Experience. Ochsner Journal, 2014, 14, 538-44.	0.5	19

#	Article	IF	Citations
2570	Fecal Microbiota Transplantation: A Review of Emerging Indications Beyond Relapsing Clostridium difficile Toxin Colitis. Gastroenterology and Hepatology, 2015, 11, 24-32.	0.2	16
2571	Clostridium difficile Infection and Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2016, 12, 334-7.	0.2	3
2572	Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2016, 16, 1-69.	3.0	4
2573	The Hoops, Hopes, and Hypes of Human Microbiome Research. Yale Journal of Biology and Medicine, 2016, 89, 363-373.	0.2	29
2574	Treating Obesity and Metabolic Syndrome with Fecal Microbiota Transplantation. Yale Journal of Biology and Medicine, 2016, 89, 383-388.	0.2	82
2575	Management of Infection. Gastroenterology and Hepatology, 2016, 12, 609-616.	0.2	8
2576	THE POWER OF POOP: FECAL MICROBIOTA TRANSPLANTATION FOR INFECTION. Transactions of the American Clinical and Climatological Association, 2016, 127, 71-80.	0.9	2
2577	The Daniel K. Inouye College of Pharmacy Scripts: Updates on Infection: Advances in Laboratory Testing to Aid Diagnosis and Treatment. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2017, 76, 59-64.	0.4	1
2578	Conventional and alternative treatment approaches for infection. International Journal of Health Sciences, 2017, 11, 1-10.	0.4	1
2579	Fecal Microbiota Transplantation: From to Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2017, 13, 209-213.	0.2	22
2580	Fecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and results. Revista Espanola De Quimioterapia, 2018, 31, 411-418.	0.5	9
2581	Organ transplantation and gut microbiota: current reviews and future challenges. American Journal of Translational Research (discontinued), 2018, 10, 3330-3344.	0.0	12
2582	A comprehensive approach for the patient with Clostridium difficile infection. Revista Espanola De Quimioterapia, 2018, 31 Suppl 1, 27-31.	0.5	0
2583	Calculated initial parenteral treatment of bacterial infections: Bacterial gastrointestinal infections. GMS Infectious Diseases, 2020, 8, Doc06.	0.5	0
2584	The developmental process of intestinal microbiota in infants and the possible novel effects of <i>Bifidobacterium</i> as a probiotic to maintain the homeostasis of infantile intestinal functions. The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2021, 55, 209-217.	0.1	0
2585	Predicting Inchinkoto efficacy, in patients with obstructive jaundice associated with malignant tumors, through pharmacomicrobiomics. Pharmacological Research, 2022, 175, 105981.	3.1	3
2586	Transplante de microbiota fecal e seu uso no tratamento de Retocolite Ulcerativa: Uma revisÃ£o de literatura / Fecal microbiota transplantation and it use on Ulcerative Colitis: A literature review. Brazilian Journal of Development, 2021, 7, 95885-95902.	0.0	0
2587	Frontiers in antibiotic alternatives for Clostridioides difficile infection. World Journal of Gastroenterology, 2021, 27, 7210-7232.	1.4	5

#	Article	IF	Citations
2588	Age-Dependent Intestinal Repair: Implications for Foals with Severe Colic. Animals, 2021, 11, 3337.	1.0	2
2589	Implications of Gut Microbiota in Complex Human Diseases. International Journal of Molecular Sciences, 2021, 22, 12661.	1.8	20
2590	Gutâ€“Lung Axis: Microbial Crosstalk in Pediatric Respiratory Tract Infections. Frontiers in Immunology, 2021, 12, 741233.	2.2	13
2591	Human immune diversity: from evolution to modernity. Nature Immunology, 2021, 22, 1479-1489.	7.0	64
2592	Next steps after 15 stimulating years of human gut microbiome research. Microbial Biotechnology, 2022, 15, 164-175.	2.0	11
2593	Current and future applications of fecal microbiota transplantation for children. Biomedical Journal, 2022, 45, 11-18.	1.4	11
2594	Fecal Microbiota Transplantation in Children. , 2022, , 709-712.		0
2595	Microbiome therapeutics: exploring the present scenario and challenges. Gastroenterology Report, 2022, 10, goab046.	0.6	35
2596	Patients and physiciansâ€™ attitudes change on fecal microbiota transplantation for inflammatory bowel disease over the past 3 years. Annals of Translational Medicine, 2021, 9, 1619-1619.	0.7	1
2597	Using the microbiome in clinical practice. Microbial Biotechnology, 2022, 15, 129-134.	2.0	11
2598	Gossip in the gut: Quorum sensing, a new player in the host-microbiota interactions. World Journal of Gastroenterology, 2021, 27, 7247-7270.	1.4	18
2599	Precision medicine journey through omics approach. Journal of Diabetes and Metabolic Disorders, 2022, 21, 881-888.	0.8	11
2600	Clostridium difficile Infection. , 2022, , 879-891.		0
2602	Where have the enteric viruses gone? - Differential effects on frequent causes of infectious diarrhoea by SARS-CoV-2 pandemic lockdown measures. Infection Prevention in Practice, 2021, 3, 100184.	0.6	9
2603	Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opinion on Therapeutic Targets, 2021, , 1-15.	1.5	5
2604	Average gut flora in healthy Japanese subjects stratified by age and body mass index. Bioscience of Microbiota, Food and Health, 2022, 41, 45-53.	0.8	13
2605	Functional roles of the microbiota-gut-brain axis in Alzheimerâ€™s disease: Implications of gut microbiota-targeted therapy. Translational Neuroscience, 2021, 12, 581-600.	0.7	21
2607	The role of the microbiota in the management of intensive care patients. Annals of Intensive Care, 2022, 12, 3.	2.2	29

#	Article	IF	Citations
2608	Role of Biological Sex in the Cardiovascular-Gut Microbiome Axis. Frontiers in Cardiovascular Medicine, 2021, 8, 759735.	1.1	14
2609	Microbiome-based therapeutics. Nature Reviews Microbiology, 2022, 20, 365-380.	13.6	165
2610	Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation. Medicina (Lithuania), 2022, 58, 84.	0.8	21
2611	Strategies for the treatment of colorectal cancer caused by gut microbiota. Life Sciences, 2022, 290, 120202.	2.0	6
2612	Pain killers: the interplay between nonsteroidal anti-inflammatory drugs and Clostridioides difficile infection. Current Opinion in Microbiology, 2022, 65, 167-174.	2.3	3
2614	A Case of Ileostomy Closure after Improving Disuse Atrophy of the Intestinal Tract Using Autologous Stools and Prebiotics. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2021, 82, 1363-1368.	0.0	0
2615	Fecal microbiota transplantation for recurrentClostridioides difficile, safety, and pitfalls. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110531.	1.4	15
2616	Long-Term Safety Following Faecal Microbiota Transplantation as a Treatment for Recurrent Clostridioides difficile Infection Compared with Patients Treated with a Fixed Bacterial Mixture: Results from a Retrospective Cohort Study. Cells, 2022, 11, 435.	1.8	8
2617	Health Effects of Drinking Water Produced from Deep Sea Water: A Randomized Double-Blind Controlled Trial. Nutrients, 2022, 14, 581.	1.7	3
2618	The Metabolic Role and Therapeutic Potential of the Microbiome. Endocrine Reviews, 2022, 43, 907-926.	8.9	26
2619	Determine independent gut microbiota-diseases association by eliminating the effects of human lifestyle factors. BMC Microbiology, 2022, 22, 4.	1.3	10
2621	The emerging potential of microbiome transplantation on human health interventions. Computational and Structural Biotechnology Journal, 2022, 20, 615-627.	1.9	14
2622	Evolution of FMT â€“ From early clinical to standardized treatments. Biologicals, 2022, , .	0.5	3
2623	Family Stool Donation Predicts Failure of Fecal Microbiota Transplant for Clostridioides difficile Infection. , 2022, 1, 141-146.		0
2624	Potential Role of the Gut Microbiome In Colorectal Cancer Progression. Frontiers in Immunology, 2021, 12, 807648.	2.2	56
2625	Patient knowledge of gut microbiota and acceptability of fecal microbiota transplantation in various diseases. Neurogastroenterology and Motility, 2022, , e14320.	1.6	2
2626	New Insights in the Pathophysiology of Hospital- and Ventilator-Acquired Pneumonia: A Complex Interplay between Dysbiosis and Critical-Illnessâ€“Related Immunosuppression. Seminars in Respiratory and Critical Care Medicine, 2022, 43, .	0.8	0
2628	Binary Toxin Expression by Clostridioides difficile Is Associated With Worse Disease. Open Forum Infectious Diseases, 2022, 9, ofac001.	0.4	16

#	Article	IF	Citations
2629	Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea. Journal of Neurogastroenterology and Motility, 2022, 28, 28-42.	0.8	11
2630	Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort. Digestive Diseases and Sciences, 2022, 67, 4866-4873.	1.1	10
2631	Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome Patients. Gastroenterology Nursing, 2022, 45, 11-20.	0.2	7
2632	Gut microbiome and health: mechanistic insights. Gut, 2022, 71, 1020-1032.	6.1	661
2634	Evaluating live microbiota biobanking using an ex vivo microbiome assay and metaproteomics. Gut Microbes, 2022, 14, 2035658.	4.3	7
2635	Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules, 2022, 12, 56.	1.8	98
2636	Proceed with caution. The human gut microbiota, an attractive target for therapeutic interventions. Nature Reviews Microbiology, 2014, 12, 149.	13.6	0
2637	Regulation of Host Immunity by the Gut Microbiota. , 2022, , 105-140.		1
2638	Simultaneous Daily Fecal Microbiota Transplantation Fails to Prevent Metronidazole-Induced Dysbiosis of Equine Gut Microbiota. SSRN Electronic Journal, 0, , .	0.4	0
2639	Impact of Probiotic and Prebiotic on Gut Microbiota in Pre-diabetes and Type 2 Diabetes. , 2022, , 77-100.		0
2640	Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target. Frontiers in Nutrition, 2022, 9, 814269.	1.6	14
2641	Gut Microbiota Modulation for Therapeutic Management of Various Diseases: A New Perspective Using Stem Cell Therapy. Current Molecular Pharmacology, 2022, 15, .	0.7	1
2642	Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine, 2022, 28, 704-712.	15.2	181
2643	The microbiome and precision oncology: an emerging paradigm in anticancer therapy. Critical Reviews in Microbiology, 2022, 48, 770-783.	2.7	1
2644	The Intestinal Microbiota May Be a Potential Theranostic Tool for Personalized Medicine. Journal of Personalized Medicine, 2022, 12, 523.	1.1	22
2645	Encapsulated Fecal Microbiota Transplantation: Development, Efficacy, and Clinical Application. Frontiers in Cellular and Infection Microbiology, 2022, 12, 826114.	1.8	21
2646	Roles of Microbiota in Cancer: From Tumor Development to Treatment. Journal of Oncology, 2022, 2022, 1-15.	0.6	8
2647	How to prepare stool banks for an appropriate response to the ongoing COVID-19 pandemic: Experiences in the Netherlands and a retrospective comparative cohort study for faecal microbiota transplantation. PLoS ONE, 2022, 17, e0265426.	1.1	1

#	Article	IF	Citations
2648	Multi-Donor Fecal Microbial Transplantation for Critically Ill Patients: Rationale and Standard Operating Procedure. Future Pharmacology, 2022, 2, 55-63.	0.6	2
2649	Intestinal Microbiota and Sclerosis Lateral Amyotrophic. Revista Ciencias Em Saude, 2022, 12, 3-13.	0.0	0
2650	The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. Gut Microbes, 2022, 14, 2038856.	4.3	16
2651	Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment. Current Drug Targets, 2022, 23, 869-888.	1.0	1
2652	Cost-effectiveness of Fecal Microbiota Transplantation for First RecurrentClostridioides difficileInfection. Clinical Infectious Diseases, 2022, 75, 1602-1609.	2.9	8
2653	Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience. Revista Espanola De Quimioterapia, 2022, 35, 279-283.	0.5	5
2654	Microbiota-targeted therapies in inflammation resolution. Seminars in Immunology, 2022, 59, 101599.	2.7	10
2655	Anaerobic singleâ€cell dispensing facilitates the cultivation of human gut bacteria. Environmental Microbiology, 2022, 24, 3861-3881.	1.8	15
2656	Regulating the Oil-Water Interface to Construct Double Emulsions: Current Understanding and Their Biomedical Applications. Chemical Research in Chinese Universities, 2022, 38, 698-715.	1.3	3
2657	The Age of Next-Generation Therapeutic-Microbe Discovery: Exploiting Microbe-Microbe and Host-Microbe Interactions for Disease Prevention. Infection and Immunity, 2022, 90, e0058921.	1.0	10
2658	Rehabilitation of a misbehaving microbiome: phages for the remodeling of bacterial composition and function. IScience, 2022, 25, 104146.	1.9	7
2659	The Influence of Gut Dysbiosis in the Pathogenesis and Management of Ischemic Stroke. Cells, 2022, 11, 1239.	1.8	55
2660	Preclinical safety, effectiveness evaluation, and screening of functional bacteria for fecal microbiota transplantation based on germ-free animals. World Journal of Meta-analysis, 2021, 9, 496-504.	0.1	0
2661	Clinical efficacy of fecal microbial transplantation treatment in adults with moderateâ€toâ€severe atopic dermatitis. Immunity, Inflammation and Disease, 2022, 10, .	1.3	28
2662	Relics and Historical Uses of Human Zootherapeutic Products in Contemporary Spanish Ethnoveterinary Medicine. Veterinary Sciences, 2021, 8, 323.	0.6	2
2663	Harnessing the microbiome to restore immunotherapy response. Nature Cancer, 2021, 2, 1301-1304.	5.7	10
2664	Ecological Dynamics and Microbial Treatments against Oomycete Plant Pathogens. Plants, 2021, 10, 2697.	1.6	2
2665	Gut Homeostasis; Microbial Cross Talks in Health and Disease Management. Current Research in Nutrition and Food Science, 2021, 9, 1017-1045.	0.3	0

#	Article	IF	Citations
2666	Human Gut Microbiota in Health and Selected Cancers. International Journal of Molecular Sciences, 2021, 22, 13440.	1.8	23
2667	Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 702414.	1.8	13
2668	Pediatric Fecal Microbiota Transplantation in Recurrent Clostridioides Difficile. Pediatric Annals, 2021, 50, e515-e521.	0.3	2
2669	Mechanism of the Gut Microbiota Colonization Resistance and Enteric Pathogen Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 716299.	1.8	79
2670	Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. Nutrients, 2022, 14, 103.	1.7	40
2671	Alcohol Use and Abuse Conspires With HIV Infection to Aggravate Intestinal Dysbiosis and Increase Microbial Translocation in People Living With HIV: A Review. Frontiers in Immunology, 2021, 12, 741658.	2.2	4
2672	The Emerging Biotherapeutic Agent: Akkermansia. Indian Journal of Microbiology, 2022, 62, 1-10.	1.5	23
2673	Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI?. Journal of Clinical Medicine, 2021, 10, 5822.	1.0	11
2674	Gut Microbes and Eye Disease. Ophthalmic Research, 2022, 65, 245-253.	1.0	8
2675	The urobiome, urinary tract infections, and the need for alternative therapeutics. Microbial Pathogenesis, 2021, 161, 105295.	1.3	8
2676	Next-generation sequencing (NGS) methods and their application in clinical microbiology, infectology and epidemiology. Problemy ZdorovÊ¹Ã¢ I Ã¨kologii, 2021, 18, 26-32.	0.0	1
2677	Health-related quality of life in patients with recurrent Clostridioides difficile infections. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210784.	1.4	4
2678	Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host and Microbe, 2022, 30, 583-598.e8.	5.1	51
2679	Inflammatory bowel disease and carcinogenesis. Cancer and Metastasis Reviews, 2022, 41, 301-316.	2.7	24
2720	Microbiota in health and diseases. Signal Transduction and Targeted Therapy, 2022, 7, 135.	7.1	494
2721	Randomised, double-blind, placebo-controlled, phase 2, superiority trial to demonstrate the effectiveness of faecal microbiota transplantation for selective intestinal decolonisation of patients colonised by carbapenemase-producing Klebsiella pneumoniae (KAPEDIS). BMJ Open, 2022, 12, e058124.	0.8	6
2723	Clinical response and changes in the fecal microbiota and metabolite levels after fecal microbiota transplantation in patients with inflammatory bowel disease and recurrent infection.. , 2021, 7, 87-98.		3
2726	Normal Gastrointestinal Tract Physiology. , 2022, , 3-28.		2

#	Article	IF	Citations
2727	Changes in the gut microbiome and colic in horses, are they cause or consequence?. Open Veterinary Journal, 2022, 12, 242.	0.3	5
2728	Research Progress of Intestinal Flora Imbalance and Persistent Diarrhea. Advances in Clinical Medicine, 2022, 12, 3162-3167.	0.0	0
2730	Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases. GastroenterologÃa Y HepatologÃa (English Edition), 2022, 45, 223-230.	0.0	0
2731	Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer. Cancers, 2022, 14, 2140.	1.7	11
2732	Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 2022, 7, 143.	7.1	83
2734	Gut Microbiome in Anesthesiology and Pain Medicine. Anesthesiology, 2022, 137, 93-108.	1.3	19
2735	Plumping up a Cushion of Human Biowaste in Regenerative Medicine: Novel Insights into a State-of-the-Art Reserve Arsenal. Stem Cell Reviews and Reports, 2022, 18, 2709-2739.	1.7	2
2736	Hostâ€"microbial interactions in metabolic diseases: from diet to immunity. Journal of Microbiology, 2022, , 1.	1.3	3
2737	Fecal Microbiota Transplant in Recurrent Clostridium Difficile Infections: A Systematic Review. Cureus, 2022, , .	0.2	2
2738	Simultaneous Daily Fecal Microbiota Transplantation Fails to Prevent Metronidazole-Induced Dysbiosis of Equine Gut Microbiota. Journal of Equine Veterinary Science, 2022, 114, 104004.	0.4	2
2739	Fomite Transmission Follows Invasion Ecology Principles. MSystems, 2022, , e0021122.	1.7	1
2740	The Gut Microbiome in Colorectal Cancer. Hematology/Oncology Clinics of North America, 2022, 36, 491-506.	0.9	3
2742	Any Future for Faecal Microbiota Transplantation as a Novel Strategy for Gut Microbiota Modulation in Human and Veterinary Medicine?. Life, 2022, 12, 723.	1.1	5
2743	Dental pulp stem cells as a therapy for congenital entero-neuropathy. Scientific Reports, 2022, 12, 6990.	1.6	3
2744	Association of the gut microbiome with cancer immunotherapy. International Journal of Clinical Oncology, 2022, , 1.	1.0	0
2745	Probiotics: insights and new opportunities for <i>Clostridioides difficile</i> intervention. Critical Reviews in Microbiology, 2023, 49, 414-434.	2.7	6
2746	è…¸ç®¡ã•è…¸å†…å¾®ç”Ÿç‰©å¢ƒã®å‰µå‚·æ²»ç™‚ã«ãŠã‘ã‚‹é‡è¦ãªå½¹å‰²(Crucial effects of an altered gut and intestinal mi Kyukyu Igakukai Zasshi, 2017, 28, 827-834.	0.0	0
2747	Novel Mechanisms and Therapeutic Targets for Ischemic Stroke: A Focus on Gut Microbiota. Frontiers in Cellular Neuroscience, 2022, 16, .	1.8	5

#	Article	IF	Citations
2748	Promises of microbiome-based therapies. Journal of Hepatology, 2022, 76, 1379-1391.	1.8	33
2749	Hommage Ã un prÃ©curseur de la transplantation fÃ©caleÂ: le Professeur Valery Korshunov. HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale, 2013, NÂ° 4, 241-242.	0.0	0
2750	SER-109 for Recurrent Clostridioides difficile Infection. New England Journal of Medicine, 2022, 386, 1956-1958.	13.9	1
2752	Review article: the future of microbiomeâ€based therapeutics. Alimentary Pharmacology and Therapeutics, 2022, 56, 192-208.	1.9	21
2753	Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection. Journal of Infection and Chemotherapy, 2022, 28, 1045-1083.	0.8	15
2754	Interaction Between Altered Gut Microbiota and Sepsis: A Hypothesis or an Authentic Fact?. Journal of Intensive Care Medicine, 2023, 38, 121-131.	1.3	6
2755	Akkermansia muciniphila Ameliorates Clostridioides difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. Frontiers in Microbiology, 2022, 13, .	1.5	15
2756	Host Species Adaptation of Obligate Gut Anaerobes Is Dependent on Their Environmental Survival. Microorganisms, 2022, 10, 1085.	1.6	3
2757	Culturing the uncultured microbial majority in activated sludge: A critical review. Critical Reviews in Environmental Science and Technology, 2023, 53, 601-624.	6.6	13
2759	Translating Microbiome Research From and To the Clinic. Annual Review of Microbiology, 2022, 76, 435-460.	2.9	12
2760	Longitudinal Evaluation of Gut Bacteriomes and Viromes after Fecal Microbiota Transplantation for Eradication of Carbapenem-Resistant Enterobacteriaceae. MSystems, 2022, 7, .	1.7	5
2761	Manipulating Microbiota to Treat Atopic Dermatitis: Functions and Therapies. Pathogens, 2022, 11, 642.	1.2	22
2763	Lipids from gut microbiota: pursuing a personalized treatment. Trends in Molecular Medicine, 2022, 28, 631-643.	3.5	2
2764	Mineralocorticoid receptor deficiency in Treg cells ameliorates DSSâ€induced colitis in a gut microbiotaâ€dependent manner. Immunology, 2022, 167, 94-104.	2.0	2
2765	Characteristics and management of children with Clostridioides difficile infection at a tertiary pediatric hospital in China. Brazilian Journal of Infectious Diseases, 2022, 26, 102380.	0.3	3
2766	Global trends in gut microbiota and clostridioides difficile infection research: A visualized study. Journal of Infection and Public Health, 2022, 15, 806-815.	1.9	6
2767	A phage cocktail combined with the enteric probiotic Lactobacillus reuteri ameliorated mouse colitis caused by S. typhimurium. Food and Function, 2022, 13, 8509-8523.	2.1	2
2769	Microbiome and Uveitides. A Review. Ceska A Slovenska Oftalmologie, 2022, 78, 47-52.	0.1	1

#	Article	IF	Citations
2770	Rejuvenating the human gut microbiome. Trends in Molecular Medicine, 2022, 28, 619-630.	3.5	10
2771	Microbiome in Immune-Mediated Uveitis. International Journal of Molecular Sciences, 2022, 23, 7020.	1.8	8
2772	Ileal Pouchâ€“Anal Anastomosis and Pouchitis: The Role of the Microbiota in the Pathogenesis and Therapy. Nutrients, 2022, 14, 2610.	1.7	4
2773	Serious Infections. , 2022, , 297-309.		0
2774	Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases. Journal of Clinical Medicine, 2022, 11, 4119.	1.0	28
2775	Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances. Frontiers in Oncology, 0, 12, .	1.3	3
2776	The Combination of Phages and Faecal Microbiota Transplantation Can Effectively Treat Mouse Colitis Caused by Salmonella enterica Serovar Typhimurium. Frontiers in Microbiology, 0, 13, .	1.5	3
2777	Gut Microbiota and Immunotherapy. Frontiers in Microbiology, 0, 13, .	1.5	8
2778	Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. Gut, 2022, 71, 2107-2122.	6.1	28
2779	The Role of Gut and Airway Microbiota in Pulmonary Arterial Hypertension. Frontiers in Microbiology, 0, 13, .	1.5	2
2780	Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan. BMC Gastroenterology, 2022, 22, .	0.8	9
2781	Gut microbiome in modulating immune checkpoint inhibitors. EBioMedicine, 2022, 82, 104163.	2.7	38
2782	Host and microbial-derived metabolites for Clostridioides difficile infection: Contributions, mechanisms and potential applications. Microbiological Research, 2022, 263, 127113.	2.5	5
2783	The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. Cancer and Metastasis Reviews, 2022, 41, 347-366.	2.7	11
2784	Microbial determinants of effective donors in faecal microbiota transplantation for UC. Gut, 2023, 72, 90-100.	6.1	13
2785	The interplay of gut microbiota between donors and recipients determines the efficacy of fecal microbiota transplantation. Gut Microbes, 2022, 14, .	4.3	19
2786	Global research on Clostridium difficile-associated diarrhoea: A visualized study. World Journal of Gastroenterology, 2022, 28, 3720-3731.	1.4	3
2787	Update on gut microbiota in gastrointestinal diseases. World Journal of Clinical Cases, 2022, 10, 7653-7664.	0.3	4

#	Article	IF	Citations
2788	Microbiota succession throughout life from the cradle to the grave. Nature Reviews Microbiology, 2022, 20, 707-720.	13.6	66
2789	Efficacy and safety of fecal microbiota transplantation for the induction of remission in active ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Annals of Translational Medicine, 2022, 10, 802-802.	0.7	9
2790	Gastrointestinal dysbiosis and Escherichia coli pathobionts in inflammatory bowel diseases. Apmis, 2022, 130, 1-38.	0.9	2
2791	The gut microbiota: a double-edged sword in endometriosis. Biology of Reproduction, 0, , .	1.2	5
2792	Influence of Foods and Nutrition on the Gut Microbiome and Implications for Intestinal Health. International Journal of Molecular Sciences, 2022, 23, 9588.	1.8	36
2793	â€œBacterial Consortiumâ€• A Potential Evolution of Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection. BioMed Research International, 2022, 2022, 1-9.	0.9	9
2794	Global research trends and hotspots of fecal microbiota transplantation: A bibliometric and visualization study. Frontiers in Microbiology, 0, 13, .	1.5	5
2795	Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics. Cell Reports Medicine, 2022, 3, 100711.	3.3	17
2796	Fecal microbiota transplantation can improve cognition in patients with cognitive decline and Clostridioides difficile infection. Aging, 2022, 14, 6449-6466.	1.4	13
2797	Gut microbiota: A new target for T2DM prevention and treatment. Frontiers in Endocrinology, 0, 13, .	1.5	29
2798	The gut microbiota â€“ A vehicle for the prevention and treatment of hepatocellular carcinoma. Biochemical Pharmacology, 2022, 204, 115225.	2.0	4
2799	Correlation between human gut microbiome and diseases. , 2022, 1, 180-191.		12
2800	Innovations for microbiome targeting interventions â€“ a patent landscape analysis indicating overall patenting activity decline and promising target disease areas. Beneficial Microbes, 2022, 13, 265-281.	1.0	1
2802	Will fecal microbiota transplantation eventually be an effective therapeutic strategy for systemic lupus erythematosus?. Clinical Immunology, 2022, 242, 109096.	1.4	3
2803	Design and manufacture of a lyophilised faecal microbiota capsule formulation to GMP standards. Journal of Controlled Release, 2022, 350, 324-331.	4.8	5
2804	Species abundance correlations carry limited information about microbial network interactions. PLoS Computational Biology, 2022, 18, e1010491.	1.5	6
2805	Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice. Lancet Haematology,the, 2022, 9, e776-e785.	2.2	8
2806	Recent topics on interorgan communication networks and gut microbiota. Folia Pharmacologica Japonica, 2022, 157, 321-324.	0.1	0

#	Article	IF	Citations
2807	Dysbiosis of human microbiome and infectious diseases. Progress in Molecular Biology and Translational Science, 2022, , 33-51.	0.9	8
2808	Fecal microbiota transfer: Basic and clinical aspects, current applications, and future perspectives. , 2022, , 265-284.		0
2809	Recent insights into the role of microbiome in the pathogenesis of obesity. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211153.	1.4	6
2810	Human microbiome and cardiovascular diseases. Progress in Molecular Biology and Translational Science, 2022, , 231-279.	0.9	3
2811	Human microbiota: role in cancer progression and therapy. , 2022, , 145-175.		1
2812	Emergence of antibiotic resistance in gut microbiota and its effect on human health. , 2022, , 211-232.		0
2813	Infectious Disease Considerations. , 2022, , 43-52.		0
2814	Gut Microbiome and Diet: Promising Approach for Treatment of Cognitive Impairment. , 2022, , 195-209.		0
2815	Bayesian Hierarchical Compositional Models for Analysing Longitudinal Abundance Data from Microbiome Studies. Complexity, 2022, 2022, 1-16.	0.9	1
2816	Editorial: Manipulation of gut microbiota as a key target to intervene on the onset and progression of digestive system diseases. Frontiers in Medicine, 0, 9, .	1.2	1
2817	The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments. Journal of Microbiology and Biotechnology, 2022, 32, 1086-1097.	0.9	2
2818	Special Issue on the â€œRegulation and Physiopathology of the Gut Barrierâ€• International Journal of Molecular Sciences, 2022, 23, 10638.	1.8	1
2819	Time series strain tracking analysis post fecal transplantation identifies individual specific patterns of fecal dominant donor, recipient, and unrelated microbial strains. PLoS ONE, 2022, 17, e0274633.	1.1	0
2820	The global incidence of adverse events associated with fecal microbiota transplantation in children over the past 20Âyears: A systematic review and metaâ€•analysis. Journal of Gastroenterology and Hepatology (Australia), 0, , .	1.4	1
2821	Current perspectives on irritable bowel syndrome: a narrative review. Journal of International Medical Research, 2022, 50, 030006052211263.	0.4	2
2822	Smoking-induced microbial dysbiosis in health and disease. Clinical Science, 2022, 136, 1371-1387.	1.8	11
2823	Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers. Cancer Immunology Research, 2022, 10, 1292-1298.	1.6	4
2825	Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases. Chinese Medical Journal, 2022, 135, 1927-1939.	0.9	27

#	Article	IF	Citations
2826	Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment. Frontiers in Immunology, 0, 13, .	2.2	21
2827	Infant gut microbiota restoration: state of the art. Gut Microbes, 2022, 14, .	4.3	5
2828	Is there a place for faecal microbiota transplantation in chronic kidney disease?. Nephrology Dialysis Transplantation, 2022, 37, 2303-2306.	0.4	1
2829	Intestinal Dysbiosis and Risk of Posttransplant Clostridioides difficile Infection in a Longitudinal Cohort of Liver Transplant Recipients. MSphere, 2022, 7, .	1.3	3
2830	Human gut microbiota stimulate defined innate immune responses that vary from phylum to strain. Cell Host and Microbe, 2022, 30, 1481-1498.e5.	5.1	22
2831	SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI). Antibiotics, 2022, 11, 1234.	1.5	15
2832	Microbiome-based interventions to modulate gut ecology and the immune system. Mucosal Immunology, 2022, 15, 1095-1113.	2.7	42
2833	Drivers and determinants of strain dynamics following fecal microbiota transplantation. Nature Medicine, 2022, 28, 1902-1912.	15.2	54
2834	Understanding and predicting the efficacy of FMT. Nature Medicine, 2022, 28, 1759-1760.	15.2	5
2835	Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 1083-1091.	3.7	37
2836	The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly. Lancet Microbe, The, 2022, 3, e969-e983.	3.4	80
2837	Transplantation of maternal intestinal flora to the newborn after elective cesarean section (SECFLOR): study protocol for a double blinded randomized controlled trial. BMC Pediatrics, 2022, 22, .	0.7	1
2838	The Use of Gut Microbial Modulation Strategies as Interventional Strategies for Ageing. Microorganisms, 2022, 10, 1869.	1.6	5
2839	The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model. Applied Microbiology and Biotechnology, 2022, 106, 6689-6700.	1.7	3
2840	Clinical study on sequential treatment of severe diarrhea irritable bowel syndrome with precision probiotic strains transplantation capsules, fecal microbiota transplantation capsules and live combined bacillus subtilis and enterococcus faecium capsules. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
2841	Controlling skin microbiome as a new bacteriotherapy for inflammatory skin diseases. Inflammation and Regeneration, 2022, 42, .	1.5	19
2842	Modulation of tumor environment in colorectal cancer â€“ could gut microbiota be a key player?. , 0, 1, .		1
2843	Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Clinical Gastroenterology and Hepatology, 2023, 21, 1330-1337.e2.	2.4	13

#	Article	IF	Citations
2844	Gut microbiome health and dysbiosis: A clinical primer. Pharmacotherapy, 2022, 42, 849-857.	1.2	16
2845	From signal transduction to protein toxinsâ€"a narrative review about milestones on the research route of C. difficile toxins. Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396, 173-190.	1.4	3
2846	Polysaccharides derived from Shenling Baizhu San improve colitis via modulating tryptophan metabolism in mice. International Journal of Biological Macromolecules, 2022, 222, 1127-1136.	3.6	18
2847	Research Progress of Gut Microbiotaâ€™s Function in Metabolic and Immunological Diseases. Open Journal of Natural Science, 2022, 10, 949-959.	0.1	0
2848	Exploring the Potential of Microbial Engineering: The Prospect, Promise, and Essence. , 2022, , 3-40.		0
2849	The emerging role of the microbiome in Alzheimer's disease. International Review of Neurobiology, 2022, , 101-139.	0.9	8
2850	Implications of Microorganisms in Alzheimerâ€™s Disease. Current Issues in Molecular Biology, 2022, 44, 4584-4615.	1.0	11
2851	Research trends on clinical fecal microbiota transplantation: A biliometric analysis from 2001 to 2021. Frontiers in Immunology, 0, 13, .	2.2	1
2852	Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nature Reviews Microbiology, 2023, 21, 236-247.	13.6	136
2853	Role of gut microbiota in the pathogenesis and treatment of diabetes mullites: Advanced research-based review. Frontiers in Microbiology, 0, 13, .	1.5	14
2854	Profiling the Fungal Microbiome after Fecal Microbiota Transplantation for Graft-versus-Host Disease: Insights from a Phase 1 Interventional Study. Transplantation and Cellular Therapy, 2023, 29, 63.e1-63.e5.	0.6	0
2855	The Role and Mechanism of Gut Microbiota in Pulmonary Arterial Hypertension. Nutrients, 2022, 14, 4278.	1.7	8
2857	Screening and characterization of vaginal fluid donations for vaginal microbiota transplantation. Scientific Reports, 2022, 12, .	1.6	6
2858	The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease. Nature Reviews Cardiology, 2023, 20, 217-235.	6.1	31
2859	Challenges and costs of donor screening for fecal microbiota transplantations. PLoS ONE, 2022, 17, e0276323.	1.1	9
2860	Gut microbiome and neurosurgery: Implications for treatment. Clinical and Translational Discovery, 2022, 2, .	0.2	3
2861	Comprehensive bibliometric and visualized analysis of research on fecal microbial transplantation published from 2000 to 2021. BioMedical Engineering OnLine, 2022, 21, .	1.3	2
2864	Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for C. difficile Infections Across Academic and Private Clinical Settings. Journal of Clinical Gastroenterology, 2023, 57, 1024-1030.	1.1	0

#	Article	IF	Citations
2865	The Role of the Human Microbiome in the Pathogenesis of Pain. International Journal of Molecular Sciences, 2022, 23, 13267.	1.8	16
2866	The Function and Molecular Mechanism of Commensal Microbiome in Promoting Malignant Progression of Lung Cancer. Cancers, 2022, 14, 5394.	1.7	3
2867	Updates in functional dyspepsia and bloating. Current Opinion in Gastroenterology, 2022, 38, 613-619.	1.0	3
2868	Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2023, 57, 23-36.	1.9	2
2869	Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. Chemical Reviews, 2023, 123, 31-72.	23.0	54
2870	A review of the preclinical and clinical studies on the role of the gut microbiome in aging and neurodegenerative diseases and its modulation. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	8
2871	Maternal anxiety, depression and stress affects offspring gut microbiome diversity and bifidobacterial abundances. Brain, Behavior, and Immunity, 2023, 107, 253-264.	2.0	30
2873	The Microbiome in Critically Ill Patients. , 2022, , 103-140.		0
2874	Application and development of fecal microbiota transplantation in the treatment of gastrointestinal and metabolic diseases: A review. Saudi Journal of Gastroenterology, 2023, 29, 3.	0.5	7
2875	The evaluation of different types fecal bacteria products for the treatment of recurrent Clostridium difficile associated diarrhea: A systematic review and network meta-analysis. Frontiers in Surgery, 0, 9, .	0.6	1
2876	Delivery of Fecal Material to Terminal Ileum Is Associated with Long-Term Success of Fecal Microbiota Transplantation. Digestive Diseases and Sciences, 2023, 68, 2006-2014.	1.1	2
2877	Recognition and attitudes of Korean physicians toward fecal microbiota transplantation: a survey study. Korean Journal of Internal Medicine, 0, , .	0.7	1
2878	Investigating dysbiosis and microbial treatment strategies in inflammatory bowel disease based on two modified Kochâ€™s postulates. Frontiers in Medicine, 0, 9, .	1.2	4
2879	Targeting the Gutâ€“Brain Axis with Fecal Microbiota Transplantation: Considerations on a Potential Novel Treatment for Parkinson's Disease. Movement Disorders Clinical Practice, 2023, 10, .	0.8	2
2880	Fecal microbiota transplantation as a promising treatment option for osteoporosis. Journal of Bone and Mineral Metabolism, 2022, 40, 874-889.	1.3	12
2881	The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660. Infectious Diseases and Therapy, 2023, 12, 1-7.	1.8	6
2882	Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	4
2883	The Pivotal Role of the Gut Microbiome in Colorectal Cancer. Biology, 2022, 11, 1642.	1.3	9

#	Article	IF	Citations
2884	Next-Generation Probiotics: Microflora Intervention to Human Diseases. BioMed Research International, 2022, 2022, 1-12.	0.9	14
2885	The gut-brain axis in ischemic stroke: its relevance in pathology and as a therapeutic target. Neurological Research and Practice, 2022, 4, .	1.0	8
2886	Faecal microbiota trasplant: Current status and perspectives beyond Clostridioides difficile infection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2023, 41, 203-205.	0.3	0
2887	Approach to the Diagnosis and Management of Gastrointestinal Tract Infections. , 2023, , 388-395.e2.		0
2888	Bacteria-driven bio-therapy: From fundamental studies to clinical trials. Nano Today, 2023, 48, 101731.	6.2	4
2889	Positive zinc intake and a Japanese diet rich in <i>n</i>-3 fatty acids induces clinical remission in patients with mild active ulcerative colitis: a randomized interventional pilot study. Journal of Clinical Biochemistry and Nutrition, 2023, 72, 82-88.	0.6	4
2890	Gut-brain axis as a key aspect of clinical conditions. International Journal of Family & Community Medicine, 2022, 6, 285-289.	0.1	1
2891	Pathogenicity and virulence of Clostridioides difficile. Virulence, 2023, 14, .	1.8	24
2892	Gut Microbiota and Cardiovascular System: An Intricate Balance of Health and the Diseased State. Life, 2022, 12, 1986.	1.1	8
2893	Initial experience of fecal microbiota transplantation in Belarus in patients with hematologic malignancies as a method for recovery of intestinal microbiocenosis. Proceedings of the National Academy of Sciences of Belarus, Medical Series, 2022, 19, 391-403.	0.2	0
2894	Management ofClostridioides difficileinfection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. Journal of Antimicrobial Chemotherapy, 2023, 78, 21-30.	1.3	11
2895	Healthy microbiome â€“ a mere idea or a sound concept?. Physiological Research, 2022, 71, 719-738.	0.4	6
2896	Characterization of Eight Bacterial Biosensors for Microbial Diagnostic and Therapeutic Applications. ACS Synthetic Biology, 2022, 11, 4184-4192.	1.9	4
2897	Spinal Cordâ€“Gutâ€“Immune Axis and Its Implications Regarding Therapeutic Development for Spinal Cord Injury. Journal of Neurotrauma, 2023, 40, 793-806.	1.7	2
2898	The central role of the gut in intensive care. Critical Care, 2022, 26, .	2.5	13
2899	Microbiota-mediated colonization resistance: mechanisms and regulation. Nature Reviews Microbiology, 2023, 21, 347-360.	13.6	49
2900	<i>Clostridioides difficile</i> â€“ a new name, the old problems with diagnosis and treatment. AlÊ¹manah KliniÄeskoj Mediciny, 2023, 50, 377-391.	0.2	1
2901	Microbiome and Metabolome Insights into the Role of the Gastrointestinalâ€“Brain Axis in Parkinsonâ€™s and Alzheimerâ€™s Disease: Unveiling Potential Therapeutic Targets. Metabolites, 2022, 12, 1222.	1.3	6

#	Article	IF	Citations
2902	Microbiome Therapeutics for Food Allergy. Nutrients, 2022, 14, 5155.	1.7	7
2903	Fecal microbiota transplantation in childhood: past, present, and future. World Journal of Pediatrics, 2023, 19, 813-822.	0.8	3
2904	The fecal bacterial microbiota of healthy and sick newborn foals. Journal of Veterinary Internal Medicine, 2023, 37, 315-322.	0.6	2
2905	Fecal Microbiota Transplantation and Other Gut Microbiota Manipulation Strategies. Microorganisms, 2022, 10, 2424.	1.6	13
2907	Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols. Frontiers in Medicine, 0, 9, .	1.2	11
2908	The Gut Microbiome of Children during the COVID-19 Pandemic. Microorganisms, 2022, 10, 2460.	1.6	2
2909	Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection. Expert Opinion on Biological Therapy, 2023, 23, 89-101.	1.4	3
2910	Upper airway microbiome transplantation for patients with chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2023, 13, 979-988.	1.5	4
2911	Gut Microbiota Changes and Parkinsonâ€™s Disease: What Do We Know, Which Avenues Ahead. Healthy Ageing and Longevity, 2023, , 257-278.	0.2	0
2912	Fecal microbiota transplantation is not a magical treatment, but better too early than too late. Korean Journal of Internal Medicine, 2023, 38, 3-4.	0.7	0
2913	Role of gut microbiota in tumorigenesis and antitumoral therapies: an updated review. Biotechnology and Genetic Engineering Reviews, 0, , 1-27.	2.4	1
2914	Fecal Microbiota Transplantation Research over the Past Decade: Current Status and Trends. Canadian Journal of Infectious Diseases and Medical Microbiology, 2023, 2023, 1-18.	0.7	3
2915	Protective Effect of Vegan Microbiota on Liver Steatosis Is Conveyed by Dietary Fiber: Implications for Fecal Microbiota Transfer Therapy. Nutrients, 2023, 15, 454.	1.7	1
2916	Manipulating the Gut Microbiome as a Therapeutic Strategy to Mitigate Late Effects in Childhood Cancer Survivors. Technology in Cancer Research and Treatment, 2023, 22, 153303382211497.	0.8	1
2917	Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection. The Lancet Gastroenterology and Hepatology, 2023, 8, 109.	3.7	2
2918	Microbiota: Â¿Sabemos de quÃ© estamos hablando?. Archivos De ColoproctologÃa, 2021, 4, .	0.0	0
2919	Antibiotic-Associated Diarrhea Beyond C. Difficile: A Scoping Review. , 2023, 2, .		1
2920	Fecal Microbiota Transplantation Across the Lifespan: Balancing Efficacy, Safety, and Innovation. American Journal of Gastroenterology, 2023, 118, 435-439.	0.2	10

#	Article	IF	Citations
2921	Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection. Open Forum Infectious Diseases, 2023, 10, .	0.4	5
2922	Practical Use of RBX2660 for the Prevention of Recurrent Clostridioides difficile Infection. American Journal of Gastroenterology, 2023, 118, 1303-1306.	0.2	8
2923	Fecal transplant. , 2023, , 391-398.		0
2924	Efficacy of lyophilised bacteria-rich faecal sediment and supernatant with reduced bacterial count for treating patients with Clostridioides difficile Infection â€“ A novel method for capsule faecal microbiota transfer. Frontiers in Cellular and Infection Microbiology, 0, 13, .	1.8	3
2925	Revisiting the â€œstarved gutâ€•hypothesis in inflammatory bowel disease. Immunometabolism, 2023, 5, e0016.	0.7	7
2927	Defining the Role of the Gut Microbiome in the Pathogenesis and Treatment of Lymphoid Malignancies. International Journal of Molecular Sciences, 2023, 24, 2309.	1.8	2
2928	Clostridium difficile infection and gut microbiota: From fundamentals to microbiota-centered strategies. , 2023, , 547-561.		0
2929	Liver Microbiome in Healthy Rats: The Hidden Inhabitants of Hepatocytes. Cellular Microbiology, 2023, 2023, 1-16.	1.1	0
2930	Gastrointestinal disorders and intestinal bacteria: Advances in research and applications in therapy. Frontiers in Medicine, 0, 9, .	1.2	4
2931	Disease mechanisms as subtypes: Microbiome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 107-131.	1.0	2
2932	First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Annals of Oncology, 2023, 34, 520-530.	0.6	13
2933	The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection â€“ A Systematic Review. Drug, Healthcare and Patient Safety, 0, Volume 15, 63-71.	1.0	0
2934	The Microbiome and Uveitis. American Journal of Pathology, 2023, 193, 1638-1647.	1.9	2
2935	Impact of Gut Microbiota on Host Aggression: Potential Applications for Therapeutic Interventions Early in Development. Microorganisms, 2023, 11, 1008.	1.6	3
2936	Metabolic independence drives gut microbial colonization and resilience in health and disease. Genome Biology, 2023, 24, .	3.8	19
2937	Possibilities of Autologous Fecal Microbiota Transplantation in patients with obesity and diabetes mellitus. Obesity and Metabolism, 2023, 19, 300-305.	0.4	0
2938	The direct correlation between microbiota and SARS-CoV-2 infectious disease. Inflammopharmacology, 0, , .	1.9	2
2939	Faecal microbiota trasplant: Current status and perspectives beyond Clostridioides difficile infection. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2023, 41, 203-205.	0.2	0

#	Article	IF	Citations
2940	Fecal Microbiota Transplantation in Diseases Not Associated with Clostridium difficile: Current Status and Future Therapeutic Option. Advances in Predictive, Preventive and Personalised Medicine, 2023, , 275-308.	0.6	0
2941	Is there a role for microbiome-based approach in common variable immunodeficiency?. Clinical and Experimental Medicine, 2023, 23, 1981-1998.	1.9	2
2942	Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review. Microorganisms, 2023, 11, 387.	1.6	10
2943	Preparing the Bowel (Microbiome) for Surgery: Surgical Bioresilience. Clinics in Colon and Rectal Surgery, 2023, 36, 138-145.	0.5	1
2944	The Evolving Landscape of Fecal Microbial Transplantation. Clinical Reviews in Allergy and Immunology, 2023, 65, 101-120.	2.9	5
2946	Update on Clostridioides difficile Infection in Older Adults. Infectious Disease Clinics of North America, 2023, 37, 87-102.	1.9	2
2947	Controlling the human microbiome. Cell Systems, 2023, 14, 135-159.	2.9	2
2948	Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease. Gut Microbes, 2023, 15, .	4.3	7
2949	Fecal microbiota transplantation attenuates Escherichia coli infected outgrowth by modulating the intestinal microbiome. Microbial Cell Factories, 2023, 22, .	1.9	4
2950	Research Progress of Fecal Microbiota Transplantation in Liver Diseases. Journal of Clinical Medicine, 2023, 12, 1683.	1.0	8
2951	Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients. Melanoma Research, 2023, 33, 136-148.	0.6	1
2952	Realising the potential of faecal microbiota transplant. The Prescriber, 2023, 34, 22-25.	0.1	0
2953	Seminars in immunology special issue: Nutrition, microbiota and immunity The unexplored microbes in health and disease. Seminars in Immunology, 2023, 66, 101735.	2.7	1
2954	The Gut Microbiota and Inflammatory Bowel Disease. , 2023, , 49-59.		0
2955	De lâ€™usage de Spinoza en biologie humaine. Revue Francaise De Psychosomatique, 2023, nÂ° 62, 57-74.	0.1	0
2956	The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis. Digestive Diseases, 2023, 41, 656-665.	0.8	4
2957	Spezielle Erreger und Infektionen. , 2022, , 313-413.		0
2958	Toward Understanding Microbial Ecology to Restore a Degraded Ecosystem. International Journal of Environmental Research and Public Health, 2023, 20, 4647.	1.2	1

#	Article	IF	Citations
2959	Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2023, 16, 175628482311562.	1.4	4
2961	Emergence of Multidrug Resistance Microbes: Bacteria, Fungi, and Viruses. , 2023, , 28-67.		0
2962	Fecal microbiota-based treatment for recurrent Clostridioides difficile infection. Cell, 2023, 186, 1087.	13.5	7
2963	Early Administration of Vancomycin Inhibits Pulmonary Embolism by Remodeling Gut Microbiota. Journal of Personalized Medicine, 2023, 13, 537.	1.1	1
2965	Development and Characterization of Hydroxyethyl Cellulose-Based Gels Containing Lactobacilli Strains: Evaluation of Antimicrobial Effects in In Vitro and Ex Vivo Models. Pharmaceuticals, 2023, 16, 468.	1.7	1
2966	The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation. Cancer Journal (Sudbury, Mass), 2023, 29, 75-83.	1.0	0
2967	Clinical trials targeting the gut-microbiome to effect ocular health: a systematic review. Eye, 0, , .	1.1	2
2968	Gut microbiomeâ€"based therapeutics in inflammatory bowel disease. Clinical and Translational Discovery, 2023, 3, .	0.2	2
2969	The New Microbiology: an international lecture course on the island of Spetses. MicroLife, 2023, 4, .	1.0	1
2970	Importance of Gut Microbiome-Based Therapeutics in Cancer Treatment. Biological and Medical Physics Series, 2023, , 831-885.	0.3	0
2971	Role of the Microbiome in Gut-Heart-Kidney Cross Talk. Circulation Research, 2023, 132, 1064-1083.	2.0	12
2972	The role of faecal microbiota transplantation in chronic noncommunicable disorders. Journal of Autoimmunity, 2023, 141, 103034.	3.0	3
2973	Precision medicine: Overview and challenges to clinical implementation. , 2023, , 513-529.		0
2981	Microbiota and epigenetics: Health impact. Progress in Molecular Biology and Translational Science, 2023, , 93-117.	0.9	0
2982	Gut Microbiomeâ€"Brain Alliance: A Landscape View into Mental and Gastrointestinal Health and Disorders. ACS Chemical Neuroscience, 2023, 14, 1717-1763.	1.7	24
2985	Microbiome therapeutics as an alternative to the antibiotics. , 2023, , 421-441.		0
2986	Overview of microbial therapeutics in immunological disorders. , 2023, , 289-353.		1
2987	Microbiome therapeutics. , 2023, , 1-40.		0

#	Article	IF	Citations
2988	Microbiome therapeutics for the cancer management. , 2023, , 197-230.		0
2989	The modulatory approaches of microbiome therapeutics. , 2023, , 95-126.		0
2996	Fulminant/Toxic Colitis. , 2023, , 1207-1225.		0
2998	Interactions Between Microbial Therapeutics and the Endogenous Microbiome. , 2023, , 421-449.		0
3004	Seven reasons for a uveitis specialist to understand the microbiome. , 2023, , 163-173.		0
3021	Gut Microbiota Links With Disease. , 2023, , 105-145.		0
3023	Gastroenteritis: Bakterielle Infektionen. , 2023, , 15-33.		0
3031	Antibiotic-induced collateral damage to the microbiota and associated infections. Nature Reviews Microbiology, 2023, 21, 789-804.	13.6	7
3033	Potential effects of gut microbiota on host cancers: focus on immunity, DNA damage, cellular pathways, and anticancer therapy. ISME Journal, 2023, 17, 1535-1551.	4.4	6
3038	Akute infektiÃ¶se Enteritiden bei Erwachsenen. , 2023, , 334-342.		0
3052	A relational framework for microbiome research with Indigenous communities. Nature Microbiology, 2023, 8, 1768-1776.	5.9	1
3071	Infecties van het maag-darmkanaal. , 2024, , 143-160.		0
3073	Pelvic Radiation Disease and the Gastrointestinal Tract. , 2023, , 269-287.		0
3075	Editorial: Continuous monitoring to improve outcome of treatmentâ€"the next step towards safe and effective faecal microbiota transplantation. Authors' reply. Alimentary Pharmacology and Therapeutics, 2023, 58, 948-949.	1.9	0
3076	Editorial: Continuous monitoring to improve outcome of treatmentâ€"the next step towards safe and effective faecal microbiota transplantation. Alimentary Pharmacology and Therapeutics, 2023, 58, 946-947.	1.9	1
3101	Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future. Clinical Infectious Diseases, 2023, 77, S463-S470.	2.9	0
3109	Emerging Technologies and Current Advances in Human Bacteriome Research. , 2023, , 161-176.		0
3115	European Practice for CDI Treatment. Advances in Experimental Medicine and Biology, 2024, , 57-84.	0.8	0

#	Article	IF	Citations
3124	Fecal Microbiota Transplantation as Emerging Treatment in European Countries 2.0. Advances in Experimental Medicine and Biology, 2024, , 85-99.	0.8	0
3128	Clostridioides difficile: from â€œdifficult to growâ€•to â€œdifficult to treatâ€• , 2024, , 945-956.		0
3129	The Microbiome Is Redefining What It Means to be Human. , 2024, , 157-169.		0
3130	Correlating the Gut Microbiome to Health and Disease. , 2024, , 1-36.		0
3144	Fecal Transplant: The Benefits and Harms of Fecal Microbiota Transplantation. , 2023, , 129-140.		0
3150	Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis: Clinical Protocol and Evaluation of Microbiota Immunity Axis. Methods in Molecular Biology, 2024, , 373-396.	0.4	0